TITLE: 
DRUG: 
IND: 
SPONSOR: 
Document M(t\R1Nl.Js 
PHARMACEUTICALS 
PROTO COL: 1042-PPD-2003 
A Phase 2, Double-blind , Placebo-controlled , Multicenter Study 
to Evaluate Safety , Tolerability and Efficac y of IV and Oral 
Admini stration of Ganaxolone in Women with Postpartum 
Depre ssion 
Ganaxo lone ( CCD 1042:3a-hydroxy -3 ~-methyl-5a -pregnan -20-one) 
135256 
Marinus Phannaceuticals, Inc. 
170 N. Radno r Ches ter Road 
Suite 250 
Radno r, PA 1 9087 
USA 
Date Globa l/Countr y/Site Spe cific 
Original Protocol -Version 1 09 Jun 2017 Global 
Amendment 1 -Version 2 15 Aug 2017 Global 
Amendment 2 -Version 3 25 Jan 2018 Global 
Amendment 3 -Version 4 05 Jun 2018 Global 
Amendment 4 -Version 5 22 Oct 2018 Global 
This document contains confiden tial and proprietary infonna tion of Marinu s and is disclosed pursuant to 
confiden tiality and non-di sclosure obligations. This informa tion should be used s olely for the purpo ses for which it 
was provided and should not be copied, shared with, or disclosed to any third party without the expre ss written 
consent of Marinu s. 
IND No. 135256 
Protocol l 042-PPD-200 3 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Marinus) Approval 
Date: 
Investigator's Acknowledgement 
I have read this protocol for Marinus Study 1042-PPD-2003. Marinus Phannaceutica1s, Inc. 
Version 5.0 /22 Oct 2018 
Title: A Phase 2, Double-blind, Placebo-controlled, Multi center Study to Evaluate Safety, 
Tolerability and Efficacy ofJV and Oral Administration ofGanaxolone in Women with 
Postpartum Depression 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, other 
than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, pennissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in accordance 
with International Council on Hannonisation guidelines on Good Clinical Practice and with the 
applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
tennination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or~) 
Signature: --------- ------
Confidential Date: 
Page 2 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 3 of 131 EMERGENCY CONTACT INFORMATION 
SERIOUS ADVERSE EVENT REPORTING:  
In the event of a serious adverse event (SAE), the investigator must e-mail or fax the Marinus 
Clinical Study Serious Adverse Event Form within 24 hours to  Marinus Safety Department at:  
Email:  safetyPPD2003@
marinuspharma.com  
Fax:  484-679-2138  
SPONSOR CONTACT
S:  
Sponsor Operational Contact:  
 
Telephone:  
Email: 
Sponsor Medical Cont
act and Medical Monitor:  
 MD  
 
Marinus Pharmaceuticals Inc. 
Telephone: 
Email: 
 

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 4 of 131 TABLE OF CONTENTS  
PROTOCOL SIGNATURE P AGE  ................................................................................................. 2 
EMERGENCY CONTACT INFORMATION ............................................................................... 3 
TABLE OF CONTENTS ................................................................................................................ 4 
LIST OF TABLES .......................................................................................................................... 8 
LIST OF FIGURES ......................................................................................................................... 9 
LIST OF APPENDICES ................................................................................................................. 9 
ABBREVIATIONS ....................................................................................................................... 10 
STUDY SYNOPSIS ...................................................................................................................... 13 
1 BACKGROUND INFORMATI ON ....................................................................................... 18 
1.1 Postpartum
 Depression (PPD) ........................................................................................... 18 
1.2 Product Background and Clinical Inf
ormation ................................................................. 18 
1.2.1 Ganaxolone :  Oral Administration .............................................................................. 19 
1.2.2  Ganaxolone:  Intravenous Administration .................................................................. 20 
2 STUDY OBJECTIVES AND PURPOSE .............................................................................. 22 
2.1 Rationale for the Study ...................................................................................................... 22 
2.2 Study Objective s ................................................................................................................ 22 
2.2.1  Objectives of the Open-label Safety Part .................................................................... 22 
2.2.1.1  Safety Objective .................................................................................................... 22 
2.2.1.2  Dosing Objective ................................................................................................... 22 
2.2.1.3  Efficacy Objective ................................................................................................. 22 
2.2.1.4 Pharmacokinetic Objective .................................................................................... 22 
2.2.2 Object ives of the Double-blind Part ............................................................................ 23 
2.2.3  Efficacy Objective ....................................................................................................... 23 
2.2.4 Safety Objective .......................................................................................................... 23 
2.2.5  Pharmacokinetic Objective  .......................................................................................... 23 
3 STUDY DESIGN ................................................................................................................... 24 
3.1 Study Design and Study Population .................................................................................. 24 
3.2 Rationale for Study Design ............................................................................................... 25 
3.3 Dose Selection ................................................................................................................... 26 
3.4 Study Duration .................................................................................................................. 28 
3.5 Planned Analyses .............................................................................................................. 28 
3.5.1  Analysis After Completion of the Open Label Part .................................................... 28 
3.5.2  Analyses After Completion of the Double-blind Placebo-controlled Part .................. 28 
3.6 Definition of Completion .................................................................................................. 29 
3.7 Sites and Regions .............................................................................................................. 29 
4 STUDY POPULATION ........................................................................................................ 30 
4.1 Inclusion Criteria ............................................................................................................... 30 
4.2 Exclusion Criteria .............................................................................................................. 30 
4.3 Reproductive Potential ...................................................................................................... 32 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 5 of 131 4.3.1 Female Contraception .................................................................................................. 32 
4.4
 Discontinuation of Subjects ............................................................................................... 32 
4.4.1 Subject Withdrawal Criter
ia ........................................................................................ 32 
4.4.2 Reasons for Discontinuation ....................................................................................... 33  
4.4.3 Subjects “Lost to Follow-up” Prior to Last Scheduled Visit ....................................... 33 
5
 PRIOR AND CONCOMITANT TREATMENT ................................................................... 34 
5.1 Prior Pharmacological T
reatment ...................................................................................... 34 
5.2 Concomitant Pharmacol
ogical Treatment ......................................................................... 34 
5.3 Concomitant Psycholog
ical Treatment ............................................................................. 34 
5.3.1 Permitted Treatm
ent .................................................................................................... 34 
5.3.1.1 Permitted Psychological Trea
tment s ..................................................................... 34 
5.3.1.2 Permitted Antidepressan t Treatments ................................................................... 34 
5.3.1.3 Other Permitted Treatment s .................................................................................. 35 
5.3.2 Prohibited Treatments ................................................................................................. 35 
6 INVES TIGATIONAL PRODUCTS ...................................................................................... 37 
6.1 Identity of Investigational Products .................................................................................. 37 
6.1.1  Ganaxolone Immediate Release Oral Capsules (0.3 Micron Formulation) ................ 37 
6.1.2  Ganaxolone IV Infusion Solution ................................................................................ 37 
6.1.3  Ganaxolone Oral Suspension  ...................................................................................... 37 
6.2 Administration of Investigational Product(s) .................................................................... 38 
6.2.1  Allocation of Subjects to Treatment ............................................................................ 38 
6.2.2 Dosing for the Open-label Treatment Part – OL TID Group ...................................... 38 
6.2.3
 Dosing for the Open-Label Treatment Part – OL QHS Group ................................... 41 
6.2.4  Dosing for the Open -Label Treatment Part – OL QHS Group – 4 Week ................... 43 
6.2.5  Dosing for the Open -Label Treatment Part – OL 1,125 mg Group ............................ 45 
6.2.6  Dosing for the Open -Label Treatment Part – OL Bolus-Oral Group .......................... 46 
6.2.7  Dose Adjustments During Open-label ........................................................................ 47 
6.2.8  Blinding ....................................................................................................................... 48 
6.3 Labeling, Packaging, and Storage ..................................................................................... 48 
6.3.1 Labeling ....................................................................................................................... 48 
6.3.2 Packagi ng and Dispensing the Study Drug ................................................................. 48 
6.3.3  Storage ................................ ................................................................ ......................... 49 
6.4 Drug Accountability .......................................................................................................... 49 
6.5 Drug Administration .......................................................................................................... 50 
7 STUDY PROCEDURES ....................................................................................................... 51 
7.1 Scre ening Period (Day -14 to -1) for OL TID and OL QHS ............................................. 52 
7.1.1  Screening Visit (Visit 1) .............................................................................................. 52 
7.2 Treatment Period (Day 1 to Day 14; Visits 2 to 5) for OL TID and OL QHS .................. 52 
7.2.1  Start of the Open -label Safety Period (Day 1; Visit 2) ................................................ 52 
7.2.2  Treatment Visits (Days 4, 7, 10) (+ 3 days) for OL TID and OL QHS ...................... 53 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 6 of 131 7.3 Follow-up Visit 1 (Day 17 ± 2) and Follow-up Visit 2 (Day 38 ± 4) for OL TID 
and OL QHS.................................................................................................................... 54 
7.4
 Screening Period (Day -14 to -1) for OL QHS 4 week ..................................................... 56 
7.4.1 Screening Visit (Visit 1)
 .............................................................................................. 56 
7.5 Treatment Period (Day 1 to Day 28; V
isits 2 to 7) for OL QHS 4 week .......................... 56 
7.5.1 Start of the Open-label Safety Period (Enrollment Visit for the OL QHS 4 
week) (
Day 1) ............................................................................................................. 56 
7.5.2 Treatment Visits (Days 2, 8, 15, 22, 29) for OL QHS 4 week .................................... 57 
7.6 Follow-up Visit 1 (
Day 36 ± 2), Follow-up Visit 2 (Day 59 ± 2), Follow-up Visit 3 
(Day 89 ± 4), and Follow-up Visit 4 (Day 119 ± 4)
 for the OL QHS 4 week group ...... 58 
7.7 Screening Period (Day -14 to -1) for OL 1,125 mg and OL Bolus-Oral groups ............... 60 
7.7.1 Screening Visit (Visit 1)
 .............................................................................................. 60 
7.8 Treatment Period (Day 1 to Day 29; V
isits 2 to 7) for OL 1,125 mg and OL Bolus-
Oral groups ...................................................................................................................... 60
 
7.8.1 Start of the Open-label Safety Period (Enrollment Visit for the OL 1,125 mg 
and OL B
olus-Oral groups) (Day 1) .......................................................................... 60 
7.8.2 Trea tment Visits (Days 2, 8, 15, 22, 29 ± 3 days [except Day 2]) for OL 1,125 
mg and OL Bolus-Oral groups ................................................................................... 62 
7.9 Follow-up Visit 1 (Day 36 ± 3), Follow-up Visit 2 (Day 57 ± 3), and Follow-up 
Visit 3 (Day 71 ± 3) for the OL 1,125 mg and OL 
Bolus-Oral groups ........................... 63 
7.10 Study Evaluations and Procedures .................................................................................... 66 
7.10.1  Demographics, Medical History, and Other Baseline Characteristics ........................ 66 
7.10.2  Informed Consent ........................................................................................................ 66 
7.10.3 Eligibility Review ........................................................................................................ 66 
7.10.4 Prior  Medication, Concomitant Medication and Concomitant Therapy Review ........ 66 
7.10.5 Physical Examination .................................................................................................. 66 
7.10.5.1 12-lead Electrocardiogram ................................................................ .................... 67 
7.10.5.2  Clinical Safety Laboratory Evaluations ................................................................ 67 
7.10.5.3 Adverse Event Collection ...................................................................................... 68 
7.10.5.4  Vital Signs ............................................................................................................. 68 
7.10.6  Interviews, Questionnaires, and Scales ....................................................................... 68 
7.10.6.1  Mini International Neuropsychiatric Interview 7.0 ............................................... 68 
7.10.6.2  The Hamilton Depression Rating Scale ................................................................ 69 
7.10.6.3  Stanford Sleepiness Scale ...................................................................................... 69 
7.10.6.4  Clinical Global Impression-Improvement and Clinical Global 
Impression-Severity ............................................................................................... 69 
7.10.6.5  Edinburgh Postnatal Depression Scale (EPDS) .................................................... 69 
7.10.6.6  Spielberg Trait-State Anxiety Inventory, 6 Item Version ..................................... 69 
7.10.6.7 SAFER Interview .................................................................................................. 70 
7.10.6.8  Columbia Suicide Severity Rating Scale (CSSRS) ............................................... 70 
7.10.7  Pharmacokinetic Sampling .......................................................................................... 70 
7.10.8  Neurosteroid Levels .................................................................................................... 70 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confide ntial Page 7 of 131 7.10.9 Volume of Blood to Be Drawn from Each Subject ..................................................... 71 
7.10.10 Safety Plan for Medical Emergencie
s ......................................................................... 72 
8 ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT .................................... 73 
8.1 Definition of Adverse Events, Perio
d of Observation, Recording of Adverse 
Events .............................................................................................................................. 73 
8.1.1
 Severity Categorization ............................................................................................... 73 
8.1.2
 Causality Categorization ............................................................................................. 74 
8.1.3 Variables
 ...................................................................................................................... 74 
8.1.4 Symptoms of the Disease Under St
udy ....................................................................... 74 
8.1.5 Adverse Events Based on Clinical Laborato
ry an d Other Safety Evaluations ............ 74 
8.1.6 Adverse Events Based on Signs and Symptoms  ......................................................... 75 
8.1.7 Pregnancy .................................................................................................................... 75 
8.2 Serious Adv
erse Event Procedures .................................................................................... 75 
8.2.1 Ref erence Safety Information ..................................................................................... 75 
8.2.2  Reporting Procedures .................................................................................................. 75 
8.2.3  Serious Adverse Event Definition ............................................................................... 76 
8.2.4 Serious Adverse Event Collection Time Frame .......................................................... 76 
8.2.5  Serious Adverse Event Onset and Resolution Dates ................................................... 77 
8.2.6  Fatal Outcome ............................................................................................................. 77 
8.2.7  Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting .................................................................................................................... 77 
9 DATA MANAGEMENT AND STATISTICAL METHODS .............................................. 78 
9.1 Data Collection .................................................................................................................. 78
 
9.2 Clini cal Data Management ................................................................................................ 78 
9.3 Statistical Analysis Plan .................................................................................................... 78 
9.3.1  Data Review Committee (DRC) and Recommendations for Dosing .......................... 78 
9.3.2  Justification for Sample Size ....................................................................................... 79 
9.3.3  Study Population ......................................................................................................... 79 
9.4 Analysis Methods .............................................................................................................. 79 
9.4.1  Demographic and Baseline Characteristics ................................................................. 79 
9.4.2  Subject Disposition ...................................................................................................... 80 
9.4.3  Investigational Medicinal Product ............................................................................... 80 
9.4.4  Concomitant Medication ............................................................................................. 80 
9.4.5 Safety Analyses ........................................................................................................... 80 
9.4.6 Ef ficacy Analyses ........................................................................................................ 80 
9.4.6.1  Primary Endpoint .................................................................................................. 80 
9.4.6.2  Secondary Endpoints ............................................................................................. 81 
  
9.4.6.4 Statistical Methods 
................................................................................................ 81 
9.4.7  Other Analyses ............................................................................................................ 82 
9.4.8  Handling of Missing and Incomplete Data .................................................................. 82 

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 8 of 131 9.4.9 Pharmacokinetic Analyses .......................................................................................... 82 
10 SPONSOR’S AND INVESTIGATOR’S RESPO
NSIBILITIES ........................................... 83 
10.1 Sponsor’s Responsibilities 
................................................................................................ 83 
10.1.1 Good Clinical Practic
e Com pliance ............................................................................ 83 
10.1.2 Public Posting of Study Information ........................................................................... 83 
10.1.3 Study Suspension, Termination, and Co
mple tion ....................................................... 83 
10.2 Investigator’s Responsibilities .......................................................................................... 83 
10.2.1 Good Clinical Practic
e Com pliance ............................................................................ 83 
10.2.2 Protocol Adherence and Investigator Agreement........................................................ 84 
10.2.3 Documentation and Retention of Records ................................
................................... 84 
10.2.3.1 Case Report Forms ................................................................................................ 
84 
10.2.3.2
 Recording, Access, and Retention of Source Dat a and Study Documents ........... 85 
10.2.3.3 Audit/Inspection .................................................................................................... 85 
10.2.3.4
 Financial Disclosure .............................................................................................. 85  
10.3  Ethical Considerations ....................................................................................................... 86 
10.3.1  Informed Consent ........................................................................................................ 86 
10.3.2  Institutional Review Board or Ethics Committee ........................................................ 86 
10.4  Privacy and Confidentiality ............................................................................................... 87 
10.5  Study Results and Publication Policy ................................................................................ 87 
11 REFERENCES ....................................................................................................................... 88 
12 APPENDICES ........................................................................................................................ 90 
 
LIST OF TABLES 
Table 1.  Study Drug Dosing Schedule – Open-Label TID Group ...................................... 40 
Table 2.  Study Drug Dosing Schedule – Open-Label QHS Group ..................................... 42 
Table 3.  Study Drug Dosing Schedule – Open-Label QHS 4 Week Group ........................ 44 
Table 4.  Study Drug Dosing Schedule – Open-label 1,125 mg Group ............................... 45 
Table 5.  Study Drug Dosing Schedule – Open-label Bolus-oral Group ............................. 46 
Table 6.  Schedule of Assessments for the Open-label OL TID and OL QHS and Double-
blind Groups .......................................................................................................... 55 
Table 7.  Schedule of Assessments for the Open-label OL QHS 4 Week Group ................ 59 
Table 8.  Schedule of Assessments for the Open-label OL 1,125 mg and OL Bolus-oral 
Groups ................................................................................................................... 64 
Table 9.  Volume of Blood to Be Drawn from Each Subject for the OL TID, OL QHS and 
Double-blind Groups ............................................................................................. 71 
Table 10.  Volume of Blood to Be Drawn from Each Subject for the OL QHS 4 Week, OL 
1,125 mg, and OL Bolus-oral groups .................................................................... 71 
Table 11.  Volume of Blood to Be Drawn from Each Subject for the PK Subgroup of OL 
1,125 mg Group ..................................................................................................... 71 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 9 of 131 Table 12.  Volume of Blood to Be Drawn from Each Subject for the PK Subgroup of OL 
Bolus-Oral Group .................................................................................................. 71 
 
LIST OF FIGURES 
Figure 1-A:  Design of Open-Label Part ....................................................................................... 14 
Figure 1-B:  Design of the Double-Blind Placebo-Controlled Part .............................................. 14 
 
LIST OF APPENDICES 
Appendix 1.   Prohibited Strong CYP3A4 Inhibitors and Inducers ............................................ 90 
Appendix 2.   Scales and Assessments ........................................................................................ 91 
Appendix 3.   Protocol History ................................................................................................... 92 
 
  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 10 of 131 ABBREVIATIONS 
AE adverse event  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AUC 0-24 area under the concentration curve  
-HCG  -human chorionic gonadotropin  
BMI  body mass index  
BP blood pressure  
BUN  blood urea nitrogen  
CGI-I Clinical Global Impression -Improvement  
CGI-S Clinical Global Impression -Severity  
Cmax maximum plasma concentration  
Cmin Minimum plasma concentration  
CNS  central nervous system  
CRA  clinical research associate  
CRC  child -resistant closure  
CRO  contract research organization  
Css concentration at steady -state 
CSSRS  Columbia Suicide Severity Rating Scale  
CTNI  Clinical Trial  Network Institute of Massachusetts General Hospital  
CYP  Cytochrome P  
DBPC  Double -blind placebo -controlled  
DRC  Data Review Committee  
EC Ethics Committee  
ECG  electrocardiogram  
ECT  Electroconvulsive Therapy  
eCRF  electronic case report form  
EMA  European Medicines Agency   
EPDS  Edinburgh Postnatal Depression Scale  
EU European Union  
FDA  Food and Drug Administration  
GABA  gamma Aminobutyric Acid  
GCP  Good Clinical Practice  
GCMS  gas chromatography mass spectroscopy  
GMP  Good Manufacturing Practices  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 11 of 131 HAMD  Hamilton Depression Rating Scale  
hCG  human chorionic gonadotropin  
HDPE  high-density polyethylene  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council on Harmoni sation  
IP Investigational product  
IRB Institutional Review Board  
IUD Intrauterine device  
IV Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
MINI 7.0  Mini International Neuropsychiatric Interview 7.0  
mITT  modified Intent to Treat  
OL open -label  
PCDH19  protocadherin 19  
PD pharmacodynamic  
PK pharmacokinetic  
PPD postpartum depression  
PTSD  Post-traumatic stress disorder  
QID 4 times daily  
Q4H  every 4 hours  
QHS  nightly at bedtime  
QTcF  QT interval Fridericia’s correction  
rTMS  rapid transcranial magnetic stimulation  
SAE  serious adverse event  
SAFER  State versus trait; Assessability; Face validity; Ecological Validity; and 
Rule of 3 Ps  
SAP statistical analysis plan  
SOP standard operating procedure  
SSRIs  selective serotonin reuptake inhibitors  
SSS Stanford Sleepiness Scale  
STAI  Spielberger State -Trait Anxiety Inventory  
TEAE  Treatment Emergent AEs  
TID 3 times daily  
TSH  thyroid stimulating hormone  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 12 of 131 ULN  upper limit of normal  
US United States  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 13 of 131 STUDY SYNOPSIS 
Protocol number:  
1042 -PPD-2003  Drug:   
Ganaxolone IV, oral suspension, and oral capsule formulation s 
Title of the study:  A Phase 2, Double -blind, Placebo -controlled, Multicenter Study to Evaluate Safety, Tolerability 
and Efficacy of IV and Oral Administration of Ganaxolone in Women with Postpartum Depression  
Design :  
This is a Phase 2, multicenter study in women with postpartum depression (PPD) consisting of 2 parts :  An Open 
Label Part  with multiple ascending dose s focused on safety and tolerability in 5 groups that differ by total daily 
dosing and formulation of study drug;  and a Double -blind P lacebo -controlled (DBPC) part focused on safety, 
tolerability and efficacy in one group .  The DBPC Part  will be gin after the Open Label Part dosin g is completed .  The 
dosing , treatment duration and timing of evaluations  for the double -blind portion of the study will be decided based 
on the results of the Open Label Part  and recommendations of the Data Review Committee (DRC).  The DRC is 
compr ised of Marinus’ Chief Medical Officer a nd 2 external physician experts.   
Figure 1-A and Figure 1-B depict the design for eac h subject group in the Open Label and DBPC  Parts, respectively.  
Number of subjects  and dose regimen fo r each tre atment arm :  
For the Open Label Part,  approximately 176 women aged 18 to 4 8 years with PPD will be screened to enroll 
approx imately 88 subject s.   
The first group (called open -label 3 times daily [ OL TID ]) of approximately 8 subject s will receive oral  ganaxolone  
(capsules)  titrated to a daily dose of 900 mg/day over 10 days, followed by a taper over 4 days.   
The second group ( called open -label administered at bedtime [ OL QHS ]) of approximately 20 subject s will receive  
oral ganaxolone  (capsules)  at bedtime  (QHS) , titrated to a dose of 675 mg QHS over 4 days and maintained until 
Day 10, followed by a taper over 4 days.  
The third group ( called OL QHS 4-week) of  approximately 20 subject s will be administered  oral ganaxolone  
(capsules)  at a dose of 675 mg QHS for 28 days, followed by a taper over 4 days.  
The fourth group (called OL 1,125 mg group) of approximately 20 subject s will receive  on the first 2 days, oral 
ganaxolone  capsules at a dose of 675 mg at approximately 7 pm (wi th dinner)  and 675 mg at 10 pm  (with a fatty 
snack) , followed by 26  days of gan axolone 1,125 mg at dinner time , and a taper over 4 days .  Approximately 6 
subjects will participate  in pharmacokinetics ( PK) collection that requires an overnight stay on Day 1.  
The fift h group (called OL Bolus -oral) of approximately 20 subjects will receive ganaxolone starting with a single 
intravenous ( IV) 12 mg bolus over 2 minutes  at approximately 4 pm of Day 1,  followed by ganaxolone oral 
suspension 750 mg at 6pm (with a fatty meal ), and 750 mg at 10pm  (with a fatty snack) .  On Day 2 , subjects will 
receive ganaxolone oral suspension 750 mg at dinner time and 750 mg at bedtime, followed by 26 days of 
ganaxolone oral suspension 1,000  mg at dinner time.  Treatment will then be taper ed over 4 days .  Approximately 6 
subjects will participate  in PK collection that requires an overnight stay on Day 1.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 14 of 131 Figure 1-A:  Design of Open -Label Part  
 
For DBPC  part, approximately 100 women with PPD aged 18 to 48 years will be screened to randomize 50 women in 
a 1:1 ratio to receive ganaxolone or matching placebo for 14 days .  The dosing , treatment duration and timing of 
evaluations  for the double -blind portion of the study will be decided based on the results of the Open Label Part  and 
recommendations of the DRC.  The total daily dose will not exceed 1,600  mg.  Randomization will be stratified by 
the use of concomitant antidepressant s so that the number of subject s who are treated with antidepressants and who 
are not treated with antidepressants will be similar in each treatment group .   
Figure 1-B:  Design of the Double -Blind Placebo -Controlled Part  
 
 
 
 
 
The investigator has the flexibility to adjust the dose  and/or timing  of the dose if the subject  experiences sedation, 
dizziness or other untoward effects in each dosing group , by reducing the dose first to a lower level and possibly 
increasing it later if tolerance develops to the untoward effects  (see Section 6.2.7 ). 
Site(s) and Region(s): Approximately 30 investigational sites in the United States  
Screening  
2 wks  
DB dosing  
2wk 
GNX n=25  
PLA n=25  
30 Day  
Follow -up 
Taper  
4 days  OL TID 
---------- ;---- ----------------- GNX n N 8 
I , C: Screen ing OL dosing 30 Day 
2 wk 2wk Follow -up 
OLQHS ---------- ,--------------------- GNX n N 20 
" I I 
2 wk 2wk 
OL QHS 4-week I 
30 Day 
Follow-up C: Screening OL dosing 
------- ---------- - - - - - - - GNX n N 20 
C: Scree ning 
2 wk OL dosing 
4wk 
OL Oral 1,125 mg ---------- ----- ----
OL dosing 
4wk C: Screening 
2 wk 
OL IV Bolus-Oral ., 
---------- ----- ----
Screening 
2 wk ,, 
OL dosing 
4wk l T 
6week 
F ollow-up 
y 
6week 
Follow-up y 
3 month 
F ollow-up 
- • GNXnN20 
• GNX n N 20 
I 
~----------------
-----------.___I -
-------------· 
''-------.,---,''1...--~,---''L...,-J ''-------~,-----___,• Dosing; 
On days 1 and 2: 
PO 675 mg at dinner time and 
675 mg at bedtime 
1,125 mg with dinner days 3-28; 
Taper: days 29-32 
Dosing: 
IV bolus 12 mg/2 min on day 1 at N4 pm 
PO 750 mg at dinner time and 
750 mg at bedtime on days 1 and 2 
1000 mg with dinner on days 3-28; 
Taper: days 29-32 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 15 of 131 Study period (planned):  
September 2017 to June 2019 Clinical phase:   Phase 2  
Objectives :  
Open -Label Part:  Safety , dosing, efficacy  and pharmacokinetics  
1. To assess the safety and tolerability of ganaxolone in women with PPD as det ermined by adverse events (AEs), 
changes from baseline in laboratory measures, vital signs, Columbia Suicide Severit y Rating Scale (CSSRS), 
electrocardiogram (ECG), Stanford Sleepiness Scale (SSS), and physical examination.  
2. To develop an optimal dosing regimen for the double -blind part.  Adverse events and other safety data, including 
sedation and dosing changes  will be adjudicated by the DRC before proceeding to the double -blind part of the 
study.   
3. To assess the efficacy of ganaxolone using the Hamilton Depression Rating Scale 17 -item version (HAMD17), 
Edinburgh Postnatal Depression Scale (EPDS), Spielberger St ate-Trait Anxiety Inventory 6 -item version 
(STAI6) and Clinical Global Impression -Severity and Improvement (CGI -S and CGI -I) scales.  
4. To collect samples of blood for PK analysis after administration of oral and IV ganaxolone to use in 
population -PK analyses, the results of which will be reported separately by the Sponsor.  
Double -Blind placebo controlled (DBPC) Part:  Safety, efficacy, and pharmacokinetics  
Safety objective:  To assess the safety and tolerability of ganaxolone vs placebo in women with PPD as determined 
by AEs and changes from baseline in laboratory measures, vital signs, CSSRS , ECG , SSS, and physical examination.   
Efficacy objective:   To assess the efficacy of  ganaxolone vs placebo using the HAMD17 , EPDS, STAI6 and CGI-S 
and CGI-I scale s.  
The primary efficacy  variable  in this study is  change from baseline in the HAMD17 total score on Day 10 of the 
DBPC part between ganaxolone and matching placebo.   
Pharmacokinetic objective:   To collect samples of blood for  PK analys es after administration of oral ganaxolone  to 
use in population -PK analyses, the results of which will be reported separately by the Sponsor.  
Rationale:  Rapidly declining plasma levels of allopregnanolone and other neurosteroids after childbirth are thought 
to be linked to triggering depression in women who are vulnerable to develop this condition.  Ganaxolone, a synthetic 
analog of allopregnanolone, may provide benefit to these women.  This study is intended to test the safety and 
efficacy of ganaxolone in the treatment of PPD.  
Investigational product, dose, and mode of administration:  Ganaxolone  IV, oral suspension, and  oral capsule 
(225 mg /capsule ) formulations and matching placebo will be used.   
Inclusion Criteria:  
1. An understanding of and ability, and willingness to fully comply with study procedures and restrictions.  
2. Ability to voluntarily provide written, signed, and dated informed consent as applicable to participate in the 
study.  
3. Female aged 18 to 48 years inclusive, at the Screening Visit  
4. Experiencing a major depressive episode, which started between the start of the third trimester and 4  weeks 
following delivery.  The major depressive episode must be diagnosed according to  Mini International 
Neuropsychiatric Interview (MINI) 7.0 interview  
5. Given birth in the last 12 months  
6. HAMD17 score of ≥ 20 at screening rated by a certified site rater.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 16 of 131 7. HAMD17 ≥ 18 (rated by CTNI) on Day 1 prior to study drug administration   
8. The diagnosis  of PPD and severity of depression must be supported by the State versus trait; Assessability; Face 
validity; Ecological Validity; and Rule of 3 Ps (SAFER) interview  
9. Must agree to stop breastfeeding from start of study treatment until 45 days after receivi ng the last dose of the 
study drug  
10. Must agree to use acceptable contraceptive methods during the study period  
11. Must have a reliable family member , significant other or a trusted friend who can take a role as the primary 
childcare provider and support person  at home (including during the night ) while the subject  is participating in 
the trial  
Exclusion Criteria  
1. Current or past history of any psychotic illness, including major depressive episode with psychotic features  
2. Any psychiatric condition that, in the inv estigator’s judgment, is considered clinically significant and could 
affect subject safety or study outcome including eating disorder, panic disorder, obsessive -compulsive disorder, 
or post-traumatic stress disorder  
3. History of suicide attempt within the pa st 3 years  
4. Active suicidal ideation ( e.g., answering “yes” to questions 4 or 5 in the CSSRS suicidal ideation section)  
5. History of severe bipolar I disorder  (e.g. hospitalization due to the illness, lifetime history of psychosis or suicide 
attempt).  
6. Uncontrolled seizure disorder  
7. Current or history within the past 3 years of alcohol or any substance use disorder, with the exception of tobacco 
or caffeine  
8. Positive drug screen for any illicit substances or prescription drugs at screening or randomizatio n.  If the drug 
screen is positive for a prescription drug that has the potential to be abused ( e.g., amphetamine, benzodiazepine), 
legitimate use of the drug must be verified by the subject’s providing the current pill bottle, prescription for the 
drug, o r a note from the prescribing physician.  Cannabis use is prohibited, and subjects with positive drug screen 
for cannabis are excluded .  However, occasional users of cannabis may be re -tested  after 5 days  if the subject  is 
willing to refrain from consuming  cannabis -based products during the trial.  If the re -test sample is negative at 
screening , the subject  can be considered eligible.   If the re -test sample is positive for cannabis , the investigator 
may ask for determination of blood levels of ∆9 -tetrahydro cannabinol (THC), and its  metabolites 11 -hydroxy -
THC and  9-carboxy -THC.  If THC is not detectable , the subject is eligible for the trial.   
9. Current or relevant history of any medical disorder that may require treatment or make the subject unlikely to be 
able to complete the study, or any condition that presents undue risk from the investigational product or 
procedure point of view  
10. Any clinically significant abnormality identified on physical examination, ECG, or laboratory tests that in the 
judgment of the investigator would compromise the subject’s safety or successful participation in the clinical 
study  
11. Subject has untreated or uncontrolled hypothyroidism  
12. Known or suspected intolerance or hypersensitivity to the investigational product(s) or allopregnanolone, or any 
of the stated ingredients  
13. Use of another investigational product within 60 days prior to the first dose of investigational product  
14. Has alanine transferase (ALT) or aspartate transferase (AST) greater than 2.5 times upper limit of normal or total 
bilirubin greater than 1.5 times upper limit of normal (unless elevation is due to Gilbert’s syndrome)  
15. Screening QT interval Fridericia’s correction (QTcF) > 470 msec  
16. Unwillingness to withhold grapefruit, Seville oranges, star fruit, or concentrated citrus derived products from diet 
between screening and last on-treatment visit  
17. Receiving concomitant treatment with strong cytochrome P (CYP)3A4 inducers or strong CYP3A4 inhibitors  
18. Body mass index (BMI) ≥ 40 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 17 of 131 19. Subject is pregnant  
20. Subject is using prohibited medications as specified in Section 5.3.2  
Maximum duration of subject involvement in the study :  Approximately 7  weeks  for the OL TID and OL QHS 
groups and the DBPC part.  The duration for the OL QHS 4 -week group is approximately 18 weeks  and the duration 
for the OL 1,125 mg and OL Bolus -oral group s is approximately 12 weeks.   
Key variables : 
Safety:   Adverse events, laboratory measures, vital signs, CSSRS, ECG, SSS, and physical examination.  
Efficacy:   HAMD17 , EPDS , STAI6, CGI-I and CGI-S scale s. 
Pharmacokinetics:  For the OL TID and OL QHS groups , a total of 5 samples of blood will be collected to 
determine ganaxolon e plasma concentrations during the study .  Samples will be collected on 3 occasions during 
treatment with ganaxolone to determine trough concentrations in plasma .  An additional 2 samples of blood will be 
collected at follow up visits, after ganaxolone treatment has been completed, to monitor the disappearance of 
ganaxolone following cessation of treatment.   For the OL QHS 4 -week , OL 1,125 mg,  and OL Bolus -oral group s, 
6 samples of  blood will be collected to determine ganaxolone plasma concentrations during the study.  Samples will 
be collected on 4 occasions during treatment in the OL QHS 4 weeks group and on 5 occasions during treatment in 
the OL 1,125 mg and OL Bolus -oral groups to determine ganaxolone trough concentrations in plasma.  Two 
additional sample s of blood  will be collected in the first  2 follow up visits in the OL QHS 4 weeks group and 
1 additional sample will be collected  in the  OL 1,125 mg, and OL  Bolus -oral group s at the first follow up visit after 
ganaxolone treatment has been completed, to monitor the disappearance of ganaxolone following cessation of 
treatment.  
Statistical Methods:   Data will be presented by study part (OL, DBPC), dosing or treatment group within study parts 
and if applicable, study visit.  Continuous variables will be summarized as numbers of observations, means, measures 
of variance (e.g., standard deviation), and percentiles (e.g., median, minimum, m aximum).  Categorical variables will 
be summarized as numbers of observations and percentages.  
Analysis Populations :  The Screened Set will consist of all subjects who have signed an informed consent.  The 
Randomized Set will consist of subjects randomized  in the DBPC part of the trial.  The Safety Set will consist of all 
subjects who received investigational product ( IP).  The modified Intent to Treat (mITT) Set will consist of all 
subjects in the DBPC part of the trial who received IP , and who have at lea st 1 post-baseline HAMD17 assessment.  
The Per -Protocol Set will consist of all subjects in the mITT set who do not have major protocol deviations that may 
affect key efficacy endpoints.  
Efficacy Analysis :  Efficacy parameters will be summarized for both t he OL and DBPC parts, but will be analyzed 
only for the DBPC part.  The primary time point of interest for all efficacy parameters will be Day  10 for the DBPC 
part and the visit at end of treatment (before initiation of taper) for the OL part.  The primary  efficacy endpoint will 
be change from baseline in HAMD17 total score at Day 10 for the DBPC part and at the visit at end of treatment for 
the OL part.  The primary efficacy analysis will be done using the mITT set (DBPC group only), and the analytical 
method will be mixed model repeated measures (MMRM) with baseline HAMD17 total score as a covariate.  
Significance will be tested at a two -sided 0.05 level.  
Secondary efficacy endpoints will be change from baseline in HAMD17 total score other than at the primary endpoint 
time point, HAMD17 response defined as at least a 50% reduction from baseline in total score, HAMD17 remission 
defined as total score <  = 7, change from baseline in EPDS total score, change from baseline in STAI6, and 
CGI-Improvement.   
  
 
 
 

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 18 of 131 1 BACKGROUND INFORMATION 
1.1 Postpartum Depression (P PD) 
Postpartum depression (PPD) is a mood disorder that occurs in about 7% of women following 
the birth of a child.1  Common symp
toms include feelings of extreme sadness, hopelessness, 
suicidal ideation, anxiety
, and fatigue, which mirror those of a major depressive episode with the 
additional criteria that the onset of depression occurs within 4 weeks of childbirth.  PPD can 
affect a mother’s ability to care for her child and may negatively affect a child’s cognitive 
development.2  
Rapid changes in the l
evels of endogenous neurosteroids during pregnancy are thought to be 
related to the development of PPD.  Plasma levels of allopregnanolone, which is a metabolite of 
progesterone and an endogenous gamma-aminobutyric acid ( GABA) receptor modulator, are 
known to increase throughout pregnancy and then precipitously drop 
after delivery.3, 4  It is 
thought that these rapid hormonal
 changes are linked to triggering depression in women who are 
vulnerable to develop this condition.  Serot
onin selective reuptake inhibitors (SSRIs) are known 
to increase allopregnanolone, and i
t has been suggested that this mechanism could explain why 
SSRIs have shown therapeutic effect in the treatment of PPD.5  There have been a limited 
number of placebo
-controlled randomized clinical trials testing the efficacy of SSRIs, or any 
other medication, in the treatment of PPD.6,5 
Data were recently published that demonstrated that a continuous infusion of allopregnanolone 
rapidly alleviates symptoms of depression in women with PPD.7  In this open-label study, 
4 women with severe PPD received a 60-hour infusion of allopregnanolone.  The mean 
Hamilton Depression Rating 
Scale for Depression (HAMD) before the infusion was 26.5, 
indicating that the women were 
severe ly depressed.  Mean HAMD total score showed robust 
reductions even at the earliest 
time point measured (Mean HAMD 4.8 at Hour 12) and remained 
substantially lower through the
 end of infusion (Mean HAMD 3.3 at Hour 24, 1.8 at Hour 36, 
2.3 at Hour 48, and 1.8 at Hour 60).  Other end points showed similar improvements.  
1.2 Product Background and Clinical Information 
Ganaxolone 
is the 3 -methylated synthetic analog of the progesterone metabolite 
allopregnanolone.  Allopregnanolone exhibits potent anxiolytic, antidepressant, antiepileptic, and 
sedative activity by virtue of its GABA A receptor modulating properties.  As with 
allopregnanolone, ganaxolone pote
ntiation of the GABA A receptor occurs at a site distinct from 
the benzodiazepine site.  However
, unlike allopregnanolone, ganaxolone cannot be converted to 
a hormonally active steroid.8  Ganaxolone has been studied in completed and ongoing clinical 
trials in healthy adults, adult subjects with e
pilepsy, adults with post-traumatic stress disorder 
(PTSD ), adults with migraine, children with refractory epilepsy and seizure disorders including 
female pediatric subjects with protocadherin 19 (PCDH19) epilepsy, and children with Fragile X 
Syndrome.   
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 19 of 131 1.2.1 Ganaxolone:  Oral Administration 
As of
  approximately 1,588 unique subjects have received treatment with 
ganaxolone oral formulations in ong
oing and completed clinical trials ranging in duration from 
1 day to more than 2 years, using doses from 50 to 2,000 mg/day.  Of these, 1,148 unique 
subjects have received ganaxolone ora
l formulation in completed studies.  In 19 completed 
Phase 1 studies, 289 healthy subjects received 
ganaxolone orally at doses of 50 to 2,000 mg/day 
for periods of up to 2 weeks.  Ganaxolone when given at doses 1,000 m
g BID to healthy 
volunteers resulted in average C max and C min concentrations of 262 ng/ml and 57 ng/ ml.  
In the 18 completed Phase 2 clinical studies, 859 unique
 subjects have received oral ganaxolone 
at doses up to 1,500 mg/day including 169 adult subjects with epilepsy, 135 pediatric subjects 
with seizure disorders, 59  pediatric subjects with Fragile X syndrome, 393 adult subjects with 
m
igraine, and 103 subjects with PTSD . 
In clinical trials of ganaxolone, adverse events 
(AEs) related to the GABAergic mechanism of 
action such as dizziness, 
sedation and sedation-related AEs (fatigue, somnolence), ataxia and 
diplopia, were reported more commonly in subjects receiving ganaxolone than placebo.  In 
general, the frequency of these events 
was dose related.  Most of these effects were reported as 
mild or moderate in severity and were reversible after dose decrease or drug discontinuation.  
In the largest clinical trial conducted so  far, Study 1042-0603, a Phase 3 trial of ganaxolone in 
adults with drug-refractory partial o
nset seizures, the safety profile of ganaxolone was consistent 
with previously conducted studies.  In the double-blind portion of this study, 359 subjects were 
randomized to receive oral ganaxolone (900 mg twice a day) or placebo for 14 weeks.  Overall, 
ganaxolone was generally safe and well tolera
ted with no imbalance between the ganaxolone and 
placebo group in the number of subjects with serious adverse events (SAEs) (5% vs 5.1%).  The 
most common AEs (>  5%) reported at greater rates than placebo were somnolence (23.5% vs 
4.5%)
, dizziness (19.6% vs 4.5%), and fatigue (11.7% vs 6.8%).  Most of these AEs were rated 
as mild in severity.  There were 44 (
25%) subjects treated with ganaxolone that discontinued the 
study compared with 26 (14%) sub
jects on placebo.  The most common reason for 
discontinuation was AE.  Nine subjects experien
ced SAEs in placebo and ganaxolone groups 
each.  
In the ganaxolone developm
ent program overall, no clinically significant trends in 
electrocardiogram (ECG) intervals, vital signs, or physical or neurological examinations have 
been noted, and no mean changes from baseline in clinical laboratory results have been 
identified.  Overall, there have been only a few clinically significant individual changes from 
baseline in clinical laboratory measurements in clinical trials of ganaxolone.  In the completed 
placebo-controlled Phase 1, 2 and 3 studies, 0.32% of subjects treated with ganaxolone and 
0.31% of subjects treated with placebo exhibited elevated liver function tests during the study 
(> 3 times the upper limit of normal [ULN] aspartate aminotransferase [AST] and/or alanine 
am
inotransferase [ALT]).  There have been no cases of Hy’s Law in the ganaxolone 
development program.  In controlled clinical trials of ganaxolone, 1.1% of subjects receiving 
placebo and 2.0% of subjects receiving 
ganaxolone reported an AE of rash or papular rash.  Most 
rashes improved either while the drug was continued or following discontinuation.  Two subjects 

IND No. 135256 
Protocol 1042 -PPD -2003 Marinus Phrumaceuticals , Inc. 
Version 5.0 / 22 Oct 2018 
paiiicipat ing in the Phase 2 study investigat ing ganaxolo ne in treatment of epilepsy developed an 
SAE of rash. Both events resolved after disco ntinu ation of the study diug. 
It is not known if ganaxolo ne is excreted in breast milk. After cessatio n of the infusion, p lasma 
ganaxolone levels are expecte d to di· op rapidly, but it is possib le that low sub-th erapeutic levels 
persist for severa l days as ganaxolone is slowly released from tissues. Therefore , a washout 
period of 45 days is required following cessat ion of ganaxolone ti·eatme nt before breast -feeding. 
Previous toxico logy studies in animals focusing on pr enata l and neonata l deve lopment h ave not 
demonstrated toxicities associated with ganaxolo ne. Ganaxolo ne has been admini stered orally to 
infants with severe fonns of epilepsy as early as 4 months of age. 
In clinical trials involving admin isti·atio n of oral ganaxo lone over several weeks , the study diug 
has been taper ed off over a 1 to 2-week period. There have been no repo1is of with drawa l 
symptoms emerging after cessatio n of ganaxolo ne. 
1.2.2 Ganaxolone: Intra venou s Admini stration 
Preclinical studies and a study in 36 healthy volunteers assess ing safety, phaimacokinetics (PK), 
and phannacody nainics of inti·aveno usly (IV) admini stere d ganaxolo ne have been completed . 
Preclin ical toxicity studies showed IV anaxolo ne to be enerall safe and AEs consistent with 
ex ected dose -related sedat ion. 
There was no evide nce of local initation when ganaxolone was given intra-or 
penveno us y in preclinical studies. Fmthen nore, IV ganaxolone did not cause hemolysis and 
was compatible with human plasma. 
Six subjects repo1ied ti·eatment emer gent AEs in Stage 1 and 2. No single AE was seen twice. 
Only 1 event (headac he) was considered by the investigato r to be related to ganaxolo ne. None of 
the ti·eatment emer gent AEs were serious, and all were of mild intensity. No clinically 
meaningful mean chan ges in laborato1 y test results, vital signs , or E CG parameters occw-red in 
any cohort. 
Confidential Page 20 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 21 of 131 Pharmacokinetic data from Study 1042-0405 showed that a bolus infusion of 30 mg ganaxolone 
over 5-minutes
 led to peak concentration levels (Cmax) of > 1,000 ng/ml with no safety concerns.  
Infusion of 30 mg/h for 1 hour and 20 mg/h for 4 hours
 led to concentrations of 258 and 
215 ng/mL respectively, again without any safety concerns.  This is consistent with findings 
from previous studies with
 the oral formulation of ganaxolone, in which C max levels of up to 
200 to 300 ng/mL were commonly observed and were not associated with major safety findings 
or toxicity (apart from
 sedation-related effects) .   
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 22 of 131 2 STUDY OBJECTIVES AND PURPOSE 
2.1 Rationale for the Study 
Rapidly declining plasma levels of allopregnanolone and other neurosteroids after childbirth are 
thought to be linked to trigge
ring depression in women who are vulnerable to development of 
this condition.  Ganaxolone, a synthetic analog of allopregnanolone, may provide benefit to these 
women.  This study is intended to explore the safety and efficacy of ganaxolone in women with 
PPD.  
2.2 Study Objectives 
2.2.1 Objectives 
of the Open-label Safety Part 
2.2.1.1  Safety Objective 
To assess the safety and tolerability of ganaxolone in women with PPD as determined by AEs 
and changes from baseline in laboratory measures, vital signs, Columbia Suicide Severity Rating 
Scale (CSSRS), electrocardiogram (ECG), Stanford Sleepiness Scale (SSS), and physical 
examination.  
2.2.1.2 Dosing Objective  
To devel
op an optimal dosing regimen for the double-blind placebo-controlled (DBPC) part of 
the study.  Adverse events and other safety data, including sedation and dosing changes, will be 
adjudicated by the Data Review Committee (DRC) before proceeding to the DBPC part of the 
study.   
2.2.1.3 Efficacy Objective 
To assess the efficacy of ganaxol
one using the Hamilton Depression Rating Scale 17-item 
version (HAMD17), Edinburgh Postnatal Depression Scale (EPDS), Spielberger State-Trait 
Anxiety Inventory 6-item version (STAI6) and Clinical Global Impression-Severity and 
Improvement (CGI-S and CGI-I) scales.  
2.2.1.4  Pharmacokinetic Objective 
To collect samples of blood for pharmacokinetic (PK) analysis after administration of oral and 
IV ganaxolone to use in population- PK analyses, the results of which will be reported separately 
by the Sponsor. 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 23 of 131 2.2.2 Objectives of the Double-blind Part  
2.2.3
 Efficacy Objective  
To assess the efficacy of ganaxol
one vs placebo using the HAMD17, EPDS, STAI6, CGI-S and 
CGI-I scales.  
The prim
ary efficacy  variabl
e in this study is  change from baseline in the HAMD17 total score 
on Day 10 of the DBPC part between ganaxolone and placebo.  
2.2.4 Safety Objective 
To assess the safety and tolerability of ganaxolone vs placebo in women with PPD as determined 
by AEs and changes from baseline in laboratory measures, vital signs, CSSRS, ECG, SSS, and 
physical examination.   
2.2.5 Pharmacokinetic Objective  
To collect sa
mples of blood for PK analysis after administration of oral doses of ganaxolone.  
Pharmacokinetics samples will be collected from the subjects participating in the open-label and 
DBPC parts of the study. 
 These data may be combined with data from other studies for 
population- PK analyses.  If such analyses a
re conducted, they will be reported separately by the 
Sponsor. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 24 of 131 3 STUDY DESIGN 
3.1 Study Design and Study Population 
This is a Phase 2, multicenter study in women with PPD consisting of 2 dosing parts: an initial 
open-label safety 
part, and a DBPC part.   
The investigator has the 
flexibility to adjust the dose amount and/or timing of dosing if the 
subject experiences untoward effects during the open-label part, by reducing the dose first to a 
lower level and possibly increasing it later, if tolerance to the untoward effects develops. 
Enrollment and dosing will be completed in the open-label safety part before proceeding to the 
DBPC part.  The goal of the open-label part is to explore the safety of IV and oral ganaxolone in 
this population, and identify a dosing regimen for the DBPC part.   
Open-label Part 
For the open-
label safety part, approximately 172 women aged 18 to 48 years with PPD will be 
screened to enroll appr
oximately 88 subjects.    
In the first group with approxi
mately 8 subjects, ganaxolone will be titrated to a daily dose of 
900 mg/day over 10 days, followed by a taper over 4 days.  This dosing group is called the 
open-label 3 times daily (OL TID) group.  
The second group with approxim
ately 20 subject s will receive ganaxolone adm inistered at 
bedtime (QHS).  For these subjects, ganaxolone will be titrated to a QHS dose of 675 mg over 
4 days, which is then maintained until Day 10, followed by a taper over 4 days.  This dosing 
group is called the OL QHS group
.   
The third group with approximately 20 subjects will receive ganaxol one administered at a dose 
of 675 mg QHS for 28 days, followed by a taper over 4 days.  This dosing group is called the 
OL QHS 4-week dosing group. 
The fourth group with approximately 20 subjects will receive on the first 2 days, ganaxolone 
capsules 675 mg at dinner time and 675 mg at bedtime (for a total of 1,350 mg per day on the 
first 2 days), followed by 26 days of ganaxolone capsules 1,125 mg at dinner time (high fat diet), 
and a taper over 4 days.  This dosing group is called the OL 1,125 mg group.  
The fifth group with approximately 20 subjects will receive ganaxolone as IV 12 mg bolus over 
2 minutes at approximately 4 pm of the first day, followed by ganaxolone oral suspension 
750 mg at dinner time (high fat diet), and 750 mg at bedtime (with a high fat snack) for a total of 
1,512 
mg on D ay 1.  On Day 2, subjects will receive ganaxolone oral suspension 750 mg at 
dinner time and 750 mg at bedtime, for a total of 1,500 mg, followed by 26 days of ganaxolone 
oral suspension 1,000 mg at dinner time and a taper over 4 days. This dosing group is called the 
OL Bolus-oral group.  
 
IND No. 135256 
Protocol 1042 -PPD -2003 
Double -blind Placebo -controlled Part Marinus Phrumaceuticals , Inc. 
Version 5.0 / 22 Oct 2018 
For the DBP C part , approximately 100 women with PPD aged 18 to 48 years will be screened to 
randomize 50 women in a 1: 1 ratio to receive ganaxolone or matching placebo for 14 days . 
3.2 Rationale for Study Design 
Rapid changes in allopregnanolo ne and other ne urostero id levels during and after pregnancy are 
thought to contribute to the biological underpinnin gs of PPD. There are also data suggest ing that 
the sensitivity of the GABA syste m is altered during pregna ncy and after childbirth, possib ly as a 
result of chan ges in the circulating neurosteroi d levels, and th at there may be a state of 
neurosteroid withdrawal after pregnancy.9 Ganaxolo ne m ay alleviate PPD by increasing 
neurosteroid activity. 
A pr evious study with IV allopregna nolone showed that allopregnano lone has the potential to 
produce a rapid and robust antide pressant activity .7 We hypothesize that a similar antidepressant 
activity may be obtained with IV and oral ganaxolo ne. 
Although ganaxolone h as been administered to more than 1, 500 subjects, there have been no 
previo us studies exploring the safety or efficacy of ganaxolo ne in PPD or other mood disorders 
m wome n. 
Various dose amounts, fonnulations, dosing schemes and treatme nt duratio ns will be eva luated 
in the Open -label pa1 t to infonn the ch oice of the tr eatme nt scheme for the DBPC pa1t. 
Approximately 8 or 20 subjects , depe nding on the group , will receive open-label ganaxolone to 
evaluate safety, tolerabi lity, kinetics and efficacy of the d rng in wome n diagnose d with PPD. 
Assessme nts of AEs, laborato 1 y , E CG, and clinical ratings for safety and efficacy will be 
gathered to evaluate the possib le differe ntial effect of the various dosing schemes. 
A double-blind evaluation of safety and efficacy will follow the completion of the ope n-label 
pait. This study pait will utilize a randomized , parallel -group, p lacebo -controlled design in 
wome n diagnosed with PPD. Evaluations of safety and tolerabi lity, as well as efficacy will 
utilize the same evaluation m ethods as in the ope n-label pait. The prim aiy efficacy endpo int will 
be change from basel ine in HAMD -17 of active vs placebo treatme nts. The concomita nt use of 
antidepressants or no use of antidepressants will be stratified 1: 1 to emoll similar numbers of 
subjects in each strntum for both the ganaxolone and placebo treatme nt groups. 
Confidential Page 25 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 26 of 131 3.3 Dose Selection  
Allopregnanolone levels increase gradually throughout pregnancy reaching peak mean 
concentrations at the end of pregnancy of about 15 to 60 ng/ml.  The levels then drop 
precipitously after deliv
ery.3, 4, 10  We hypothesize that substitution of the low allopregnanolone 
levels with ganaxolone would alleviate 
or reverse the symptoms of PPD.  The target trough 
ganaxolone exposure level of approximatel
y 50 ng/ml was chosen to achieve a level similar to 
that of allopregnanolone at the end of pregnancy.   
Open-label TID dosing group  
Ganaxolone doses are titrated for the OL TID dosing group from 225 mg on Day 1 to a daily 
dose of 900 mg starting on Day 7.  Previous studies have shown that the sedating effects of 
ganaxolone may be minimiz
ed via dose titration.  
With the proposed dosing regimen for the OL TID dosing group, the ganaxolone mean trough 
and peak plasma concentrations during the
 Days 8, 9, and 10 are predicted to fluctuate between 
40 ng/ml and 100 ng/ml respectively, based on PK modelling.  This dose ra nge is considered to 
provide adequate ganaxolone plasma exposure from the point of view of testing whether the dose 
range of 50 to 60 ng/ml is necessary for alleviating the symptoms of PPD.  Based on the previous 
ganaxolone studies, plasm
a levels below 100 ng/ml have not been sedating in most subjects.  
The bedtime doses for the OL T
ID dosing group are selected to be higher than the daytime doses, 
and are expected to y
ield plasma mean peak concentrations up to 180 ng/ml during the night on 
Days 8, 9 and 10.  These levels may be sedating in some subjects.  Since disrupted sleep is a 
hallmark of depression, the pot
ential sleep promoting effect of ganaxolone may in fact be 
beneficial.  
Approximately 8 subjects
 will be allocated for the OL TID group.   
Open-label QHS dosing group 
 
A QHS dosing group is included in the open-label part to explore whether QHS dosing only is 
well-tolerated and shows comparable therapeutic effect to the TID dosing.  In the QHS dosing 
group,  the trough ganaxolone levels are expected to be below 40 ng/ml.  However, constant 
plasma exposures may not be necessary for antidepressant effect but the therapeutic efficacy 
under this dosing scenario could arise via other mechanisms, such as modulation of sleep 
architecture.  
Approximately 20  subjects will be allocated to the OL QHS group.  The enrollment for the OL 
QHS group will start after all subjects allocated to the OL TID group have started their dosing.  
Open-label QHS 4-
week dosing group  
A QHS 4-week dosing group is included in the open-label part to explore whether administering 
ganaxolone at 675 mg QHS is well-tolerated and shows sustained therapeutic effect over 
4-weeks of dosing, and whether the therapeutic effects are maintained over a 3-month follow-up 
period.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 27 of 131 Approximately 20 subjects will be allocated to the OL QHS 4-week dosing group.  The 
enrollment for the OL QHS 4-week group will start after all subject s allocated to the OL QHS 
group have started their dosing.  
Open-label 1,125 mg dosing group  
The OL 1,125 mg dosing group is included in the open-label part to explore whether 
administering ganaxolone orally at doses up to 1,125 mg per day over 4 weeks (including 
1,350 mg in the first 2 days) are safe and well-tolerated and show sustained effects, and whether 
the therapeutic effects are m
aintained over a 6-week follow-up period.  
The two evening 675 mg oral doses, within 3 hours of each other on Day 1 are ex pected to 
provide mean C max plasma conc
entrations of approximately 250-300 ng/mL, which may be 
mildly sedating.  Twin evening dos
ing on Day 2 is expected to lead to similar exposure.  In 
previous studies, ganaxo
lone has been given up to a daily dose of 2000 mg, and at single doses 
of 1000 mg.  Based on previous experie
nce, this dose is expected to be safe.  
 
Approximately 20 subjects will be a
llocated to the OL 1,125 mg dosing group.  The enrollment 
for the OL 1,125 mg group will start 
after all subject s allocated to the OL QHS 4-week group 
have started their dosing.  
Open-label IV Bolus-oral dosing group  
The OL IV Bolus-oral  dosing group is included in the open-label part to explore whether 
administering IV 12 mg ganaxolone bolus followed by oral suspension dosing of up to 1,000 mg 
per day (including up to 1,500 mg in the first 2 days)
 is safe and well-tolerated, and shows 
sustained therapeutic e
ffect over 4 weeks of dosing, and whether the therapeutic effects are 
maintained over a 6-
week follow-up period.  
This initial bolus infusion is targeted to provide a fast onset of antidepressant activity by delivery 
of rapid plasma exposures to ganaxolone.  Together with the two evening 750 mg oral doses 
within 3 hours of each other, Day 1 dosi
ng is expected to provide mean C max plasma 
concentra
tions of approximat
ely 250-300 ng/mL, which may be mildly sedating.  Twin evening 
dosing on Day 2 is expected t
o lead to similar exposure.  In previous studies, ganaxolone has 
been given up to a daily dose of 2,000 mg, and at single doses of 1,000 mg.  Based on previous 
experience, this dose is expected to be safe.   
 
Approxim
ately 20 subjects will be allocated to the OL Bolus-oral dosing group.  The enrollment 
for the OL Bolus-oral group will sta
rt after all subjects allocated to the OL 1,125 mg group have 
started their dosing.  
Dose Justificat
ion in the Context of Previous Experience with IV Ganaxolone 
In Study 1042-0405, a completed Phase 1 study in healthy volunteers investigating the safety of 
IV ganaxolone, the highest bolus dose tested was 30  mg, which was infused over 5 minutes (the 
same rate [6 mg/min]  as in the OL Bolus-o ral group).  This dose led to peak concentration levels 
(Cmax) of > 1,000 ng/mL, with no safety concerns (except sedation).  This safety profile is 
consistent with findings from pre
vious studies with the oral formulation of ganaxolone, where 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 28 of 131 Cmax levels of up to 200 to 300 ng/mL were commonly observed and were not associated with 
major safety findings or toxicity (apart from
 sedation-related effects) .  
Double-blind Placebo-c
ontrolled (DBPC) Part 
For the DBPC part of the study,  the targeted ganaxolone plasma concentrations and the final 
dosing formulations will be determined based on the safety and efficacy results of the open-label 
safety data ( Section 3.5) .  Additional information for the dose-selection for the DBPC part may 
be obtained from the ongoing phas
e 2A study in PPD with the ganaxolone IV formulation 
(conducted under IND No. 106104).  
Blinding Schem
e 
Subjects will be randomized to ganaxolone or placebo in a 1:1 ratio.  The randomization scheme 
will be prepared by an independent third-party vendor.  Treatment assignments will be obtained 
by the investigator (or designee)
 via an Interactive Voice and/or Web Response System (IxRS).  
The placebo infusion and placebo capsules are identical to the ganaxolone infusion and capsules, 
respectively, in their appearance.  An unblinded study pharmacist at the investigative site will 
prepare the ganaxolone and placebo IV solutions and allocate capsule supply for the DBPC part.  
Members of the DRC will be
 unblinded.  All other study personnel, including persons involved 
in the evaluation of the s
tudy subjects (e.g., investigators, sub-investigators, and 
physicians/nurses), with the excepti
on of the study pharmacist, will remain blinded at all times, 
except in case of an emergency.  Subjects will be blinded.   
3.4 Study Duration  
For both the open-label safety OL TID and OL QHS groups, and the DBPC part of the study, the 
screening period will be up to 2 weeks, followed by a 14-day outpatient 
treatment period and a 
14-day follow-up period.  For the OL QHS 4-week dosing group, the screening period will be up 
to 2 weeks, followed by a 28-day outpatient treatm
ent period, a 4-day taper and a 3-month 
follow-up period.  For the OL 1,125 mg and OL Bolus-Oral dosing groups,the screening period 
of up to 2 weeks will be followed by a 28-
day outpatient treatment period, a 4-day taper, and a 
6-week follow-up period (from Day 29). 
3.5 Planned Analyses 
3.5.1 A
nalysis After Completion of the Open Label Part  
At the completion of the open-label part, adverse events and other safety data, including sedation 
and dosing changes, will be adjudicated by the DRC before proceeding to the DBPC part of the 
study.  These data will be used to determine the dosing regimen for the DBPC part.   
3.5.2 Analyses After Completion of the Double-blind Placebo-controlled Part 
After completion of the DB
PC part, the data will be evaluated by an independent DRC.  Based 
on the analysis and recommendation by t
he DRC , the study may be closed at that point, or an 
additional approximately 50 women with PPD will be treated with ganaxolone or placebo under 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 29 of 131 a similar study design but using a different dosing regimen.  The daily dose may be lowered, 
increased, or the previous dosing ma
y be repeated.   
3.6 Definition of Completion   
A dosing group is considered complete when the final subject in the group has completed the 
final protocol-defined assessment, including follow-up visits for the group. 
 
The Study Completion Dat
e is defined as the date the final subject, across all sites, completes her 
final protocol-defined assessment s for the DBPC part, and includes all follow-up visits.  
3.7 Sites and Regions 
The study will b
e conducted in the United States at approximately 30 investigational sites.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 30 of 131 4 STUDY POPULATION 
Each subject must participate in the informed consent process and provide written informed 
consent before any procedures specified in the protocol are performed. 
4.1 Inclusion Criteria 
The subject will not be considered eligible for the study without meeting all of the criteria below: 
1. An underst anding of and ability, and willingness to fully comply with study procedures and 
restrictions.  
2. Ability to voluntarily provide written, signed, and dated informed consent as applicable to 
participate in the study. 
3. Female aged 18 to 48 years, inclusive, at the Screening Visit 
4. Experiencing 
a major depressive episode, which started between the start of the third 
trimester and 4 weeks following deli
very.  The major depressive episode must be diagnosed 
according to Mini I
nternational Neuropsychiatric Interview (MINI) 7.0 interview  
5. Given birth in the last 12 months 
6. HAMD17 score of ≥  20 at  screening rated by a certified site rater 
7. HAMD17 ≥ 18 on Day 1 prior to study drug administrat
ion  
8. The diagnosis of PPD and severity of depression must be suppor
ted by the State versus trait; 
Assessability; Face validity; Ecological Validity; and Rule of 3 Ps (SAFER) interview 
9. Must agree to stop breastfeeding from start of study treatment until 45 days after receiving 
the last dose of the study drug 
10. Must agree to use acceptabl
e contraceptive methods during the study period 
11. Must have a reliable family mem
ber, significant other or a trusted friend who can take a role 
as the primary childcare provider and support person at home (including during the night) 
while the subject is participating in the trial  
4.2 Exclusion Crit eria 
Subjects are excluded from the study if any of the following exclusion criteria are met:  
1. Current or past history of any psychotic illness, including major depressive episode with 
psychotic features 
2. Any psychiatric condition that, in the investigator’s judgment, is considered clinically 
significant and could affect subject safety or study outcome including eating disorder, panic 
disorder, obsessive-compulsive disorder, or post-traumatic stress disorder   
3. History of suicide attempt within the past 3 years 
4. Active suicidal ideation (e.g. , answering “yes” to questions 4 or 5 in the CSSRS suicidal 
ideation section) 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 31 of 131 5. History of severe bipolar I disorder (e.g., hospitalization due to the illness, lifetime history of 
psychosis or suicide attempt) 
6. Uncontr
olled seizure disorder  
7. Current or history within the past 3 years of alcohol or any substance use disorder, with the 
exception of tobacco or caffeine 
8. Positive drug screen for any illicit substances or prescription drugs at screening.  If the drug 
screen is positive for a prescription drug that has the potential to be abused (e.g., 
amphetamine, benzodiazepi
ne), legitimate use of the drug must be verified by the subject ’s 
providing the current pill bottle, prescription for the drug, or a note from the prescribing 
physician.  Cannabis use is prohibited and subjects with positive drug screen for cannabis are 
excluded.  However, occasional users of cannabis may be re-tested after 5 days if the subject 
is willing to refrain from consuming c
annabis-based products during the trial.  If the re-test 
sample is negative at screening the subject can be considered eligible.  If the re-test sample is 
positive for cannabis the investigator may ask for determination of blood levels of 
∆9-tetrahydrocannabinol (THC), and its metabolites 11-hydroxy-THC and, 9-carboxy-THC.  
If THC is not detectable the subject is eligible for the
 trial.   
9. Current or relevant history of any medical disorder that may require treatment or make the 
subject unlikely to be able to complete the study, or any condition that presents undue risk 
from the investigational product or procedure point of view 
10. Any clinically significant abnormality identified on physical examination, ECG, or 
laboratory tests, that in the judgment of the investigator would compromise the subject ’s 
safety or successful participation in the clinical study 
11. Subject has untreated or uncontrolled hypothyroidism  
12. Known or suspected intolerance or
 hypersensitivity to the investigational product(s) or 
allopregnanolone, or any of the st
ated ingredients 
13. Use of another investigational product within 60 days prior to the first dose of investigationa l 
product  
14. Has alanine transferase (ALT) or aspartate transferase (AST) greater than 2.5 times upper 
limit of normal or tota
l bilirubin greater than 1.5 times upper limit of normal (unless 
elevation is due to Gilbert’s syndrome) 
15. Screening QT interval Fridericia’s correction (QTcF) > 470 msec 
16. Unwillingness to withhold grapefruit, Seville oranges, star fruit, or concentrated citrus 
derived products from diet between screening and last on-treatment visit 
17. Receiving concomitant treatment with strong cytochrome P ( CYP )3A4 inducers or strong 
CYP3A4 inhibitors 
18. Body mass index (BMI) ≥ 40 
19. Subject is pregnant 
20. Subject is using 
prohibited medications as specified in Section 5.3.2 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 32 of 131 4.3 Reproductive Potential 
4.3.1 Female Contraception 
Sexual
ly active females of childbearing potential should be using an acceptable form of 
contraception throughout the study period between screening and last follow-up visit.  
Acceptable methods of contraception are: 
 Intrauterine device (IUD) plus condoms (If the subject has a hormone-releasing IUD, this 
must have been in place for a minimum of 30 days) 
 Double-barrier methods (e.g. , condoms with spermicidal gel, foam or sponge, diaphragm 
with spermicidal gel, foam or sponge) 
 Hysterectomy or tubal ligation at or after delivery 
4.4 Discontinuation of Subjects 
A subject may withdraw from the study at any time for any reason without prejudice to their 
future medical care by the physician or at the institution.  The investigator or sponsor may 
withdraw the subject at any time (e.g., in the interest of subject safety).  The investigator is 
encouraged to discuss withdrawal of a subject f
rom the investigational product with the medical 
monitor when possible.  Withdrawn subjects who have not received IP will be replaced. 
If the investigational product is discontinued, regardless of the reason, the evaluations listed for 
Day 10 for OL TID and OL QHS groups or Day 29 for the OL QHS 4-week, OL 1,125 mg, and 
OL Bolus-oral groups are to be performed as completely as possible.  Whenever possible, all 
discontinued subjects should a
lso undergo the protocol-specified follow-ups.  Comments 
(spontaneous or elicited), compla
ints, or AEs reported by the subject must be recorded in the 
source documents.  The 
reason for discontinuation and the date and time of discontinuation of 
the investigationa
l product must be recorded in the electronic case report form (e CRF ) and 
source documents.  
4.4.1 Subject Withdrawal Criteria 
All subjects reserve t
he right to withdraw from the clinical study at any time, as stated in the 
informed consent form (ICF).  The investigator may discontinue subjects from the clinical study 
for any of the following reasons: 
1. Electrocardiogram evidence of QT prolongation (QTcF > 530 msec, or an increase of QTcF 
> 60 m
sec above baseline to a value > 480 msec on the 12-lead ECG, confirmed on a repeat 
12-lead ECG taken after resting at least 5 minutes in a supine or semi-recumbent position 
after the original finding of prolonged QTcF).  
2. It is the investigator’s op
inion that it is not in the subject’s best interest to continue in the 
study. 
3. Any subject who exhibits any Suicidal Behavior or Suicidal Ideation (e.g., subject answers 
“yes” to question 4 or 5 in
 the Suicidal Ideation section of the CSSRS).  These subjects 
should be evaluated by a psychiatrist immediately. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 33 of 131 4. Rash that is clinically significant and considered to be related to the study drug (e.g., 
morbiliform, urticarial, papular).  
5. Subject experiences
 an SAE considered to be related to the study drug 
Decisions to discontinue the study will be made at each participating site by the principal 
i
nvestigator.  If feasible, the reason for discontinuation should be discussed with the medical 
monitor.  
4.4.2 Reasons for Discontinuation 
The re
ason for withdrawal must be determined by the investigator and recorded in the subject’s 
medical record and on the e CRF .  If a subject is withdrawn for more than 1 reason, each reason 
should be documented in the sour
ce document and the most clinically relevant reason should be 
entered on the e CRF .  
Reasons for discontinuation include but are not limited to: 
 AE 
 Protocol deviation 
 Withdrawal of
 consent by subject 
 Lost to follow-up 

 Lack of efficacy 

 Other 
(If “Other” is selected, the investigator must specify the reason on the e CRF ) 
4.4.3 Subjects “Lost t
o Follow -up” Prior to Last Scheduled Visit  
A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at 
any time point prior to the last scheduled contact (office visit or telephone contact).  At least 1 of 
these documented attempts must
 include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that she 
return to the site for final safety evaluations.  If contact is made but the subject refuses or is 
unable to come to the final safety evaluation, it should be documented i n the eCRF.  
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 34 of 131 5 PRIOR AND CONCOMITANT TREATMENT 
All non-study treatments (including herbal treatments and vitamins) received within 60 days 
prior to the screening 
visit (Visit 1) and through the final study contact (including 
protocol-defined follow-
up period) must be recorded on the appropriate eCRF page. 
5.1 Prior Pharmacological Treatment 
Prior pharmacological treatment includes all treatments (including herbal treatments and 
vitamins) that 
the subject received and stopped within 60 days of the date of the screening visit.  
For example, if the subject
 had been treated with sertraline during pregnancy but it was 
discontinued 3 weeks prior to th
e screening visit , this medication would be recorded on the prior 
medication eCRF page.  
5.2 Concomitant Pharmacological T
reatment  
Concomitant treatment refers to all treatments (including herbal treatment and vitamins) taken 
between the screening visit
 and the end of the follow-up period regardless of the start date of the 
concomitant medication.  For example, if the subject was started on a prenatal vitamin and it was 
continued through the stu
dy period, this treatment would be recorded on the concomitant 
medication e CRF  page.  
5.3 Concomitant Psycholog
ical Treatment 
Concomitant psychological treatment refers to all psychological care the subject received from 
the time of the screening visit through the end of the follow-up period.  Concomitant 
psychological treat
ment information must be recorded on the concomitant psychological 
treatments eCRF page. 
5.3.1 Permitted Treatment 
5.3.1.1 Permitted Psychological Treat
ments 
The subj
ect may continue their current form of psychological treatment (e.g., cognitive 
behavioral therapy, psychodynamic psychotherapy, supportive psychotherapy) throughout the 
tr
eatment period.  Initiation of a new therapy ( a new treatment modality or switching a therapist ) 
is prohibited during the treatment period.  After the treatment period, psychotherapy should be 
continued using the same modality and at the same frequency as during the treatment period, 
provided that this is medically justified, in order to be able to determine whether there are 
sustained effects from the treatment the over the 30-, 42-, or 90-day follow-up periods.  Any 
changes must be recorded on the concomitant psychological treatments eCRF page.   
5.3.1.2  Permitted Antidepressant Treatments  
The subject may continue their current SSRI, serotonin and norepinephrine reuptake inhibitors,  
bupropion,  other serotonin , or norepinephrine modulating antidepressant (e.g. , vortioxetine, 
mirtazapine) treatment, provided the regimen conforms to the standard of care and the 
medication was started at least 21 days before the screening visit,  and there has not been a dose 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 35 of 131 change within 7 days of the screening visit.  The antidepressant medication must have been 
approved for treatment of maj
or depressive disorder by the United States (US) Food and Drug 
Administration (FDA)
.  Monoamine inhibitors are prohibited (including all formulations of 
selegiline).  Tricyclic a
ntidepressant medications will be decided on a case-by-case basis after 
discussion with the medical monitor.  
5.3.1.3 Ot her Permitted Treatments 
The subject may continue her current non-psychiatric medications with the exception of 
medications that are strong inducers or i
nhibitors of CYP3A4 (Appendix 1. ).  
The subject may use
 diphenhydra
mine 25 to 50 mg, trazodone 25 to 50 mg, or doxepine 3 to 
5 mg for severe insomnia as needed.  Only 1 dose of 1 of the medications is allowed per night.  
Other hypnotics, such as zol
pidem or zaleplon, are prohibited.  
If the subject is treated with an atypical antipsychotic medication that was started with the 
purpose of augmenting the therapeutic
 effect of an antidepressant (i.e., the antipsychotic is not 
intended for treatment of psychosis or mood stabilization, and it is used in combination with an 
antidepressant), and the medication has been approved by the US Food and Drug Administration 
as an add-on therapy for major depression, she may continue this treatment throughout the study 
period provided that the medication is taken within the approved dose range.  Examples of such 
treatments would be quetiapine 50 mg at bedtime and aripiprazole 10 mg daily.  However, the 
antipsychotic medication must have been started at least 21 days before screening, and there 
should not have been a dose change within 7 days of screening.  
Other medications and medication combinations should be discussed with the medical monitor 
before enrolling the subject in the study.  
After completion of the treat
ment period, any changes to the antidepressant or antianxiety 
medication regimen are not prohibited, but investigators are encouraged to maintain such drugs 
at stable doses if possible.  Any changes in the medication regimen must be recorded on the 
concomitant medication 
eCRF page.   
5.3.2 Prohibited Treatments 
The following cla
sses of medications and treatments are prohibited during the study.  If the 
subject has been taking any of these m
edications before enrollment, there should be a 
medication-free period of a minimum of 5 days or 5 half-lives of that medication, whichever is 
longer, before admission to the unit.  In general, subjects who require extensive washouts may 
not be candidates for participation and those cases should be discussed with the medical monitor.  
 Benzodiazepines and barbiturates  
 Gabapentin and pregabalin 
 Anticonvulsants and mood stabilizers 
 All hypnotics and sleep aids (with the exception of low-dose diphenhydramine, doxepin, and 
trazodone as described above) 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 36 of 131  Opioids  
 Cannabis  
 Electroconvulsive Therapy (ECT
), rapid transcranial magnetic stimulation (rTMS), vagal 
nerve stimulation 
 Experim
ental (including hormonal and herbal) treatments of postpartum d epr ession 
 Strong inhibitors and inducers of CYP3A4 (Appendix 1. ) 
 Antipsychotic medi
cations (unless the antipsychotic is used to augment anti dep ressant 
medication, is used in combination with an antidepressant, and is approved by the FDA as an 
add-on therapy for major depression )  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 37 of 131 6 INVESTIGATIONAL PRODUCTS 
6.1 Identity of Investigational Products 
6.1.1 Ganaxolone Immediate Releas e Oral Capsules (0.3 Micron Formulation )  
Ganaxolone capsules will be provided in size 00 white/opaque gelatin capsules packaged in 
high-density polyethylene (HDPE) bottles with a foil induction seal and child resistant closure.  
Each bottle will contain 28 or 70 cap
sules.  Each capsule contains 225 mg ganaxolone 
(3α-hydroxy-3β-methyl
-5α-pregnan-20-one), and hydroxypropyl methylcellulose, sucrose, 
polyethylene glycol 3350, polyethy
lene glycol 400, sodium lauryl sulfate, sodium benzoate, 
citric acid anhydrous, sodium methyl paraben, microcrystalline cellulose, 30% Simethicone 
Emulsion, gelatin capsules, polysorbate 80, and sodium chloride. 
Placebo formulation is comprised of sucrose spheres of comparable size to the ganaxolone spray 
layered spheres encapsulated in a size 00 whit e/
opaque gelatin capsule.  The weights of placebo 
capsules are matched to ganaxolone capsules.  The placebo capsules will be provided to the sites 
in bottles identical to the active drug.  
All study medication will be labeled according to regional regulatory requirements.  At a 
minimum, labels will contain the study number; a blinded bottle number; contents including 
quantity; dose and form; route of ad
ministration; storage conditions; instructions for study drug 
administration; caution that this compound is an investigative drug intend
ed for clinical trial use 
only; warning to keep out of reach of children; and the identity of manufacturer and Sponsor.  
For those regions that require it, a blinded lot number and an expiry date will also be listed. 
 
6.1.2 Ganaxolone IV Infusion Solution  
 
Vehicle
:  Captisol® containing sterile IV solution  
Formulation:  IV 
Strength:  3 mg/
ml solution in a glass vial, which is to be diluted with 0.9% saline for the 
infusion.  For details regarding preparation of the infusion solution, please see pharmacy manual.  
Route of administration:  IV 
6.1.3 Ganaxol one Oral Suspension 
 
Vehicle: The oral suspension contains ganaxolone (50 mg/mL), hydroxypropyl methylcellulose, 
polyvinyl alcohol, sodium lauryl sulfate, simethicone, methylparaben, propylparaben, sodium 
benzoate, citric acid, and sodium citrate at pH 3.8 to 4.2, and is sweetened with sucralose and 
flavored with artificial cherry. 
Formulation: Oral suspension 
Stre
ngth: 50 mg/mL oral suspension; 110 mL in 125 mL HDPE bottles 

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 38 of 131 6.2 Administration of Investigational Product(s) 
All study medication will be stored at the research pharmacy prior to dispensing, or in a locked 
cabinet accessible only to members of the investigational research team.  Ganaxolone capsules 
and ganaxolone oral sus
pension should be stored at room temperature 15°C to 25°C (59°F to 
77°F).  Ganaxolone stock solution investigational product for IV administration will be stored at 
refrigerated te m
perature 2ºC to 8ºC (36ºF to 46ºF).  Oral investigational product should be taken 
within ± 15 minutes of a fatty meal or snack (e.g., yogurt, nuts, avocado), and with 240 mL 
(8 oz) of water.   
For the IV bolus, ganaxolone 12 mg in 24 mL will be administered over 2 minutes via an 
indwelling catheter, or a butterfly inserted in a vein on the arm or hand.  The investigational 
product should be given as c
ontinuous infusion as instructed.  The catheter should be flushed 
with saline at the end of the bolus infusion.
  For details, please see pharmacy manual.  
6.2.1 Allocation of Subjects to Treatment  
Subject numbers are assigned to all subjects as they consent to take part in the study.  Within 
each site (numbered uniquely within a protocol), the subject number is assigned by the 
Electronic Data Capture (EDC) syste m to subjects according to the sequence of presentation for 
study participation.  
In the open-label part, the first approximately 8 subject s will be assigned to OL TID dosing 
group.  After approximately 8 subjects have started dosing in the OL TID group, the dosing for 
the OL QHS group will commence.  Approximately 20 subjects will be dosed for the OL QHS 
group.  After approxim
ately 20 subjects have started dosing in the OL QHS group, the 
enrollment into the
 OL QHS 4-week group will commence.  After approximately 20 subjects 
have started dosing in the OL Q
HS 4-week group, enrollment into the OL 1,125 mg group will 
commence.  Approximately 20 subjects will be dosed for the OL 1,125 mg group.  After 
approximately 20 subje
cts have started dosing in the OL 1,125 mg group, enrollment into the OL 
Bolus-oral group will co
mmence.  Approximately 20 subjects will be dosed for the OL 
Bolus-oral group. 
In the 
DBPC part, subjects will be randomized to receive ganaxolone or matching placebo in a 
1:1 ratio.  Randomization will be stratified by the use of concomitant antidepressants so that the 
nu
mber of subject s who are treated with antidepressants and who are not treated with 
antidepressants will be similar in each treatment group. 
After being enrolled, a subject will be replaced only if she discontinues prior to receiving study 
treatment. 
6.2.2 Dosing  for the Open-label Treatment Part – OL TID Group 
Subjects start taking the study drug at bedtime (HS) on Day 1 (enrollment).  The first dose to be 
taken will be one 225 mg capsule
.  The next evening (Day 2), the dose will be increased to 
450 mg (2 capsules) to be taken HS.  This dose is taken on Day 2 and Day 3.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 39 of 131 There will be a study visit on Day 4, which should be scheduled to occur in the morning.  On 
Day 4, the dose is increased to 225 mg QA
M (to be started after the study visit) and 450 mg 
QHS .  This dosing (225 mg QAM and 450 mg QHS) is continued on Day 5 and Day 6.   
There will be a study visit on Day 7 which should be scheduled to oc
cur in the morning.  The 
morning dose of the study medicat
ion on Day 7 should be taken as scheduled before the study 
visit.  The dose will be increased on Day 7 to 225 mg QAM, 225 mg Q2PM and 450 mg QHS.  
This dos
e will be continued on Days 8 to 10.  The subject should take the new additional 
afternoon dose that day (Day 7). 
There will be a study visit on Day 10
, which is the final visit before the taper is started.  The visit 
shoul d occur in the morning of Day 10 before
 noon.  The morning dose of the study drug should 
be ta ken as scheduled before the visit.  
On D ays 11-14, the study drug is tapered off following the schedule in Table 1.  The last dose is 
to be  taken on Day 14 QHS .  
All doses taken must be recorded in the eCRF. 
The st udy visits are intended to allow evaluation of the subject by the principal investigator and 
making dose adjustments when necessary.  If there have been no adverse events, and the subject 
has not improved clinica
lly, the investigator should follow the titration schedule and increase the 
dose.   
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 40 of 131 Table 1. Study Drug Dosing Schedule – Open -Label TID Group  
                     V2      V3     V4      V5 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
QAM         225 mg  225 mg 225 mg 225 mg 225 mg 225 mg 225 mg 225 mg 225 mg     
Q2PM    
     225 mg 225 mg 225 mg 225 mg 
    
QHS  225 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 450 mg 225 mg 
Total  225 mg 450 mg 450 mg 675 mg  675 mg 675 mg 900 mg 900 mg 900 mg 900 mg 675 mg 675 mg 450 mg 225 mg 
QAM = approximately 8 am, QHS = approximately 10 pm, or before going to bed for the night  
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 41 of 131 6.2.3 Dosing for the Open-Label Treatment Part –  OL QHS Group 
Subjects start taking the study drug at bedtime (HS) on Day 1 (enrollment).  The first dose to be 
taken will be one 225 mg capsule.  The next evening (Day 2) 
the dose will be increased to 450 
mg (2 capsules) to be taken HS.  This dose is taken on Day 2 and Day 3.  
There will be a study visit on Day 4, which should be scheduled to occur in the morning.  On 
Day 4, the dose is increased to 675 mg QHS which is continued (through Day 7 visit) until Day 
10.  There is no planned dose adjustment at Day 7 visit.  
There will be a study visit on Day 10, which is
 the final visit before the taper is started.  The visit 
should occur in the morning of Day 10 before noon.   
On Days 11-14 the study drug is tapered off following the schedule in Table 2.  The last dose is 
to be taken on Day 14 QHS.  
All doses taken must be recorded in the eCRF. 
The study visits are intended to allow evaluation of the subject by the principal investigator and 
making dose adjustments when necessary.  If there have been no adverse events the investigator 
should follow the dosing schedule.   
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 42 of 131 Table 2. Study Drug Dosing Schedule – Open -Label QHS Group  
                    V2     V3    V4     V5 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
QAM                     
Q2PM    
           
  
QHS  225 mg  450 mg  450 mg  675 mg  675 mg  675mg  675 mg  675 mg  675 mg  675 mg  450 mg  450 mg  225 mg 225 mg  
Total  225 mg  450 mg  450 mg  675 mg  675 mg  675 mg  675 mg 675 mg 675 mg 675 mg 450 mg 450 mg 225 mg 225 mg  
QAM = approximately 8 am, QHS = approximately 10 pm, or before going to bed for the night  
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 43 of 131 6.2.4 Dosing for the Open-Label Treatment Part –  OL QHS Group – 4 Week 
Subjects start taking the study drug at bedtime (QHS) on Day 1 (enrollment).  The first dose to 
be taken will be 675 mg (3 capsules), continuing through Day 28 at QHS.  
There will be a study visit on Day 2, Day 
8, Day 15, and Day 22.  There is no planned dose 
adjustment at any of thes
e visits.  
There will be a study visit on Day 29, which is the final visit before the taper is started. The visit 
should occur in the morning of Day 29 before noon. 
On D
ays 29 to 32 the study drug is ta
pered off following the schedule in Table 3. The last dose 
will be ta
ken on Day 32 QHS.  
All doses taken must be recorded in the eCRF. 
The study visits are intended to allow evaluation of the subje ct by the principal investigator and 
making dose adjustments when necessary.  If the
re have been no adverse events the investigator 
should follow the dosing schedule.   
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 44 of 131 Table 3. Study Drug Dosing Schedule – Open -Label QHS 4 Week Group  
 V2 V3 V4 V5 V6 V7    
Day 1 2 8 15 22 29 30 31 32 
QHS  675 mg  675 mg  675 mg  675 mg  675 mg  450 mg  450 mg  225 mg  225 mg  
Total  675 mg  675 mg  675 mg  675 mg  675 mg  450 mg  450 mg  225 mg  225 mg  
 
There will be total of 11 study visits for the QHS 4-week dosing group: Screening, Day 1, Day 2, Day 8, Day 15, Day 22, Day 29 and 4 safety follow-up visits on 
Day 36, Day 59, Day 89, and Day 1 19. 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 45 of 131 6.2.5 Dosing for the Open-Label Treatment Part –  OL 1,125 mg Group 
Subjects will start taking ganaxolone capsules, 675 mg (3 capsules) at dinner time (7 pm) 
followed by 675 mg (3 capsules) at bedtime (HS) on Day 1 an d Day 2 followed by 1,125 mg 
(5 capsules) at dinner time (7 pm) on the next 26 days (Day 3 through Day 28).  A 4-day taper 
will follow: 900 mg (4 capsul
es) on Day 29, 675 mg (3 capsules) on Day 30, 450 mg 
(2 capsules) on Day 31, and 225 mg (1 capsule) on Day 32 (Table 4) all at dinner time. 
In addition to screening, there will be study visits on days 1, 2, 8, 15, 22, 29, 36, 57, 71.  
Day 29 is the final visit before taper 
is started.  The visit should occur in the morning of Day 29 
before noon. 
All doses taken must be recorded in the eCRF.  
The study visits are intended to allow evaluation of the subject by the principal investigator  and 
making dose and/or timing adjustments when necessary (see Section 6.2.7).  If there have bee n 
no adver
se events the investigator should follow the dosing schedule.   
Oral ganaxolone should be taken within ± 15 minutes of a fatty meal or snack (e.g., yogurt, nuts, 
avocado) and with 240 mL (8
 oz) of water.  
Table 4. Study Drug Dosing Schedule 
– Open-label 1,125 mg Group 
Visit  V2 V3  V4 V5 V6 V7    
Day 1 2 3 8 15 22 29 30 31 32 
Q7PM  675 mg  675 mg  1,125 
mg 1,125 mg  1,125 mg  1,125 mg  900 mg 675 mg  450 
mg 225 
mg 
QHS  675 mg 675 mg         
Total  1,350  mg 1,350  mg 1,125 
mg 1,125 mg  1,125 mg  1,125 mg  900 mg  675 mg  450 
mg 225 
mg 
 
There will be total of 10 study visits for the OL 1,125 mg dosing group: Screening, Day 1, Day 
2, Day 8, Day 15, Day 22, Day 29 and 3 safety follow-up visits on Day 36, Day 57, and Day 71. 
 
  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 46 of 131 6.2.6 Dosing for the Open-Label Treatment Part –  OL Bolus -Oral Group 
Dosing in the Bolus-Oral group will start with ganaxolone IV bolus 12 mg over 2 minutes at 
approximately 4 pm on Day 1.  Subjects will start taking ganaxolone 750 mg oral suspension 
(15 mL at 50 mg per mL) 
at dinner time (7 pm) followed by 750 mg oral suspension at bedtime 
(HS) on Day 1.  On Day 2 subjects will again 
take 750 mg oral suspension at dinner time (7 pm) 
followed by 750 mg at bedtime (HS).  For the following 26 days (Day 3 through Day 28) 
subj
ects will take ganaxolone 1,000 mg oral suspension (20 mL at 50 mg per mL) at dinner time 
(7 pm).  A 4-day taper will follow: 750 mg (15 mL) on Day 29, 500 mg (10 mL) on Day 30, 500 
mg (10 mL) on Day 31, and 250 mg (5 mL) on D
ay 32 (Table 5) all at dinner time.  
In addition to screening, there will be study visits on days 1, 2, 8, 15, 22, 29, 36, 57, 71.  
Day 29 is the final visit before taper is started.  The visit should occur in the morning of Day 29 
before noon. 
All doses taken  must be recorded in the eCRF. 
The st udy visits  are intended to a
llow evaluation of the subject by the principal investigator and 
making dose and/or timing adjustments when necessary (see Section 6.2.7).  If there have been 
no AEs, the  investigator should follow the dosing schedule.   
Oral ganaxolone should be taken with
in ±15 minutes of a fatty meal or snack (e.g., yogurt, nuts, 
avoca do) and with 240 mL (8 oz) of water.   
Table 
5. Study Drug Dosing Schedule – Open-label Bolus-oral Group 
Visit  V2 V3  V4 V5 V6 V7    
Day 1 2 3 8 15 22 29 30 31 32 
4PM  12 mg IV  Bolus          
Q7PM  750 mg 750 mg 1,000 
mg 1,000 mg 1,000 mg 1,000 mg 750 mg 500 mg 500 
mg 250 
mg 
QHS  750 mg 750 mg         
Total  1,512 mg 1,500  mg 1,000 
mg 1,000 mg  1,000 mg  1,000 mg  750 mg  500 mg  500 
mg 250 
mg 
 
There will be total of 1 0 study visits for the OL Bolus-Oral dosing group: Screening, Day 1, 
Day 2, Day 8, Day 15, Day 22, Day 29 and 3 safety follow-up visits on Day 36, Day 57, and 
Day 71. 
  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 47 of 131 6.2.7 Dose Adjustments During Open-label  
Adjust
ing doses for the OL TID dosing group 
During the study the investigator has the opportunity to de-escalate, skip dose escalation and 
re-escalate during the titration on Days 1 to 10 at the sche duled study visits if the subject is 
experiencing adverse events
.  The dose adjustments done at the study visits should follow the 
schedule outlined in Table 1.  The investigator should de -escalate to a previous dosing schedule, 
repeat the current dosing schedule
 or re-escalate to dosi ng scheme outline in the table.  Other 
flexible adjustments are not allowed.  
Example 1 :  
If the subject at Day 4 visit reports adverse effects (e.g., sedation) with the 450 mg QHS dose, 
the investigator may decrease the dose to 225 mg QHS (de-escalation) or continue the 450 mg 
QHS dose (skip dose escalation).  The investigator may then attempt to re-escalate the dose to 
the next dose level at the next visit (Day 7).  If the investigator opted to maintain the 450 mg 
QHS dose at the Day 4 visit, the investigator may then increase the dose to the next scheduled 
dose level (225 mg QAM and 450 mg QHS) at Day 7 visit provided that the subject has 
developed a tolerance to the sedative effects
.  
Example 2:  
If the subjec
t at study visit on Day 7 reports intolerable sedation after the morning dose, the 
investigator may choose to drop the dosing to 450 mg QHS or skip the escalation and maintain 
the current dosing (225 mg QAM and 450 mg QHS). 
Subjects who do not reach the 900 mg daily dose (225 mg QAM, 225 mg Q2PM and 450 mg 
QHS) will be tapered off the study medication by reducing the dose by about 225 mg per day or 
every other day over the Days 11 to 14.  The QHS dose should be the last dose before the drug is 
discontinued completely.  
The subjects who do not tolerate the first dose of 225 mg QHS should be considered for 
disc
ontinuation.  
All doses taken must be recorded in the eCRF. 
If the study visit falls on the weekend, or if the subject is not able to come to the study scheduled 
study visit, each visit has a window + 3 days.  Under this scenario, the subject would continue at 
the prescribed dose level until the study visit.  
Adjusting doses for the OL QHS dosing group 
During the study the investigator has the opportunity to defer a dose escalation to 675 mg at 
Day 4 Visit if the subject reports adverse events (e.g., sedation in the morning) and attempt 
escalation at Day 7 Visit or
 continue the dosing at 450 mg QHS until Day 10 Visit.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 48 of 131 Adjusting doses for the OL QHS 4 week dosing group 
The investigator has the flexibility to adjust treatment reducing the dose to one or two capsules, 
if the subject experiences sedation, dizziness or other untoward effects during the OL part.   
Adjusting dose and/or tim
ings for the OL 1,125 mg dosing group 
The investigator has the flexibility to adjust dose by reducing the dose to 450 mg (2 capsules) at 
the second of Day 1 doses (at HS) and/or at either of Day 2 doses, and/or reduce to 900 mg, 
675 mg, or 450 mg on Day 3 through Day 28 (at dinner time) if subject experiences sedation, 
dizziness or other untoward effects d
uring the OL part.  The investigator can also change the 
timing of the evening dose bringing it closer to bedtime and taking it with a fatty snack instead of 
dinner.  Any further adjustments as well as adjusted taper period doses should be discussed with 
the medical monitor. 
 The investigator may increase the dose back to default levels if tolerance 
develops to the untoward effects.  
Adjusting dose and/
or timings for the OL Bolus-oral dosing group  
The investigator has the flexibility to adjust dose by reducing the dose to 500 mg (10 mL) for the 
second of Day 1 doses (at HS) and/or either of Day 2 doses, and/or reduce to 750 mg (15 mL), or 
500 mg (10 mL) at dinner time on D
ay 3 through Day 28 if subject experiences sedation, 
dizziness or other untoward effects during the OL part.  The investigator can also change the 
timing of the evening dose bringing it closer to bedtime and taking it with a fatty snack instead of 
dinner.  Any further adjustmen ts as well as adjusted taper period doses should be discussed with 
the medical monitor. 
 The investigator may increase the dose back to default levels if tolerance 
develops to the untoward effects.  
6.2.8 Blinding 
During t
he DBPC part, subjects randomized to placebo will receive placebo capsules which are 
ide
ntical to the active ganaxolone capsules.  
6.3 Labeling, Packaging, and Storage 
6.3.1 Labeling 
Bottles will be labeled before shipping to the sites.  In the DBPC part, the contents of each bottle 
will be blinded using labels.  The randomization schedule will match a subject number to a bottle 
number.  
6.3.2 Packaging and Dispensing the Study Drug 
Ganaxolone capsules and matching placebos will be provided in HDPE bottles. 
All packaging and labeling operations will be performed according to good manufacturing 
practice (GMP) and good clinical practice (GCP) guidelines.  Investigational products are 
prepared and distributed by the site pharmacist.   
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 49 of 131 The site pharmacy or delegated site staff will be responsible for dispensing the study treatment to 
the subject.  Sufficient amount of supplies will be provided to the subject until the next study 
visit and a minimum of 3 day s’ overage to cover for weekends, study site closures and 
unexpected need for rescheduli
ng the study visit .  
Detailed instructions on when to take the m
edication and a reminder to take oral study 
medication with in ± 15 m
inutes of a fatty meal or snack (e.g., fatty yogurt, nuts, avocado) and 
with 240 mL (8 oz) of water will be p
rovided to the subject. 
6.3.3 Storage 
The investigator has ove
rall responsibility for ensuring that investigational products are stored in 
a secure, limited-acc
ess location.  Limited responsibility may be delegated to the pharmacist, but 
this delegation must be docum
ented.  
The ganaxolone stock solution investigational p
roduct for the IV administration will be stored at 
refrigerated temperature 2ºC to 8ºC (36ºF to 46ºF).   
The 0.3-micron ganaxolone capsules (225 mg), oral suspension, and matching placebos are 
stored in HDPE bottles 
with a foil induction seal and child resistant closure at room temperature 
(15oC to 25oC; 60ºF to 75ºF).  
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range .  The investigator is responsible 
for ensuring that the temper
ature is monitored throughout the duration of the study and that 
records are maintained.  The temperature should be monitored continuously through use of either 
an in-house system, a 
mechanical recording device such as a calibrated chart recorder, or by 
manual means, such that
 both minimum and maximum thermometric values over a specific time 
period can be recorded and retrieved as required.  The sponsor or sponsor’s delegate must be 
notified immediately upon dis
covery of any excursion from the established range.  Temperature 
excursions will require site investigation as to cause and remediation.  The sponsor will 
determine the ultim
ate impact of excursions on the investigational product and will provide 
supportive documentation as necessary.  Under no circumstances should the product be 
dispensed to subjects until the impact has been determined and the product is deemed appropriate 
for use by the sponsor. 
The sponsor or sponsor’s delegate should be notified immediately if there are any changes to the 
stor
age area of the investigational product that could affect the integrity of the product(s), e.g., 
fumigation of a storage room. 
6.4 Drug Accountability 
Drug kits containing the study drug and supplies needed for each subject for the entire study will 
be supplied to the investigational site by the sponsor or a distributor on behalf of the sponsor.  
The pharmacist or delegated site staff will inventory and acknowledge receipt of all shipments of 
the kits.  The study drugs must be kept in a locked area with restricted access and stored and 
handled in accordance with the manufacturers’ instructions.  The pharmacist will also keep 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 50 of 131 accurate records of the quantities of study drug dispensed and used.  The pharmacist is 
responsible for all drug 
supplies; written documentation is mandatory.  The study monitor will 
periodically check the 
supplies of the study drug held by the pharmacist to verify accountability 
of all kits used.  The pharmacist will dispense the study drug according to the dosing plan.  Upon 
receiving study drugs, the 
principal investigator and the team members will administer them only 
to the identified subjects in this study, following the procedures described in this study protocol 
and documented in the appropriate eCRF.  At the conclusion of the study, all unused study drug 
will be returned or destroyed per the site’s Standard Operating Procedures (SOP) or instructions 
from the sponsor.  The sponsor will verify that a final report of drug accountability to the 
unit-dose level is prepa
red and maintained in the principal investigator’s study file. 
6.5 Drug Administration 
Oral doses of the investigational product should be taken with in ±15 minutes of a fatty meal or 
snack (e.g., fatty yogurt, nuts,
 avocado), and with 240 mL (8 oz) of water.   
For the IV bolus ganaxolone 12 mg in 24 mL will be administered over 2 minutes via an 
indwelling catheter or a butterfly, inserted in a vein on the arm or hand.  The investigational 
product should be given as c
ontinuous infusion as instructed.  The catheter should be flushed 
with saline at the end of the bolus infusion.
  For details please see pharmacy manual.  
Subjects will be informed about possible side effects from the study medication and cautioned to 
avoid quick postural changes.  They should not carry the baby or sleep with the baby in the same 
bed due to the possible side-
effect of dizziness and sedation.  Subjects will be advised not to 
drive, operate heavy machinery, or participate in any potentially hazardous activity during the 
study that requires full mental alertness until they are sure the medication is not affecting 
alertness.  They will also be cautioned that non-adherence to the dosing instructions (e.g., 
increasing the dose, taking the study medication doses too close together) could produce side 
effects.  
The interaction between alcohol and ganaxolone is not known.  Alcohol use is prohibited during 
the treatment period. 
 
The subject must have a reliable family member, significant other or a trusted friend who can 
take the role for being the pr
imary childcare provider and a support person at home (including at 
nighttime) while the subject is participating in the trial, including for subjects who may stay 
overnight on the unit as part of the screening process and/or the PK subgroup. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 51 of 131 7 STUDY PROCEDURES 
This is a Phase 2, multicenter study in women with postpartum depression (PPD) consisting of 
2 dosing part s: an initial open-label safety part and a DBPC part.   
For the open-label safety part, approximately 172 women 18 to 48 years of age with PPD will be 
screened to enroll approxim
ately 88 subjects.  During this open-label safety part, for the first 
approximately 8 subjects, ganaxol
one will be titrated to a daily dose of 900 mg/day over 10 days, 
followed by a taper over 4 days.  This dosing group is called OL TID group. 
 
For the next approximately 20 subjects, ganaxolone will be administered at QHS .  For these 
subjects, ganaxolone will be ti
trated to a QHS dose of 675 mg over 4 days which is then 
maintained until day 10, foll
owed by a taper over 4 days. This dosing group is called OL QHS 
group. 
For the next approximately 20 subj
ects, ganaxolone will be administered at bedtime (QHS). For 
these subjects ganaxolone t
reatment will be a QHS dose of 675 mg over 28 days, followed by a 
taper over 4 days. This dosing group is called OL QHS 4-week group. 
The next approximately 20 subj
ects of the open-label safety part will receive on the first 2 days 
ganaxolone capsules 675 m
g at dinner time and 675 mg at bedtime (for a total of 1,350 mg per 
day on the first 2 days) followed by 26 days of ganaxolone c
apsules 1,125 mg at dinner time, 
followed by a taper over 4 days.  This dosing group is called O
L 1,125 mg group.  
For the next approximately 20 subje
cts of the open-label safety part, ganaxolone will be 
administered as IV bolus 12 mg over 2 minutes at approximately 4 pm on Day 1 followed by 
ganaxolone oral suspension 750 mg at
 dinner time and 750 mg at bedtime, for a total of 
1,512 mg on the first day. On Day 2 subjects will receive ganaxolone oral suspension 750 mg at 
dinner time and at 750 mg at bedtime
, for a total of 1,500 mg, followed by 26 days of 
ganaxolone oral suspension 1000 mg at dinne
r time, followed by a t aper over 4 days. This dosing 
group is called OL Bolus-Oral group . The investigat
or has the fle xibility to  adjust the dose 
and/or timing of the dose if the subject experiences sedation, dizzi ness or other untoward effects 
during the OL part (see Section 6.2.7)
.  
The open-label safety part will be en
rolled, and dosing completed before proceeding to the 
DBPC part.  The goal of the open-lab
el part is to explore safety of IV and oral ganaxolone in this 
population and identify a dosing regimen 
for the DBPC part.  
For t he DBPC part, approximately 100 women with PPD 18 to 48 years of age will be screened 
to randomize 50 women in a 1:1 
ratio to receive ganaxolone or matching placebo for 14 days.  
The dosing for the DBPC portion of the study w
ill be decided based on the results of the 
open-label portion and r
ecommendations of the DRC.  The DRC is comprised of Marinus’ Chief 
Medical Officer and 2 external physician experts.  The daily dose will not exceed 1,600 mg.  
Rando
mization will be stratif
ied by the use of concomitant antidepressants so that the number of 
subjects who are treated with antidepressants and who are not treated with antidepressants will 
be similar in each treat
ment group. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 52 of 131 7.1 Screening Period (Day -14 to - 1) for OL TID and OL QHS 
7.1.1 Screening Visit (Visit 1) 
 Obtain written informed conse
nt  
 Collect demographics, medi
cal history, review prior medications, review of concomitant 
medications and therapies,  
 A
ssess CGI-S 
 Conduct Mini  International Neuropsychiatric Interview 7.0 (MINI 7.0)   
 Conduct HAMD17 interview (if a HAMD17 interview was conducted for Marinus PPD 
study
 1042- PPD-2002 at the same investigative site within 2 weeks of the screening visit the 
scr
eening HAMD17 interview do es not have to be repeated).  
 Perform EPDS 
 Perform STAI6 

 Perform a physical exam
inati on  
 Collect vital signs (blood pressure [ BP], pulse, temperature , respiratory rate [RR]) 
 Collect ECG 
 Collect urin
e for urinalysis, urine drug screen and urine pregnancy test  
 Collect safety la
boratory test s  
 Measure height and weight
  

 Conduct CSSRS interview  
 Review  inclusion and exclusion criteria.  Screen failure is defined as a subject who has given 
informed consent, and failed to meet the inclusion criteria and/or met the exclusion criteria 
 Schedule a SAFER interview if the subject meets the eligibility criteria.  The SAFER 
interview will be conducte
d during the screening period.  The investigational site must wait 
for the results of the SAFER interview before enrolling the subject into the treatment phase 
of the study (if a SAFER interview was conducted within 2 weeks for Marinus PPD study 
1042- PPD-2002 at the same investigative site the SAFER interview do es not have to be 
repeated. In 
this instance the HAMD17 score from the SAFER interview can be used to 
qualify the subject for the study).  
 Screening period may be extended to 21 days with approval from the medical monitor (e.g., a 
laboratory sample w as hemolyzed and had to be repeated causing a delay). 
7.2 Treatment Period (Day 1 to Day 14; Visits 2 to 5) for OL TID and OL QHS 
7.2.1 Start of the Open-label Safety Period (Day 1; Visit 2) 
 The subject  arrives in the clinic to complete baseline assessments on Day 1.  
 Conduct HAMD17 interview 
 Perform EPDS 
 Perform STAI6 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 53 of 131  Assess CGI-S 
 Review concomitant me
dications an d therapies  
 Collect vital signs (BP, pulse, temperature, RR )  
 Measure weight  
 Collect ECG  

 Collect urin
e for urinalysis, urine drug screen and urine pregnancy test 
 Collect safety laboratory tests 
 Collect neurosteroid l
evel 
 Collect SSS 
 Collect AEs
 
 Conduct CSSRS int
erview  
 Review
 inclusion and exclusion criteria (including hematology, chemistry, urinalysis, urine 
drug s
creen and pregnancy tests from the screening visit); HAMD17 must be ≥ 18 for 
enrollment. 
 If the subject continues to meet the inclusion criteria and has not developed any exclusion 
criteria the subject will be enrolled in the study.  
 Dispense medication after enrollment to the open-label.  Provide the subject with dosing 
instructions.  
 The subject  will be instructed to take the first dose of the study medication that night 
(225 mg)  
 If the s ubject is breastfeeding, she is encouraged to “pump and dump” during the study 
period and for 45 days after the last dose.  She should be provided with a breast pump if she 
does not have one.  Breast feeding is prohibite
d during the treatment phase and until 45 days 
following the last dose of the study drug. 
 
7.2.2 Treatment Visits (Days 4, 7, 10) (+ 3 days) for OL TID and OL QHS 
 Conduct interviews for HAMD17  
 Conduct interviews f
or CGI- I  
 EPDS  
 STA I6  
 Collect AEs 
 Collect ECG (Day 7, Day 10) 
 Collect vital signs (BP, pulse, RR, temperature)  
 Collect SSS  
 Collec t a PK sample  
 Record concomitant medications  
 Collect safety laboratory tests (Day 10 only) 
 Collect neurosteroid level (Day 10 only) 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 54 of 131  Collect urine for urinalysis, urine drug screen and urine pregnancy test  

 Conduct CSSRS interview  
 Perform a physical examination and collect weight (Day 10 only) 
 Dispense study medication with a supply to last until the next visit (+ 3 days overage to cover 
for unexpected need to re-schedule a study visit or weekends).  Provide the subject with 
dosing instructions.  
 Start study drug taper on Day 11 
7.3 Follow- up Visit 1 (Day 17  ± 2) and Follow- up Visit 2 (Day 38 ± 4) for OL TID 
and OL QHS 
 The Follow-up Visit 1 should occur about 1 week after D10 visit, and about 3 days after the 
subject has taken her last dose of the study medication.  The Follow-up Visit 2 should occur 
approximately 3 weeks after Fol
low-up Visit 1 (unless there is a medical need to see the 
subject sooner; an additional safety visit
 can be scheduled as per the investigator’s 
discretion).  
 Conduct inter
views for 
HAMD17 and CGI- I  
 Perform EPDS 
 Perform STAI6 
 Review concomitant medications and therapies  
 Collect vital signs (BP, pulse, temperature, RR) 
 Collect safety laboratory test
s (Follow-up Visit 1 only) 
 Collec t neurosteroid level (Follow-up Visit 1 only)  
 Collect PK sample 
 Collect urin
e for urinalysis, urine drug screen, and urine pregnancy test  
 Measure weight  
 Conduct CSSRS interview 
 Collect SSS 

 Collect AEs  
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 55 of 131 Table 6. Schedule of Assessments for the Open-label OL TID and OL QHS and Double-blind Groups 
VISIT Screening  (V1) Day1  
(V2) Day4  
(V3) Day7  
(V4) D10  
(V5) Day17  
(V6, 1st FU)  Day38   
(V7, 2nd FU) 
Informed consent X       
Demographics, medical history  X       
MINI neuropsychiatric interview  X       
Inclusion/Exclusion criteri a X X      
Randomize patient (DB only)   X      
Dispense medication   X X X X   
Concomitant Medications and Prior Therapy 
Review  X X X X X X X 
Physical examination  X    X   
SAFER Interview (during screening)  X       
Vital signs (BP, Pulse, RR, temperature) X X X X X X X 
Height (screening only) and weight  X X   X X X 
ECGs X X  X X   
Safety Laboratory Tests  X X   X X  
Neurosteroid sample collection   X   X X  
Urinalysis  Drug Screen and Pregnancy Tests  X X X X X X X 
Record AEs   X X X X X X 
PK sample collection    X X X X X 
HAMD17  X X X X X X X 
CGI-I   X X X X X 
CGI-S X X      
EPDS  X X X X X X X 
STAI6 X X X X X X X 
CSSRS  X X X X X X X 
SSS  X X X X X X 
Start Taper      X   
The following priority order will be in effect when more than 1 assessment is required at a particular time point:  1) HAMD17 2) CGI -I/CGI -S 3) EPDS 
4) STAI6 5) SSS 6) CSSRS 7) vital signs 8) ECG 9) safety labs 10) neurosteroid sample 11) PK sample 12) urinalysis, urine drug screen and pregnancy test 13) 
physical exami nation .  SAFER interview is scheduled if subject meets the eligibility criteria at the Screening visit.  The SAFER interview will be c onducted 
during the screening period.  The investigational site must wait for the results of the SAFER interview before enrolling the subject  into the treatment phase of the 
study . Screening period may be extended to 21 days with approval from the medical monitor.  
 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 56 of 131 7.4 Screening Period (Day -14 to - 1) for OL QHS 4 week 
7.4.1 Screening Visit (Visit 1) 
 Obtain written informed conse
nt  
 Collect demographics, medi
cal history, review prior medications, review of concomitant 
medications and therapies,  
 Assess  CGI-S 
 Conduct Mini Internatio nal  Neuropsychiatric Interview 7.0 (MINI 7.0)   
 Conduct HAMD17 interview (if a HAMD17 intervie w was conducted for Marinus PPD 
study 1042- PPD-2002 at the same investigative site within 2 weeks of the screening visit the 
screening HAMD17 interview does not have to be repeated).  
 Perform EPDS 
 Perform STAI6 

 Perform a physical exam
ination  
 Collect vital 
signs (blood pressure [BP], pulse, temperature, respiratory rate [RR]) 
 Collect ECG 
 Collec
t urin
e for urinalysis, urine drug screen and urine pregnancy test  
 Collect safety laboratory test
s  
 Measure height and weight  

 Conduct CSSRS interview 
 
 Review inclusi on and exclusion criteria.  Screen failure is defined as a subject who has given 
informed consent, and failed to meet the inclusion criteria and/or met the exclusion criteria 
 Schedule a SAFER interview if the subject meets the eligibility criteria.  The SAFER 
interview will be conducted during the screening period.  The investigational site must wait 
for the results of the SAFER interview before enrolling the subject into the treatment phase 
of the study (if a SAFER interview was conducted within 2 weeks for Marinus PPD study 
1042- PPD-2002 at the same investigative site the SAFER interview does not have to be 
repeated. In this instance the HAMD17 score from the SAFER interview can be used to 
qualify the subject for the study).  
 Screening period may be e
xtended to 21 days with approval from the medical monitor (e.g., a 
laboratory sample was hemolyzed and had to be repeated causing a delay ). 
7.5 Treatment Period (Day 1 to Day 28; Visits 2 to 7) for OL QHS 4 week 
7.5.1 Start  of the Open-label Safety Period (Enrollment Visit for the OL QHS 4 week ) 
(Day 1) 
 The subject arrives in the clinic to complete baseline assessments on Day 1.  
 Conduct HAMD17 interview 
 Perform EPDS 
 Perform STAI6 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 57 of 131  Assess CGI-S 
 Review concomitant me
dications an d therapies  
 Collect vital signs (BP, pulse, temperature, RR)  
 Measure weight  
 Collect ECG 
 Collec
t urin
e for urinalysis, urine drug screen and urine pregnancy test 
 Collect safety laboratory tests 
 Collect neurosteroid l
evel 
 Collect SSS 
 Collect AEs
 
 Conduct CSSRS int
erview  
 Review inclusi
on and exclusion criteria (inc luding hematology, chemistry, urinalysis, urine 
drug screen and pregnancy tests from the screening visit); HAMD17 must be ≥ 18 for 
enrollment. 
 If the subject continues to meet the inclusion criteria and has not developed any exclusion 
criteria the subject will be enrolled in the study  
 Dispense medication bottle after enrollment to the open-label    Provide the subject with 
dosing instructions and subject diary com
pletion. 
 The subject  will be instructed to take the first dose of the study medication that night 
(675 mg for the OL QHS 4 week group)  
 If the s ubject is breastfeeding, she is encouraged to “pump and dump” during the study 
period and for 45 days after the last dose.  She should be provided with a breast pump if she 
does not have one.  Breast feeding is prohibited during the treatment phase and until 45 days 
following the last dose of the study drug. 
 
7.5.2 Treatment Visits (Days 2, 8, 15, 22, 29) for OL QHS 4 week 
 Conduct interviews for HAMD17  
 Conduct interviews f
or CGI- I  
 EPDS  
 STA I6  
 Collect AEs 
 Collect ECG (Day 7, Day 14 ) 
 Collect vital signs (BP, pulse, RR, temperature)  
 Collect SSS  
 Collect a PK sample  
 Record concomitant medications  
 Collect safety laboratory tests (Day 14 only) 
 Collect neurosteroid lev
el (Day 14 only) 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 58 of 131  Collect urine for urinalysis, urine drug screen and urine pregnancy test  
 Conduct CSSRS interview 
 
 Perform
 a physical examination and collect weight (Day 14 only) 

 Dispense study medication with a supply to last until the next visit (+ 3 days overage to cover 
for unexpected need to re-sche du
le a study visit or weekends).  Provide the subject with 
dosing instructions.  
 Start study drug taper Day 29-32 
 
7.6 Fo
llow-up Visit 1 (Day 36 ± 2), Follow-up Visit 2 (Day 59 ± 2), Follow- up 
Visit 3 (Day 89 ± 4), and Follow-up Visit 4 (Day 1 19 ± 4) for the OL QHS 
4 week group 
 The Follow-up Visit 1 should occur about 1 week after D29 visit, and about 4 days after the 
subj
ect has taken her last dose of the study medication.  The Follow-up Visit 2 should occur 
approximately 30 days a
fter Follow-up Visit 1. The Follow-up Visit 3 should occur 
approximately 30 days after Follow-up Visit 2. The Follow-up Visit 4 should occur 
approximately 30 days after Follow-up Visit 3. (All Follow-up visits should be scheduled 
within visit window unless there is a 
medical need to see the subject sooner; an additional 
safety visit can be scheduled as per the investigator’s discretion) 
 Conduct interviews for HAMD17 and CGI- I  
 Perform EPDS 
 Perform STAI6 
 Review concomitant medications and therapies  
 Collect vital signs (BP, pulse, temperature, RR) 
 ECG (Follow-up Visit 1 only) 
 Collect safety laboratory tests (Follow-up Visit 1 and 2 only) 
 Collect neurosteroid level (Follow-up Visit 1 and 2 only)  
 Collect PK sample (Follow-up Visit 1 and 2 only) 
 Collect urine for urinalysis, urine drug screen and urine pregnancy test  
 Mea sure weight (Follow-up Visit 4 only) 
 Conduct CSSRS interview 
 Collect SSS 
 Collec t AEs  
 Collect study medication bottle dispensed at Day 29 (Follow-up Visit 1 only).  Review 
subject dosing diary and complete drug accountability while subject is present.  
 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 59 of 131 Table 7. Schedule of Assessments for the Open-label OL QHS 4 Week Group 
VISIT Screening 
(V1)  Day1  
(V2)  Day2  
(V3)  Day8  
(V4)  D15  
(V5)  Day22  
(V6)  Day29  
(V7)  Day3 6 
(V8; 1st 
FU) Day5 9 
(V9; 2nd 
FU) Day8 9 
(V10; 3rd 
FU) Day 1 19 
(V11; 4th 
FU) 
Informed consent X           
Demographics, medical history  X           
MINI neuropsychiatric interview  X           
Inclusion/Exclusion criteri a X X          
Dispense medication  / Return 
Accountability  
  X X X X X X X    
Concomitant Medications and Prior 
Therapy Review  X X X X X X X X X X X 
Physical examination  X      X     
SAFER Interview (during screening)  X           
Vital signs (BP, Pulse, RR, 
 X X X X X X X X X X X 
Height (screening only) and weight  X X     X    X 
ECGs X    X  X X    
Safety Laboratory Tests  X X   X  X X X   
PK sample collection    X X X  X X X   
Neurosteroid sample collection   X X X X  X  X X   
Urinalysis e Drug Screen and Pregnancy 
 X X  X X X X X X X X 
Record AEs   X X X X X X X X X X 
HAMD17  X X X X X X X X X X X 
CGI-I   X X X X X X X X X 
CGI-S X X          
EPDS  X X X X X X X X X X X 
STAI6 X X X X X X X X X X X 
CSSRS  X X X X X X X X X X X 
SSS  X X X X X X X X X X 
Start Taper        X     
The following priority order will be in effect when more than 1 assessment is required at a particular time point:  1) HAMD17  2) CGI -I/CGI -S 3) EPDS 
4) STAI6 5) SSS 6) CSSRS 7) vital signs 8) ECG 9) safety labs 10) neurosteroid sample 11) PK sample 12) urinalysis, urine drug screen and pregnancy test 13) 
physical examination.  SAFER interview is scheduled if subject meets the eligibility criteria at the Screening visit.  The SA FER interview will be conducted 
during the screening period.  The investigational  site must wait for the results of the SAFER interview before enrolling the subject into the treatment phase of the 
study. Screening period may be extended to 21 days with approval from the medical monitor.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 60 of 131 7.7 Screening Period (Day -14 to -1) for OL 1,125 mg and OL Bolus-Oral groups 
7.7.1 Screening Visit (Visit 1) 
 Obtain written informed conse
nt  
 Collect demographics, medi
cal history, review prior medications, review of concomitant 
medications and therapies,  
 Assess  C GI-S 
 Conduct Mini Internatio nal  Neuropsychiatric Interview 7.0 (MINI 7.0)   
 Conduct HAMD17 interview (if a HAMD17 intervie w was conducted for Marinus PPD 
study 1042- PPD-2002 at the same investigative site within 2 weeks of the screening visit the 
screening HAMD17 interview does not have to be repeated).  
 Perform EPDS 
 Perform 
STAI6 
 Perform a physical examination  
 Collect vital signs (blood pressure [BP], pulse, temperature, respiratory rate [RR]) 
 Collect ECG 
 Collect urine for urinalysis, urine drug screen and urine pregnancy test  
 Collect safety laboratory tests  
 Measure height and weight  
 Conduct CSSRS interview  
 Review inclusion and exclusion criteria.  Screen failure is defined as a subject who has given 
informed consent, and failed to meet the inclusion criteria and/or met the exclusion criteria 
 Schedule a SAFER interview if the subject meets the eligibility criteria.  The SAFER 
interview will be conducted during the screening period.  The investigational site must wait 
for the results of the SAFER interview before enrolling the subject into the treatment phase 
of the study (if a SAFER interview was conducted within 2 weeks for Marinus PPD study 
1042- PPD-2002 at the same investigative site the SAFER interview does not have to be 
repeated. In this instance the HAMD17 score from the SAFER interview can be used to 
qualify the subject for the study).  
 Screening period may be extended to 21 days with approval from the medical monitor (e.g., a 
laboratory sample was hemolyzed and had to be repeated causing a delay ). 
7.8 Treatment Period (Day 1 to Day 29; Visits 2 to 7) for OL 1,125 mg and OL 
Bolus-Oral groups  
7.8.1 Start of the Open-label Safety Period (Enrollment Visit for the OL 1,125 mg and 
OL Bolus-Oral groups) (Day 1) 

 The subject arrives in the clinic to complete baseline assessments on Day 1.  
 C TNI to conduct HAMD17 interview 
 Perform EPDS 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 61 of 131  Perform STAI6 
 Assess CGI-S 
 Review concom
itant medications an
d thera pies  
 Collect vital signs (BP, pulse, temperature, RR)  
 Measure weight  
 Collec t EC
G 
 Collect u
rine for urinalysis, urine drug screen and urine pregnancy test 
 Collect safety laboratory tests 

 Collect neurosteroid level
 
 Collect SSS 
 Collect AEs 
 Conduct CSSR
S interview  
 Review inclusi
on and exclusion 
criteria (includin g hematology, chemistry, urinalysis, urine 
drug screen and pregnancy tests from the screening visit); HAMD17 (as determined by 
CTNI) must be ≥ 18 for enrollment
. 
 If the subject continues to m
eet the inclusion criteria and has not developed any exclusion 
criteria the subject will b
e enrolled in the study  
 Dispense medication bottle after enrollment. Provide the subject with dosing instructions and 
subject diary completion. 

 For the OL 1,125 mg group: the subject will be instructed to take the first oral doses of the 
study medication that evening (675 mg [3 capsules] at dinner time [at 7 pm] and at bedtime 
[at 10 pm] )  
 For the OL Bolus-Oral group:
 the subject will receive IV bolus 12 mg over 2 minutes at 
approximately 4 pm (preferabl
y ±1 hour) while on the unit, be observed for development of 
sedation and/or other untoward effects for at least 1 hour post-bolus and then be discharged 
and instructed to take the first oral
 doses of the study medication that evening (750 mg [15 
mL oral suspension at 50 mg per m
L] at dinner time [at 7 pm] and at bedtime [at 10 pm] )  
 Oral IP should be taken within ±15 minutes of a fatty meal or snack (e.g., yogurt, nuts, 
avocado), and with 240 mL (8 oz) of water.   
 A sub-group
 of 6 subjects (to be called ‘PK sub-group’, Section 7.10.7) in each of the OL 
1,125 mg and OL Bolus-Oral groups 
will stay overnight on the unit between Day 1 and Day 
2 to undergo comprehensive PK assessment as follows: for
 the OL 1,125 mg group plasm a 
samples for PK analysis will be drawn at t
he following times after the first oral dos e on Day 
1 (i.e., the 675 mg oral capsules dose at 7 pm at dinner time; 0hr): +1hr, +2hr, +3hr (i.e., just 
prior to the 10 pm 675 mg dose), at 
+4hr, +5hr, +6hr, and at 8 am on Day 2. For the OL 
Bolus-Oral group plasma sample
s for PK analyses will be drawn at the following times after 
the IV bolus on Day 1 (e.g., the 12 mg IV bolus at 4 pm; 0hr): +1hr, +2hr, +3hr (i.e., just 
prior to the first oral dose of 750 mg oral suspension at dinner time), at +4hr, +5hr, +6hr (i.e., 
just prior to the second 750 mg oral suspension evening dose), at + 7hr, +8hr, and at 8 am on 
Day 2. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 62 of 131  If the subject is breastfeeding, she is encouraged to “pump and dump” during the study 
period and for 45 days after the 
last dose.  She should be provided with a breast pump if she 
does not have one.  Breast feeding is prohibited during the treatment phase and until 45 days 
following the last dose of the study drug.  
7.8.2 Treatment Visits (Days 2, 8, 15, 22, 29 ± 3 days [except Day 2]) for OL 1,125 mg 
and OL 
Bolus-Oral groups 

 CTNI to conduct interview for HAMD17  
 Conduct interview for CGI- I  

 EPDS  
 STAI6  
 Collec
t AEs 
 Collec
t ECG (Day 2, Day 8, Day 1
5, Day 29) 
 Collect vital signs (BP, p
ulse, RR, temperature)  
 Measure weight (Day 15, Day 29) 

 Collect SSS  
 Collect a PK sample
  
 Record c
oncomitant m
edications  
 Collect safety laboratory tests 
(Day 15, Day 29) 
 Collect neurosteroid level
 (Day 2, Day 8, Day 15, Day 29) 
 Collect urine for urinalysis, urine drug screen and urine pregnancy test (Day 8, Day 15, Day 
22, Day 29) 
 Conduct CSSR S interview  
 Perform a physical examination ( Day 29) 
 Dispense study medicat
ion with a supply to last until the next visit (+ 3 days overage to cover 
for unexpected need to re-schedule a
 study visit or weekends).  Provide the subject with 
dosing instructions.  
 For the OL 1,125 mg group: t
he subject will be instructed to take Day 2 oral doses of the 
study
 medication that evening (675 mg [3 capsules] at dinner time [at 7 pm] and 675 mg [3 
capsules] at bedtime [at 10 pm
]) followed by 26 days of 1,125 mg (5 capsules) at dinner time 
 For the OL Bolus-Oral group: the subject will be instructed to take Day 2 oral doses of the 
study medication that eveni
ng (750 mg [15 mL oral suspension at 50 mg per mL] at dinner 
time [at 7 pm] and 750 mg [15 mL 
oral suspension at 50 mg per mL] at bedtime [at 10 pm] ) 
followed by 2 6 days of 1,000 mg (20 mL oral suspension at 50 mg per mL ) at dinner time 
 Oral IP should be taken within ±15 minutes of a fatty meal or snack (e.g., yogurt, nuts, 
avoca do), and with 240 mL (8 oz) of water.   
 During Visit 7 (Day 29) s
tart study drug taper (Day 29- 32) (See Sections 6.2.5 and 6.2.6) 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 63 of 131 7.9 Follow-up Visit 1 (Day 36 ± 3), Follow-up Visit 2 (Day 57 ± 3), and Follow- up 
Visit 3 (Day 71 ± 3) for the OL 1,125 mg and OL Bolus-Oral groups 
 The Follow-up Visit 1 should occur 
about 1 week after D29 visit, and about 4 days after the 
subject has taken her last dose of the study medication.  The Follow-up Visit 2 should occur 
approximately 21 days after Fol
low-up Visit 1. The Follow-up Visit 3 should occur 
approximately 14 days after Follow-up Visit 2 (All Follow-up visits should be scheduled 
within visit window unless there is a medical need to see the subject sooner; an additional 
safety visit can be scheduled as per the investi
gator’s discretion). 
 CTNI to conduct interview for HAMD17  
 Conduct interview for CGI-I  
 Perform EPDS 
 Perform
 STAI6 

 Review concomitant me
dications an d therapies  
 Collect vital signs (BP, pulse, temperature, RR) 
 ECG (Follow-up Visi
t 1 only) 

 Collect safety laboratory tests (Follow-up Visit 1 and 3 only) 
 Collect neurosteroid level (Follow-up Visit 1 and 3 only)  
 Collect PK sample (Follow-up Visit 1 only) 
 Collect urine for urinalysis, urine drug screen and urine pregnancy test  
 Measure weight (Follow-up Visit 3 only) 
 Conduct CSSRS interview 

 Collect SSS 
 Collect AEs  
 Collect study medication bottle dispensed at Day 29 (Follow-up Visit 1 only).  Review 
subject dosing diary and complete drug accountability while subject is present.  
 
  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 64 of 131 Table 8. Schedule of Assessments for the Open-label OL 1,125 mg and OL Bolus-oral Groups 
VISIT Screening 
(V1)  Day1  
(V2)  Day2  
(V3)  Day8 ±3d 
(V4)  D15 ±3d 
(V5)  Day22 ±3d 
(V6)  Day29 ±3d 
(V7)  Day36  ±3d 
(V8; 1st FU) Day57  ±3d 
(V9; 2nd FU) Day71  ±3d 
(V10; 3rd FU) 
Informed consent X          
Demographics, medical history  X          
MINI neuropsychiatric interview  X          
Inclusion/Exclusion criteri a X X         
Dispense medication / Return  
Accountability  
  X X X X X X X   
Concomitant Medications and Prior 
Therapy Review  X X X X X X X X X X 
Physical examination  X      X    
SAFER Interview (during screening)  X          
Vital signs (BP, Pulse, RR, 
 X X X X X X X X X X 
Height (screening only) and weight  X X   X  X   X 
ECGs X X X X X  X X   
Safety Laboratory Tests  X X   X  X X  X 
b Bolus (OL Bolus -Oral  group only)   X         
PK sample collection    X X X X X X   
PK subgroup sample collection   c X         
Neurosteroid sample collection   X X X X  X  X  X 
Urinalysis,  Drug Screen and Pregnancy 
 X X  X X X X X X X 
Record AEs   X X X X X X X X X 
a HAMD17  X X X X X X X X X X 
CGI-I   X X X X X X X X 
CGI-S X X         
EPDS  X X X X X X X X X X 
STAI6 X X X X X X X X X X 
CSSRS  X X X X X X X X X X 
SSS  X X X X X X X X X 
Start Taper        X    
 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 65 of 131  
a CTNI will conduct all HAMD ratings except the one at screening 
b IV bolus is to be done at approximately 4 pm (preferably within ±1 hour) and allowing for at least 1-hour post-bolus follow-up at the site before discharge 
c A sub-group of 6 subjects (to be called ‘PK sub-group’) in each of the OL 1,125 mg and OL Bolus-Oral groups will stay overnight on the unit between Day 1 
and Day 2 to undergo comprehensive PK assessment as follows: for the OL 1,125 mg group plasma samples for PK analysis will be drawn at the following times 
after the first oral dose on Day 1 (e.g., the 675 mg oral capsules dose at 7 pm at dinner time; 0hr): +1hr, +2hr, +3hr (i.e., just prior to the 10 pm 675 mg dose), at 
+4hr, +5hr, +6hr, and at 8 am on Day 2. For the OL Bolus-Oral group plasma samples for PK analyses will be drawn at the following times after the IV bolus on 
Day 1 (e.g., the 12 mg IV bolus at 4 pm; 0hr): +1hr, +2hr, +3hr (i.e., just prior to the first oral dose of 750 mg oral suspension at dinner time), at +4hr, +5hr, +6hr 
(i.e., just prior to the second 750 mg oral suspension evening dose), at + 7hr, +8hr, and at 8 am on Day 2. 
 
The following priority order will be in effect when more than 1 assessment is required at a particular time point:  1) HAMD17 2) CGI-I/CGI-S 3) EPDS 
4) STAI6 5) SSS 6) CSSRS 7) vital signs 8) ECG 9) safety labs 10) neurosteroid sample 11) PK sample 12) urinalysis, urine drug screen and pregnancy test 13) 
physical examination.  SAFER interview is scheduled if subject meets the eligibility criteria at the Screening visit.  The SAFER interview will be conducted 
during the screening period.  The investigational site must wait for the results of the SAFER interview before enrolling the subject into the treatment phase of the 
study. Screening period may be extended to 21 days with approval from the medical monitor.
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 66 of 131 7.10 Study Evaluations and Procedures 
7.10.1 Demographics, Medical History, and Other Baseline Characteristics  
Demographics, medical history,
 and other baseline characteristics will be collected and recorded 
on the appropriate sections of the eCRF at t
he time of the screening visit.  
7.10.2 Informed Consent 
The nature of the study a
nd its risks and benefits will be explained to the subject by the principal 
investigator or designated study personnel.  The purpose of this study will be discussed with the 
subject.  
7.10.3 Eligibility Review 
An eligib
ility review will be conduc
ted by the investigator at the visits specified in Table 8, 
using the subject inclusion 
and exclusion criteria as detailed in Section 4.  
7.10.4 Prior Medication, Concomitant Medication and Concomitant Therapy Review 
At screening, prospective subjects will be asked 
about medications they have taken in the 
previous 60 days, including prescription medications, non-prescription medications, herbal 
medications, vitamins, and supplem
ents.  At subsequent visits, the subjects will be asked about 
medications taken since the last vis
it.   
The medications that were taken within t
he past 60 days will be recorded.  The medications that 
were taken within the past 60 days 
but stopped before the screening visit are recorded on the 
prior medications eCRF page.  The m
edications that were taken during the study period between 
the screening visit and last follow-u
p visit, regardless of whether the medication was started 
during the study period or before the study period, ar
e recorded on the concomitant medications 
eCRF page.  
The following data will be recorde
d for all medications used by the subject:  drug name, dose, 
regimen, route of administrati
on, start and stop dates, and the indication for use.  
The type of psychological counseling the subject received from the time of screening through the 
last follow-up visit wi
ll be recorded on the Concomitant Psychological Treatment eCRF page.  
7.10.5 Physical Examination 
A co
mpl
ete physical examination will be performed at screening and at Day 10 visit (Day 29 for 
OL QHS 4 week, OL 1,125 mg and OL 
Bolus-Oral groups).  
The physi
cal examination will include a review of the following body systems: 
 General appearance 
 Skin  
 Head, eyes, ears, nose, mouth and throat 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 67 of 131  Neck/thyroid/breastfeeding status  

 Musculoskeletal 
 Respiratory 
 Cardiovascular 
 Neurological 
 Abdomen 
The physical examination will be documented in the subject’s source documents and on the 
physical examination eCR
F.  If a new clinically significant abnormal finding (i.e., not noted at 
screening) occurs after the 
screening examination, it must be captured as an AE and documented 
on the appropriate AE eCRF page.  
7.10.5.1  12-lead Electrocardiogram 
A 12-lead ECG will be conducted as ou
tlined above.  Before each measurement, the subject 
should be resting in a supine or sem
i-recumbent position for 10 minutes.  RR, PR, QRS, QTcF 
and QTcB will be collected.  ECGs will be measured with equipment calibrated as per the ECG 
vendors’ standard operating procedure.  The ECG results will be assessed by a qualified 
clinician.  The i
nvestigator’s assessment of normal or abnormal will be recorded and entered in 
the eCRF page.  If a new clinically significant  ab
normal finding (i.e., not noted at Screening) 
occurs after the Screening examination, it  must be
 captured as an AE or SAE (if it meets criteria 
for an SAE – see Section 8) and docu m ented on the appropriate AE eCRF page and, if an SAE, 
submitted to Marinus Safety Departm ent on the SAE form.   
7.10.5.2  Clinical Safety Laboratory Evaluations  
The name and address of the central clinical laboratory for this study will be maintained in the 
Investigator’s files at each study site.  
All clinical laboratory assays will be performed according to the laboratory’s normal procedures.  
Reference ranges are to be supplied by the laboratory and will be used to assess the clinical 
laboratory data for clinical significance and out- of-range pathological changes.  The investigator 
should assess out-of-range clinical laboratory values for clinical significance, indicating if the 
values are clinically significant or not.  Abnormal clinical laboratory values, which are 
unexpected or not explained by the subject’s clinical condition, may, at the discretion of the 
investigator or sponsor, be repeated as soon as possible until confirmed, explained, or resolved. 
The following clinical laboratory assessments will be performed:  
Biochemistry  
Sodium, potassium, glucose, chloride, carbon di
oxide, creatinine, total protein, blood urea 
nitrogen (BUN), albumin, total bilirubin (with reflex fractionation to direct and indirect bilirubin 
if total bilirubin is elevated and outside of the normal range), ALT, AST, alkaline phosphatase, 
thyroid stimulating hormone (with reflex to free T4 if thyroid stimulating hormone (TSH) is 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 68 of 131 outside of the normal range).  The investigator may determine serum β human chorionic 
gonadotropin ( HCG) levels to confirm
 or exclude pregnancy.  
Hematology 
Hem
oglobin, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, 
mean corpuscular hemoglobin concentration, platelet count, and white blood cell count with 
differential.  
Subjects are not required to be fasti
ng prior to collection of the blood samples. 
Urinalysis Including Pregnancy Test and Urine Drug Screen 
Leukocytes, nitrites, protein, blood, specific gravity, glucose, ketones, urine pregnancy test, urine 
drug screen (cannabis, opioids [including oxycodone, methadone and buprenorphine], cocaine, 
benzodiazepines, barbiturates, alcohol [ethanol], and phencyclidine).  
Confirmatory testing of positive drug screen findings using for example gas chromatography 
mass spectroscopy (GC MS) may be conducted.  
7.10.5.3  Adverse Event Collection 
Please refer to Section 8, Adverse and Serious Adverse Events Assessment. 
7.10.5.4  Vital Signs 
Vital signs including BP , puls e, respirations, and temperature (recorded in Celsius [°C]) will be 
monitored at the time points as outlined above.  Vital signs should be collected after the subj ect 
has been supine for 5 minutes.  If a vital sign measurement is scheduled at the same tim e as a 
blood draw, vital signs should be
 collected prior to the blood draw.  Blood pressure sho uld be 
determined by an appropriately-sized cuff (using the same method, the same arm and in t he same 
position throughout the study).  Any abnormal screening vital sign results considered to be 
clinically significant should be repeated to confirm the finding.  Height (in centimeters) will be 
collected at the screening visit.  Weight (i
n kilograms) will be collected as outlined above.  
Any clinically significant deviations 
from baseline vital signs that are deemed clinically 
significant in the opinion of the investigator are to be recorded as an AE.  
7.10.6 Inte rviews, Questionnaires, and Scales 
The scales and assessments are listed in Appendix 2.  A separate file containing each 
scale/assessment will be provided to the
 site. 
7.10.6.1  Mini International Neuropsychiatric Interview 7.0 
The Mi ni International Neuropsychiatric Interview (MINI) is a short, clinician-administered, 
structured diagnostic interview, with an administration time of approximately 15 minutes.  The 
MINI will be administered at the screening visit.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 69 of 131 7.10.6.2  The Hamilton Depression Rating Scale  
The HAMD is a commonly-used semi-structured clinician-rated instrument which assesses the 
range of symptoms that are m
ost frequently observed in subjects with major depression.  HAMD 
has undergone a considerable amount of psychometric study and is accepted as a valid standard 
of symptom outcome assessment in studies of major depression.  In this study, the symptoms of 
depression will be scored 
using the original 17-item HAMD scale (HAMD17).  The 6-item 
version of this scale, known as HAM
D6, will be derived from these data and used as an 
additional measure of changes in symptoms of depression.  The items on the HAMD6 scale are 
as follows :  depressed mood, work and interests, gener
al somatic symptoms (tiredness), anxiety, 
guilt feelings, and psychomotor retardation.  Both HAMD6 and HAMD17 have been validated 
and used in many clinical trials of antidepressant medications.11  The use of the 6-item scale is 
justified because many items on the
 17-item version cannot be expected to change over short 
period of time (e.g. weight).  
7.10.6.3  Stanford Sleepiness Scale 
Stanford Sleepiness Scale (SSS) 
is a simple 8-item self-rated scale measuring level of sleepiness 
the subject is feeling.  Level 1 is “feeling active, vital, alert or wide-awake” level 7 is “no longer 
fighting sleep, sleep onset soon; having dream-like thoughts”; level 8 is sleeping.   
7.10.6.4  Clinical Global Impression-Improvement and Clinical Global 
Impression -Severity  
The CGI-I is a 7-point scale that asks the clinician to assess how much the subject's illness has 
improved or worsened relative to a baseline state at the beginning of the intervention.  It is rated 
as:  1, very much improved; 2,  much improved; 3, minimally improved; 4, no change; 5, 
minimally worse; 6, much worse; or 7, very much worse.  The Clinical Global Impression – 
Severity scale (CGI-S) is a 7-point scale that asks the clinician to rate the severity of the subject's 
depression at the time of assessment, relative to the clinician's past experience with subjects who 
have the same diagnosis.  Considering total clinical experience, a subject is assessed on severity 
of depression at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 
4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. 
7.10.6.5  Edinburgh Postnatal Depression Scale (EPD S) 
The EPDS is a 10-question self-rated instrument for assessment symptoms of PPD, such as 
worry, sleep, mood,  and enjoyment.  Two questions assessing obsessive thoughts (Obsessive 
Thoughts Questionnaire) are added to this questionnaire (“How much of your time is occupied 
by obsessive thoughts over the past 24h?” and “How much distress do your obsessive 
thoughts cause you?),  but they are not included in the calculation of the total EPDS score in the 
statistical analysis.  These 2 questions are rated on a 5-point scale.  
7.10.6.6  Spielberg Trait-State Anxiety Inventory, 6 Item Version  
The STAI6 is a short questionnaire evaluating anxiety state.  The STAI6 has 6 questions, such as 
“I feel calm,” “I feel tense,” which the subject rates on a scale corresponding to “not at all, ” 
“somewhat,” “moderately”, and “very much.”12  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 70 of 131 7.10.6.7  SAFER Interview 
Staff psychiatrists or psychologists at the Massachusetts General Hospital Clinical Trials 
Network and Institute (CTNI) will perform ind
ependent remote SAFER interview (State versus 
trait; Assessability; Face validity; Ecological Validity; and Rule of 3 Ps (pervasive, persistent, 
and pathological)) for the scre
ened subjects who are deemed eligible for enrollment to confirm 
validity of the diagnosis of PPD and 
eligibility for the study from depression perspective.  If the 
subject was screened by the SAFER team
 for Marinus study 1042- PPD-2002 and confirmed to 
have postpartum depression but the HAMD17 severity criteria were not met, the subject could be 
considered eligible for this s
tudy without repeating the SAFER interview provided that the 
original interview was done within 2 weeks of the screening visit for the current study. 
CTNI will also perform all HAMD ratings e
xcept the one done at screening. 
7.10.6.8  Columbia Suicide Severity Rating Scale (CSSRS) 
The CSSRS 
is a unique, simple, and short m
ethod of assessing both behavior and ideation that 
tracks all suicidal events, and provides a summary of suicidality.13  It assesses the lethality of 
attempts and other features of
 ideation (frequency, duration, controllability, reasons for ideation, 
and deterrents) that are significantly predictive of completed suicide. 
7.10.7 Pharma cokinetic Sampling 
Blood sampl
es for pharmacokinetic analysis will be drawn at the times specified in Table 8 to 
allow determination of 
ganaxolone plasma levels.  
A sub-group of 6 subjects (to be called ‘PK sub
-group’) in each of the OL 1,125 mg and OL 
Bolus-Oral groups will stay overnight on the unit between Day 1 and Day 2 to undergo 
comprehensive PK assessment as follows: for the OL 1,125 mg group plasma samples for PK 
analysis will be drawn at the following times after the first oral dose on Day 1 (i.e., the 675 mg 
oral capsules dose at 7 pm at dinner time; 0hr): +1hr, +2hr, +3hr (i.e., just prior to the 10 pm 675 
mg dose), at +4hr, +5hr, +6hr, and at 8 am on Day 2. For the OL Bolus-Oral group plasma 
samples for PK analyses will be drawn at
 the following times after the IV bolus on Day 1 (e.g., 
the 12 mg IV bolus at 4 pm; 0hr): +1hr, +2hr, +3hr (i.e., just prior to the first oral dose of 750 mg 
oral suspension at dinner time), at +4
hr, +5hr, +6hr (i.e., just prior to the second 750 mg oral 
suspension evening dose), at + 7hr, +8hr, and at 8 am on Day 2. 
The first 6 consecutively enrolled subjects who are in units with overnight inpatient capabilities 
and who consent
 for inclusion in the PK subgroup will be included in the PK subgroup. 
 
7.10.8  Neurosteroid Levels  
Blood samples for determination of neurosteroid levels (allopregnanolone and potentially other 
metabolites of progesterone) will be col
lected at time points specified in Table 8 .  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 71 of 131 7.10.9 Volume of Blood to Be Drawn from Each Subject 
Tab
le 9. Volume of Blood to Be Drawn from Each Subject for the OL TID, OL QHS and 
Double-blind Groups 
Assessment  Approximate Sample 
Volume (mL)a Number of 
Samples  Approximate Total 
Volume (mL)  
Pharmacokinetic samples  4 5 20 
Safety hematology  3 3 9 
Safety chemistry  7 3 21 
Neurosteroid level  4 2 8 
Total mL    58 
 
 
Table 10. Volume of Blood to Be Drawn from Each Subject for the OL QHS 4 Week, OL 
1,125 mg, and OL Bolus-oral groups 
Assessment  Approximate Sample 
Volume (mL)a Number of 
Samples  Approximate Total 
Volume (mL)  
Pharmacokinetic samples  4 6 24 
Safety hematology  3 6 18 
Safety chemistry  7 6 42 
Neurosteroid level  4 7 28 
Total mL    112 
 
 
Table 11. Volume of Blood to Be Drawn from Each Subject for the PK Subgroup of OL 
1,125 mg Group 
Assessment  Approximate Sample 
Volume (mL)a Number of 
Samples  Approximate Total 
Volume (mL)  
Pharmacokinetic samples  4 12 48 
Safety hematology  3 6 18 
Safety chemistry  7 6 42 
Neurosteroid level  4 7 28 
Total mL    136 
 
 
Table 12. Volume of Blood to Be Drawn from Each Subject for the PK Subgroup of OL 
Bolus-Oral Group 
Assessment  Approximate Sample 
Volume  (mL)a Number of 
Samples  Approximate Total 
Volume (mL)  
Pharmacokinetic samples  4 14 56 
Safety hematology  3 6 18 
Safety chemistry  7 6 42 
Neurosteroid level  4 7 28 
Total mL    144 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 72 of 131 During this study, approximately 58 mL of blood will be drawn from all subjects during the 
study for the OL TID, OL QHS and Double-blin
d groups.  Approximately 112 mL of blood will 
be drawn from all subjects during the 
study for the OL QHS 4 week, OL 1,125 mg, and OL 
Bolus-Oral groups. 
Subjec
ts in the ‘PK subgroup’ of the OL 1,125 mg and OL Bolus-oral groups (6 subjects in each 
subgroup) will have additional 6 and 8 samples, respectively, at 4 mL each, for a total of 
approximately 136 mL and 144 mL of blood drawn, respectively.  
7.10.10  Safety Plan for Medical Emergencies 
If the subject exhibits suicidal ideation during the study visit (for example answering “yes” to 
questions 4 and 5 in the suicidal ideation part of the CSSRS) she must be evaluated by a 
psychiatrist immediately.  Suicidality assessment and the decision regarding further evaluation 
and treatment m
ay be done by a psychiatrist principal investigator (or a sub-investigator). If a 
psychiatrist is not available at the study site, the site must have a plan how to access psychiatric 
care immediately, for example at a local emergency room or other acute care facility.  
Each investigative study site must provide 24-hour medical coverage to address questions from 
the subjects and respond to medical emergencies, such as suicidal ideation and adverse events, 
including during the off-duty hours. Each subject will be provided with a wallet card and 
information how to contact the study site at all hours.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 73 of 131 8 ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT 
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events 
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment.  An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease tem
porally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product 
(International Council on Harmonisation [ICH] Guidance E2A 1995).  
At each study visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (e.g., “Have you had any health problems since the previous 
visi
t/you were last asked?”).  All AEs are collected from the time the informed consent is signed 
until the end of the follow-up period.  This includes events occurring during the screening period 
of the study, regardless of whether or not investigational product is administered.  Where 
possible, a diagnosis rather than a list of symptoms should be recorded.  If a diagnosis has not 
been made, then each symptom should be listed individually.   All AEs should be captured on the 
appropriate AE pages in the eCRF and in source documents.  In addition to untoward AEs, 
unexpected benefits outside the investigational product indication should also be captured on the 
AE eCRF. 
All AEs must be followed to closure, regardless of whether the subject is still participating in the 
study.  Closure indicates that an outcome is reached (AE has resolved), stabilization achieved 
(the investigator does not expect any further improvement or worsening of the event), or the 
event is otherwise explained.  When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented. 
8.1.1 Severity Categorization 
The severity of AEs must be recorded during the course of the event including the start and stop 
dates for each change in severity.  Any changes in the severity of the AE must be recorded. 
The medical assessment
 of severity is determined by using the following definitions: 
Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic interve
ntion.  The event does not generally interfere with usual activities of daily 
living. 
Moderate:   A type of AE that is usually alleviated with specific therapeutic intervention.  The 
event interferes with usu
al activities of daily living, causing discomfort but poses no significant 
or permanent risk of harm to the research subject. 
Severe:  A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or
 may require intensive therapeutic intervention. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 74 of 131 8.1.2 Causality Categorization 
The investigator will assess caus
al relationship between the investigational product and each AE 
(i.e, their relationship to study drug), and answer “yes” or “no” to the question, “ Do you consider 
that there is a reasonable possibility that the event may have been caused by the investigational 
product?”  
8.1.3 Variables 
The following variable
s will be collected for each AE: 
 AE  
 The date when the AE started and stopped 
 Maximum i
ntensity or intensity or changes in intensi ty 
 Whether the AE is s
erious or not 
 Investigator causality rating again
st the study drug (yes or no) 
 Action taken with r
egard to investigational product (none, dose reduced, interrupted, 
withdrawn)  
 AE caused subject ’s discontinuation from study (yes or no ) 
 Outcome (fatal, not recovered/not resolved, recovered/resolved with sequelae, 
recovering/resolving, recovered/reso
lved, unknown) 
 
8.1.4 Symptoms of the Disease Under Study 
Sym
ptoms of the disease under study (e.g., depression) should not be classified as AEs as long as 
they are within the normal day- to-da
y fluctuation or expected progression of the disease and are 
part of the efficacy data to be collected in the study; however, significant worsening of the 
symptoms should be recorded as an AE. 
8.1.5 Adverse Events Based on Clinical Laboratory and Other Safety Evaluations 
A change in the value of a cli
nical laboratory, vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during treatment with the investigational product, a shif t 
of a parameter is observed from a normal value to an abnormal value, or a there is a further 
worsening of an already abnormal value.  When evaluating such changes, the extent of deviation 
from the reference range, the duration until return to the reference range, either while continuing 
treatment or after the end of treatment with the investigational product, and the range of variation 
of the respective parameter within its reference range, must be taken into consideration. 
If, at the end of the treatment period, there are abnormal clinical laboratory, vital sign, or ECG 
values which were not present at the pretreatment value observed closest to the start of study 
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (e.g. , concomitant disease) is found for the 
abnormal values. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 75 of 131 The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory, vital sign, or ECG parameter is clinically 
significant and therefore represents an AE. 
8.1.6 Adverse Events Based on Signs and Symptoms 
All AEs spontaneously reported by the subject or reported in response to the open question from 
the study personnel: “ Have you
 had any health problems since the previous visit/you were last 
asked? ” or revealed by observation, will be collected and recorded in the eCRF. 
8.1.7 Pregnancy 
All pregnancies are to be reported from
 the time informed consent is signed until the end of the 
follow-up period. 
Any report of pregnancy for any study participant must be reported within 24 hours to Marinus 
Safety Department or its delegate using the Pregnancy Report Form (and any applicable 
follow-up reports).  The study partici
pant must be withdrawn. 
Every effort should be made to gather inf
ormation regarding the pregnancy outcome and 
condition of the infant.  It is the responsibility of the investigator to obtain this information 
within 30 calendar days afte
r the initial notification and approximately 30 calendar days 
postpartum.  
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported using the Marinus Serious Adverse Event Form.  
Note :  An elective abortion is not considered an SAE. 
In addition to the above, if the i
nvestigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Marinus Serious Adverse Event Form to Marinus Safety 
Department.  The test date of the first positive serum/urine -HCG test or ultrasound result will 
determine the pregnancy onset date. 
8.2 Serious Adverse Event Procedures 
8.2.1 Reference Safety Information 
The re
ference for safety information for this study is the Investigator’s Brochure (IB), which the 
sponsor has provided under separate cover to all investigators. 
8.2.2 Reporting Procedures 
All initial and f
ollow-up SAE reports must be reported by the investigator to Marinus Safety 
Department within 24 hours of the first awareness of the event.  
The investigator must complete, sign, and date the Marinus Serious Adverse Event Forms and 
verify the accuracy of the information recorded on the form with the corresponding source 
documents and fax or e-mail the form to :  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 76 of 131 Email:  safetyPPD2003@marinuspharma.com  
Fax:  484-679-2138  
Note:  The 24-hour repo
rting requirement for SAEs does not apply to reports of abuse, misuse, 
overdose, or medication er
rors unless they result in an SAE.  
8.2.3 Serious Adverse Event Definition 
An SAE is any untoward medical
 occurrence (whether considered to be related to investigational 
product or not) that a
t any dose: 
 Results in death 
 Is life-threatening.  Note:  The term “life-threatening” in the definition of “serious” refers to 
an eve
nt in which the subject was at risk of death at the time of the event; it does not refer to 
an event that hypothetically might have caused death if it was more severe. 
 Requires inpatient hospitaliz ation or prolongation of existing hospitalization.  Note:  
Hospit
alizations, which are the result of elective or previously scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs.  For example, an admission for a previously scheduled ventral hernia 
repair would not be classified as an SAE; how
ever, complication(s) resulting from a 
hospitalization for an elective or previously scheduled surgery that meet(s) serious criteria 
must be reported as an SAE(s). 
 Results in persistent or significant disabi
lity/incapacity. 
 Is a congen ital abnormality or birth defect.  

 Is an important medical event.  
Note:  Important medical
 events that may not result in death, be life-threatening, or require 
hospitalization may be considered 
an SAE when, based on appropriate medical judgment, 
they may jeopardize the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home; blood 
dyscrasias or convulsions that do not result in inpatient hospitalization; or the development of 
drug dependency or drug abuse.  
8.2.4 Serious Adverse Event Collection Time Frame 
All SAEs (regardless of relationship to st
udy) are collected from the time the subject signs the 
informed consent until the end of the follow-up period and must be reported to the Marinus 
Safety Department or its delegate within 24 hours of the first awareness of the event.  In 
addition, the Marinus medical monitor should be informed of the event within 24 hours via either 
email or a phone call.  
In addition, any SAE(s) considered “related” to the investigational product and discovered by the 
investigator at any interval after the study has completed must be reported to the Marinus Safety 
Department within 24 hours of the first awareness of the event.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 77 of 131 8.2.5 Serious Adverse Event Onset and Resolution Dates 
The onset date of the SAE is defined 
as the date the event meets serious criteria.  The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the 
date the event is considered chronic.  In the case of hospitalizations, the hospital admission and 
IV dates are considered the onset and resolution dates, respectively. 
In addition, any signs or 
symptoms experienced by the subject after signing the informed consent 
form or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
 
8.2.6 Fatal Outcome 
Any SA
E that results in the subject’s death (i. e. the SAE was noted as the primary cause of 
death) must have fatal checked as an outcome with the date of death recorded as the resolution 
date.  For all other events ongoing at the time of death that did not contribute to the subject’s 
death, the outcome should be consid
ered not resolved, without a resolution date recorded. 
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (e.g., drug interrupted, reduced, 
withdrawn), the action taken wit
h the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received the investigational product).  The 
investigational product action of “withdrawn” should not be selected solely as a result of the 
subject’s death.  
8.2.7
 Regulatory Agency, Institutional Review Boar d, Ethics Committee, and Site 
Reporting 
The sponsor or its delegate is responsible for notifying the relevant regulatory authorities of 
related, unexpected SAEs. 
In addition, the sponsor or its delegate is responsible for notifying active sites of all related, 
unexpected SAEs occurring during 
all interventional studies across the ganaxolone clinical 
development program.  
The investigator is responsible for notifying the local Institutional Review Board (IRB), local 
Ethics Committee (EC), or the relevant local regulatory authority of all SAEs that occur at his or 
her site as required. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 78 of 131 9 DATA MANAGEMENT AND STATISTICAL METHODS 
9.1 Data Collection 
The investigators’ authorized site personnel must enter the information required by the protocol 
on the eCRFs.  A study monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data
 against the source data for completeness and accuracy.  Discrepancies 
between source data and data entered 
on the eCRF will be addressed by qualified site personnel.  
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel.  Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting.  Once a subject
 is enrolled, it is expected that site personnel 
will complete the eCRF entr
y within approximately 2 business days of the subject’s visit.   
9.2 Clinical Data Management 
Data are to be entered into a clinical database as specified in the eCRF completion guidelines or 
data management plan.  Quality control and data validation procedures are applied to ensure the 
validity and accuracy of the clinical database. 
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures.  Data queries requiring clarification are 
to be communicated to the site for resolution.  Only authorized personnel will make corrections 
to the clinical database, and al
l corrections are documented in an auditable manner. 
9.3 Statistical Analysis Plan 
The SAP will provide the statistical methods and definitions for the analysis of the safety and 
efficacy data, and it will describe the approaches to be taken for summarizing other study 
information such as subject disposition, demographics and baseline characteristics, 
investigational product exposure, and prior and concomitant medications .  The SAP will also 
include a description of
 how missing data will be addressed.  
The SAP will be finalized prior to database lock and/or unblinding of any portion of the trial to 
preserve the integrity of the statistical analysis and study conclusions.  
9.3.1 Data Review Committee (DRC) and Recommendations for Dosing  
Adverse events and other safety data, including sedation and dosing changes, will be adjudicated 
by the DRC before proceeding to the double-blind part of the study.  The dose recommendation 
will be made by a DRC compri
sed of the Marinus Chief Medical Officer and 2 external 
physician s and potentially other experts familiar with the clinical care of women with major 
depression or PPD and with experience in conducting clinical trials. The DRC may also consult 
other experts, such as a 
statistician and a pharmacokineticist.  A separate guidance document will 
outline the functions and membership of the DRC.  
After completion of the double-blind part, the data will be evaluated by an independent DRC.  
Based on the analysis and recommendation by the DRC , the study may be closed at that point, or 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 79 of 131 an additional approximately 50 women with PPD will be treated with ganaxolone or placebo 
under a similar study de
sign but using a different dosing regimen.  The daily dose may be 
lowered, increased, or the previous dosing may be repeated.  However, the total daily dose will 
not exceed 1,200 mg and no single dose will be higher than 675 mg. 
Marinus may decide to stop the study, or make the data public at any time during the open-label 
portion of the trial or after
 completion of the double-blind part of the study. 
9.3.2 Justification for Sample Size 
With a sample
 size of 50 subjects/group, the DBPC part of the trial will be able to detect a 
medium effe
ct size (per Cohen’s d) with 93% power using a two-sided significance level of 0.05. 
9.3.3 Study Population 
The Screened Set  will consist of all subjects who have signed an informed consent. 
The Randomized Set  will consist of subjects randomized in the DBPC part of the trial.  
The Safety Set  will consist of all subjects who received IV IP .  
The modified  Intent to Treat Set  (mITT) will consist of all subjects in the DBPC part of the 
trial who received IP and who have at least 1 post-base
line HAMD17 assessment.  The mITT set 
will be the primar
y efficacy population for the DBPC part of the trial.  
The Per-Protocol Set  will consist of all subjects in the mITT set who do not have major protocol 
deviations that may affect key effic
acy endpoints.  
9.4 Analysis Methods 
Data will be pre
sented by study part (OL, DBPC), dosing or treatment group within study part 
and, if applicable, study visit. Continuous var
iables will be summarized as numbers of 
observations, means, measures of variance (e.g., standard deviation), and percentiles (e.g., 
median, minimum, maximum).  Categorical variables will be summarized as numbers of 
observations and percentages. 
9.4.1 Demographic and Baseline Characteristics 
Baseline characteristics will
 include a summary of the following: 
 Subject demographics 
 Pre-existing medical conditions 
 Prior therapies 
 Medical history 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 80 of 131 9.4.2 Subject Disposition 
Frequencies and percentages of subj
ects who discontinued the study and reasons for 
discontinuation will be summarized. 
9.4.3 Investigational Medicin al Product 
Overall exposure to investigational product, such as duration of exposure, as well as dose 
adjustments (i.e., deviations from the scheduled titration scheme) will be summarized. 
9.4.4 Concomitant Medication 
Concomitant medi
cations will be coded using the World Health Organization Drug Dictionary 
(WHO-DD) and will be summarized by drug class and preferred drug name. 
9.4.5 Safety Analyses 
Reported AEs terms will be coded u
sing the Medical Dictionary for Regulatory Activities 
(MedDRA).  The incidence of treatment emergent AEs (TEAEs), defined as AEs that started or 
worsened after first administration of IP, will be summarized by system organ class and 
preferred term. Separate summaries of TEAEs by severity and relatedness will be done.  SAEs 
and TEAEs leading to discontinuation of the study drug will also be summarized separately.  
The absolute values and change from baseline in laboratory tests, vital signs, SSS, ECG 
parameters, and CSSRS will be summarized.  
Results of physical examinations will be listed.  
9.4.6 Efficacy Analyses 
Efficacy parameters will be summarized for both the open-label and DBPC parts but will be 
analyzed only for the DBPC part.  For the open-label part, referring to efficacy endpoints as 
“primary,” “secondary,” and “exploratory”
 is related to the degree of influence each type of 
endpoint is expected to have on decision-making rather than to considerations associated with 
inferential analysis (such as control of type 1 error). The primary time point of interest for all 
efficacy parameters will be Day 10 for the DBPC part and the visit at end of treatment (before 
initiation of taper) for the open-label part. 
9.4.6.1 Prim ary Endpoint 
The primary efficacy endpoint will be HAMD17 total score change from baseline; this will be 
assessed at Day 10 for the DBPC part and at the visit at end of treatment for the open-label part. 
The primary efficacy analysis will be done using the mITT set (DBPC part only). The analytical 
method will be mixed model repeated measures (MMRM) with baseline HAMD17 total score as 
a covariate. Significance will be tested at a two-sided 0.05 level. Unstructured covariance will be 
specified although alternative covariance structures may be used, if appropriate, to achieve 
convergence or greater efficiency. Sensitivity analysis will be used to evaluate the assumption of 
data missing at random (MAR), if applicable. 
IND No. 135256 
Protocol 1042 -PPD -2003 
9.4.6.2 Secondary Endpoint s Marinus Phrumaceuticals , Inc. 
Version 5.0 / 22 Oct 2018 
The ti·ial will also evaluate the following seco ndaiy endpoints at each post-base line data 
collect ion time point to provide additio nal evide nce of the efficacy of ganaxolo ne in ti-eating 
PPD: 
• Chan ge from baseline in HAMD 17 total score other than at the primaiy endpoint time 
point 
• HAMD l 7 respo nse defined as at least a 50% reduction from base line in total score 
• HAMD 17 remiss ion defined as total score <= 7 
• Chan ge from baseline in EPDS total score 
• Chan ge from baseline in ST AI6 
• CGI-I -
I 
I 
I 
I 
I 
I 
9.4.6.4 Statistical Method s 
Efficacy pai·ameters will be sUilllnai·ized for open-label and DBPC paiis. Observed values and 
chan ges from baseline for HAMD 17, EPD S, and STA I6 total scores, subsca les, and individual 
items will be smnmai· ized by visit. The categorical outco mes of HAMD 17 respo nse, HAMD 17 
remissio n, and CGI- I will be sUilllnarized by visit. 
For the DBP C paii, the prefe ned approach for anal yses of ti·eatine nt group diffe rences in 
seco ndaiy and explorato 1 y continuous efficacy vai·iables will be MMRM but other approac hes 
such as t-tests, analysis of covai· iance, or non-p arameti· ic methods may be used if necessa1y or 
more practical. Simi larly, the prefened approac h for analysis of seco ndaiy and explorato 1 y 
Confidential Page 81 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 82 of 131 categorical efficacy variables will be repeated measures (e.g., generalized estimating equations) 
but other approaches such as chi square or Fisher’s exact tests may be used. 
 
9.4.7 Other Analyses 
No other analyses are planned in this study. 
9.4.8 Handling o f Missing and Incomplete Data 
While every attempt must be made by the investigator to provide complete data, there are cases 
in which this may not always be possible (e.g., incomplete subject recall of start and stop dates).  
Unrecorded values will be treated as missing, except for severity and relationship to 
investigational medicinal product for AEs.  If the severity or relationship to investigational 
medicinal product is missing for an AE, which occurred post administration of investigational 
medicinal product, the event will be regarded as severe and related to investigational medicinal 
product, respectively. 
After completion of the study, a set of sensitivity analyses will be conducted to evaluate the 
impact of missing data on the results.  The methodologies for the addressing missing data will be 
specified in the Statistic
al Analysis Plan (SAP).   
9.4.9 Pharmacokinet ic Analyses 
Five samples of blood will be collected to determine ganaxolone plasma concentrations during 
the study.  Samples will be collected on 3 occasions during treatment with ganaxolone to 
determine trough concentra
tions in plasma.  An additional 2 samples of blood will be collected at 
follow up visits, after ganaxolone t
reatment has been completed, to monitor the disappearance of 
ganaxolone following cessation of treatment. 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 83 of 131 10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES  
This study is conducted in accordance with current applicable regulations, ICH, European Union 
(EU) Directive 2001/20/EC and its updates, and local ethical and legal requirements.  
The nam
e and address of each third-party vendor (e.g., contract research organization [ CRO ]) 
used in this study will be maintained in the investigator’s and sponsor’s files, as appropriate. 
10.1 Sponsor’s Responsibilities  
10.1.1 Good Clinical Practice Compliance 
The study sponsor and any third party to whom
 aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations. 
Visits to sites are conducted by representatives of the study sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and eCRFs in accordance with current Good Clinical Practice ( GCP ) and the 
respective local and (inter)national government regulations and guidelines.  Records and data 
may additionally be reviewed by auditors or by regulatory authorities. 
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study.  The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of
 any regulatory authority approvals required prior to release of 
investigational product for shipment to the site. 
10.1.2 Public Posting of Study Information 
The sponsor is responsible for posting appropriate study inf
ormation on applicable websites.  
Information included in clinical study registries may include participating investigators’ names 
and contact information.  
10.1.3 Study Suspe nsion, Termination, and Completion 
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason.  
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate.  Additionally, the discontinuation of a 
registered clinical study which has been posted to a designated public website will be updated 
accordingly. 
10.2 Investigator’s Responsibilities  
10.2.1 Good Clinical Practice Compliance  
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 84 of 131 It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
personnel are available at the site prior to commitment to participate in this study.  The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period. 
The primary diagnosis and eligibility for the trial are assessed by a qualified licensed physician 
investigator (or his/her delegate) at the study site. The physician at the study site will be 
accountable for clinical assessments, physical examinations, and medication administration 
(including deciding whether the dose is escalated or not). The remote SAFER interview will be 
conducted to confirm the diagnosis of PPD and eligibility for the trial from the depression 
severity point of view.  
The investigat
or will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification.  Curriculum vitae for investigators and sub-investigators are provided to the study 
sponsor (or designee) before
 starting the study. 
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study. 
10.2.2 Protocol Adherence and Investigator Agreement 
The investigator and any co-investigators must adhere to the protocol as detailed in this 
docum
ent.  The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria.  Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol. If the investigator 
suspends or terminates the study at their site, the investigat
or will promptly inform the sponsor 
and the IRB/EC and provide them with a detailed written explanation.  The investigator will also 
return all investigational product, containers, and other study materials to the sponsor.  Upon 
study completion, the in
vestigator will provide the sponsor, IRB/EC, and regulatory agency with 
final reports and summaries as required by (inter)national regulations. 
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement. 
10.2.3 Documentat ion and Retention of Records 
10.2.3.1  Case Report Forms 
Electronic case report forms are supplied by the CRO  and should be handled in accordance with 
instructions from the sponsor. 
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto eCRFs, which have been designed to record all 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 85 of 131 observations and other data pertinent to the clinical investigation.  Electronic case report forms 
must be completed by the investigator or designe
e as stated in the site delegation log. 
All data will have separate source documentation; no data will be recorded directly onto the 
eCRF .  All data sent to the sponsor must be endorsed by the investigator. 
The clinical research associate ( CRA)/study monitor will verify the contents against the source 
data per the monitoring plan. 
 If the data are unclear or contradictory, queries are sent for 
corrections or verifi
cation of data. 
10.2.3.2  Recording, Access, and Retention of Source Data and Study Documents 
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, including past psychiatric history.  
The investigator must permit authorized representatives of the sponsor, the IRB/EC, and auditors 
to inspect facilities and to have direct access to original source records relevant to this study, 
regardless of media. 
The CRA/study monitor will check the eCRF entries against the source documents.  The consent 
form includes a statement
 by which the subject agrees to the monitor/auditor from the sponsor or 
its representatives, national or local regulatory authorities, or the IRB/EC, having access to 
source data (e.g., subject’s medical file, appointment books, original laboratory reports, X-rays 
etc.).  
These records must be made a
vailable within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (e.g., the US FDA) or 
an auditor. 
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor. 
10.2.3.3  Audit/Inspection 
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory authorities), the European Medicines Agency ( EMA), the 
Medicines and Healthcare Products Regulatory Agency, other regulatory authorities, the sponsor 
or its representatives, and the IRB/EC for each site. 
10.2.3.4  Financial Disclosure 
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby the outcome of the study could be influenced by the val
ue of the compensation for 
conducting the study, or other payments the investigator received from the sponsor.  The 
following information is collected:  any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing researc
h, compensation in the form of equipment, retainer for 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 86 of 131 ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998). 
10.3 Ethical Considerations 
10.3.1 Informed Consent 
It is the resp
onsibility of the investigator to obtain written informed consent from all study 
subjects prior to any study-related procedures including screening assessments.  All consent 
documentation must be in accordance with applicable regulations and GCP.  Each subject is 
requested to sign and date the subject inf
ormed consent form or a certified translation if 
applicable, after the subject has received and read the written subject information and received 
an explanation of what the study involves, including but not limited to:  the objectives, potential 
benefits and risk, inconveni
ences, and the subject’s rights and responsibilities.  A copy of the 
informed consent documentation (i
.e, a complete set of subject information sheets and fully 
executed signature pages) must be given to the subject.  This document may require translation 
into the local language.  
Signed consent forms must remain in each subject’s study file and must 
be available for verification at any time. 
If local IRB/EC is used, the principal investigator provides the sponsor or its delegate with a 
copy of the consent that was reviewed by the IRB/EC and received their favorable 
opinion/approval.  A copy of the IRB/EC’s written favorable opinion/approval of these 
documents must be provided to the sponsor prior to the start of the study unless it is agreed to 
and documented prior to study start that another party (i.e, CRO or coordinating principal 
investigator) is responsible for this action.  Additionally, if the IRB/EC requires modification of 
the sample subject information and consent document provided by the sponsor, the 
documentation supporting this requirement must be provided to the sponsor or delegate. 
10.3.2  Institutional Review Board or Ethics Committee 
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement. 
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue. 
Investigational product supplies will not be released until the sponsor or its delegate has received 
written IRB/EC approval of and copies of revised documents. 
The investigator is responsible for keeping the IRB/EC apprised of the progress of the study and 
of any changes made to the protocol, but in any case, at least once a year.  The investigator must 
also keep the local I
RB/EC informed of any serious and significant AEs. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 87 of 131 10.4 Privacy and Confidentiality 
All sites and laboratories or entities providing support for this study, must, where applicable, 
comply with the Health Insurance Portability and Accountability Act (HIPAA) act of 1996.  A 
site that is not a covered entity as def
ined by HIPAA must provide documentation of this fact to 
the sponsor or its delegate. 
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines. 
After subjects have consented to take part in the study, the sponsor and/or its representatives may 
review their medical records and data collected during the study.  These records and data may, in 
addition, be reviewed by othe rs
 including the following:  independent auditors who validate the 
data on behalf of the sponsor; national or local 
regulatory authorities; and the IRB/EC which 
gave approval for the study to proceed.  The sponsor and/or its representatives accessing the 
records and data will take all reasonable precautions in accordance with applicable laws, 
regulations, and guidelines to maintain the confidentiality of subjects’ identities. 
Subjects are assigned a unique identifying number; however, their initials and date of birth may 
also be collected and used to assist the sponsor in verifying the accuracy of the data (e.g., to 
confirm that laboratory results have been assigned to the correct subject).  
The results of studies - containing subjects’ unique identifying number, relevant medical records, 
and possibly initials and dates of birth – will be recorded.  They may be transferred to, and used 
in, other countries which may not afford the same level of protection that applies within the 
countries where this study is conducted.  The purpose of any such transfer would include:  to 
support regulatory submissions, to conduct new data analyses to publish or present the study 
results, or to answer questions asked by regulatory or health authorities. 
10.5 Study Results and Publication Policy 
Marinus will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative.  
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, public presentations to the investors in the company, invited lectures, 
opinion pieces, book chapters, electronic postings on medical/scientific or company website, or 
other disclosure of the study results, in printed, electronic, oral or other form.  The results may be 
made public after completion of either the open- label part or double- blind part.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 88 of 131 11 REFERENCES 
1. Gavin NI, Gaynes BN, Lohr KN , et al. Perinatal Depression. A Systematic Review of 
Prevalence and Incidence. Obstetrics and Gynecology. 2005;106:1071 -83.  
2. Kaplan PS, Danko CM, K alinka CJ, et al. A developmental decline in the learning -promoting 
effects of infant- directed speech for infants of mothers with chronically elevated symptoms 
of depression. Infant Behav Dev. 2012;35:369–79.  
3. Luisi  S, Petraglia F, Benedetto C, et al. Serum allopregnanolone levels in pregn ant women: 
changes during pregnancy, at delivery, and in hypertensive patients . J Clin Endocrinol Metab. 
2000;85:2429 –33.  
4. Gilbert Eva ns SE, Ross LE, Sellers EM, et al. 3a -reduced neuroactive steroids and their 
precursors during pregnancy and the postpartum period. Gynecological Endocrinology. 
2005;21:268 -79.  
5. Hantsoo L, Ward -O’Brien D, Czarkowski KA, et al. A randomized, placebo -controlled, 
double- blind trial of sertraline for postpartum depression. Psychopharmacology. 
2014;231:939 –48. 
6. Y onkers K, Lin H, Howell HB, et al. Pharmacological Treatment of Postpartum Women with 
New Onset Major Depressive Disorder: A Randomized Controlled Trial with Paroxetine. 
Journal of Clinical Psychiatry. 2008;69: 659 –65. 
7. Kanes S, Colquhoun H, G unduz -Bruce H, et al, Sage -547 (allopregnanolone) and Sage -217: 
Investigational Neuroactive Steroid Targeting the GABAA Receptors for treatment of CNS 
Disorders. ASCP Annual Meeting Abstract Book TH25. 2016.  
8. Cart er RB, Wood PL, Wieland S,  et al. Characterization of the anticonvulsant properties of 
ganaxolone (CCD 1042; 3alpha -hydroxy- 3beta -methyl -5alpha -pregnan -20-one) , a selective, 
high-affinity, steroid modulator of the gamma -aminobutyric acid(A) receptor. The Journal of 
Pharmacology and Experimental Therapeutics. 1997;280:1284 –95 
9. Maguire J and Mody I. Steroid hormone fluctuations and GABAAR plasticity. 
Neuropsychoendocrinology. 2009;34:S84 -S90. 
10. T urkmen S, Backstrom T, Wahlstrom G. Tolerance to allopregnanolone with focus on the 
GABAA receptor. British Journal of Pharmacology. 2011;162:311 –27. 
11. Kyle PR, Lemming OM, Timmerby N, et al. The Validity of the Different Versions of the 
Hamilton Depression Scale in Separating Remission Rates of Placebo and Antidepressants in 
Clinical Trials of Major Depression. J Clin Psychopharmacol. 2016;36:453 -6. 
12. Mar teau TM and Bekker H. The development of a six item short -form of the Spielberger 
Stait- Trait Anxiety Inventory. British Journal of Clinical Psychology. 1992;31:301 -6. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 89 of 131 13. Posner K, Oquendo MA, Gould M, et al. Columbia classification algorithm of suicide 
assessment (C
-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk 
analysis of antidepressants. Am J Psychiatry. 2007;164:1035-43. 
14. Helmreich I, Wagner S, Mergl R, et al. Sensitivity to changes during antidepressant 
tr
eatment: a comparison of unidimensional subscales of the Inventory of Depressive 
Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients 
with mild major, minor or subsyndromal depression. Eur Arch Psychiatry Clin Neurosci. 
2012 Jun;262(4):291-304 
15. Boessen R1, Groenwold RH
, Knol MJ, et al. Comparing HAMD (17) and HAMD subscales 
on their ability to differentiate active treatment from placebo in randomized controlled trials. 
J Affect Disord. 2013 Mar 5;145(3):363-9. 
16. Thase ME, Chen D, Edwards J, Ruth A. Efficacy of vilazodone on anxiety symptoms in 
patients with 
major depressive disorder. Int Clin Psychopharmacol. 2014 Nov;29(6):351-6. 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 90 of 131 12 APPENDICES 
Appendix 1.   Prohibited Strong CYP3A4 Inhibitors and Inducers  
Prohibited strong inhibitors  Prohibited strong inducers  
Indinavir  Efavirenz  
Nelfinavir  Nevirapine  
Ritonavir  Barbiturates  
Clarithromycin  Carbamazepine  
Itroconazole  Enzalutamide  
Ketoconazole  Glucocorticoids  
Nefazadone  Modafinil  
Saquinavir  Oxcarbazepine  
Suboxone  Phenobarbital  
Telithromycin  Phenytoin  
Grapefruit juice  Pioglitazone  
 Rifabutin  
 Rifampin  
 St. John’s Wort  
 Troglitazone  
Source:  The Flockhart Table (http://medicine.iupui.edu/clinpharm/ddis/main -table)  
 
 
  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 91 of 131 Appendix 2.   Scales and Assessments 
The following scales/assessment
s will be utilized in this study: 
Full Title of Scale/Assessment  Version  
Hamilton Depression Rating Scale (HAMD17)  17-item version  
Spielberg Trait -State Anxiety Inventory  6-item version  
Edinburgh Postnatal Depression Scale (EPDS)  Two obsession items are added to the standard 
EPDS questionnaire  
Columbia Suicide Severity Rating Scale  Baseline and since last visit  (standard)  
Stanford Sleepiness Scale  NA  
Mini International Neuropsychiatric Assessment  Version 7.0  
Clinical Global Impression - Improvement  NA 
Clinical Global Impression - Severity  NA 
 
A separate master file containing each scale/assessment listed above will be provided to the site . 
Updates to scales/assessments during the study (if applicable) will be documented in the table 
above and a new master file containing the revised scale/assessment will be provided to the site.  
  
IND No. 135256 
Protocol 1042-P PD-2003 
Amendm ent 4 Summa ry of Changes from version June 5, 2 018 to 22 Oct, 2018 
Page 
13 Section, Title, 
Para ra h, Line 
Title Page 
Study Synop sis Title 01iginal Text 
TITL E: A Phase 2, Double-bl ind, Placebo -controlled , 
Multicenter Study to Evaluate Safety , Tolerability and 
Efficacy of Oral Adminis tration ofGanaxo lone in Women 
with Postpartum Depression 
Reaso n for Chan ge: Addi tion of intravenous administration of Ganaxolone to study 
1 T itle Page Glob al/Co unt 
ry/Si te 
Documen t Date Specific 
Origina l Protocol - 09 Jun 2017 Globa l 
Version 1 
Amendm ent 1 - 15Aug2017 Globa l 
Version 2 
Amendm ent 2 - 25 Jan 2018 Globa l 
Version 3 
Amendm ent 3 - 05 Jun 2018 Globa l 
Version 4 
Reaso n for Chan e: Adminis trative cha · 
2 Protocol Signature Page 
Reaso n for Chan e: Chan°e to S nsor Medical Contact and Medica l Moni tor 
Confidential Marinus Phrumaceutica ls, Inc. 
Versi on 5.0 / 22 Oct 2018 
Revised Text 
TITLE : A P hase 2, Double -blind, Placebo -controll ed, 
Multicent er Study to Evaluate Safety , Tolerability and Efficacy 
of IV and Oral Adrninis tration of Ganaxolone in Wom en with 
Postprutum Depression 
Global/Co unt 
1·y/Site 
Document Date S pecific 
Origina l Protocol - 09 Jun 2017 Global 
Version 1 
Amendment 1 -Version 15 Aug 2017 Global 
2 
Amendment 2 -Version 25 Jan 2018 Global 
3 
Amendment 3 -Version 05 Jun 2018 Global 
4 
Ame ndm ent 4 - 22 Oct 2018 Glo bal 
Version 5 
Page 93 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 94 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
3 Sponsor Contacts  MD, PhD  
Telephone: 
Email:  
 MD  
Marinus Pharmaceuticals Inc.  
Telephone:  : 
Email: 
Reason for Change:  Change  to Sponsor Medical Contact and Medical Monitor  
13 Study Synopsis  Drug:  Ganaxolone oral capsule formulation  Drug:  Ganaxolone IV, oral suspension, and oral capsule 
formulations  
Reason for Change:  Addition  of intravenous administration of Ganaxolone to study  and clarification of oral formulations  
13 Study Synopsis   Design:  
This is a Phase 2, multicenter study in women with 
postpartum depression (PPD) consisting of 2 parts:  Open 
Label Part: multiple ascending dose open -label focused on 
safety and tolerability in 5 groups that differ by total daily 
dosing and formulation of study drug; and Double -blind 
Part is a double -blind placebo -controlled (DBPC) focused on 
safety, tolerability and efficacy in one group.  The Double -
blind Part will begin after t he Open Label Part dosing is 
completed. The dosing, treatment duration and timing of 
evaluations  for the double -blind portion of the study will be 
decided based on the results of the Open Label Part and 
recommendations of the Data Review Committee (DRC).  
The DRC is comprised of Marinus’ Chief Medical Officer 
and 2 external physician experts.   
Figures 1A and 1B depict the design for each subject group 
in the Open Label and Double -blind Parts, respectively.  
Reason for Change:  Clarification  of study design  
13 Study Synopsis  Number of subjects (total and for each treatment arm):    
This is a Phase 2, multicenter study in women with 
postpartum depression (PPD) consisting of 2 dosing groups:  
an initial open -label safety group and a double -blind 
placebo -controlled group .  The open -label safety group will Number of subjects  and dose regimen for each treatment 
arm:  
For Open Label Part, approximately 176 women 18 to 48  
years of age with PPD will be screened to enroll 

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 95 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
be enrolled and dosing completed before proceeding to the 
double -blind group .  The goal of the open -label group is to 
explore the safety of oral ganaxolone in this population and 
identify a dosing  regimen for the double -blind phase .    
For the open -label safety group approximately 48 women 18  
to 48 years of age with PPD will be screened to enroll 
approximately 24 patients .  During this open -label safety 
phase, for the first approximately 8 patients , ganaxolone will 
be titrated to a daily dose of 900 mg /day over 10 days, 
followed by a taper over 4 days .  This dosing group is called 
open -label 3 times daily (OL TID) group. For the next 
approximately 8 patients, ganaxolone will be administered at 
bedti me (QHS). For these patients ganaxolone will be 
titrated to a dose of 675 mg QHS over 4 days, which is then 
maintained until day 10, followed by a taper over 4 days. 
This dosing group is called OL QHS group. For the next 
approximately 8 patients of the ope n-label safety group, 
ganaxolone will be administered at a dose 675 mg QHS for 
28 days, followed by a taper over 4 days. This dosing group 
is called OL QHS 4 -week dosing group.  
The investigator has the flexibility to adjust the dose if the 
patient experien ces sedation, dizziness or other untoward 
effects  in each dosing group.  
For the double -blind group, approximately 100 women with 
PPD 18  to 48 years of age will be screened to randomize 50 
women in a 1:1 ratio to receive ganaxolone or matching 
placebo for 1 4 days .  The dosing for the double -blind portion 
of the study will be decided based on the results of the open -
label portion and recommendations of the Data Review 
Committee (DRC).  The DRC is comprised of Marinus’ 
Chief Medical Officer and 2 external phys ician experts .  The 
total daily dose will not exceed 1200 mg .  Randomization 
will be stratified by the use of concomitant antidepressants 
so that the number of patients who are treated with 
antidepressants and who are not treated with antidepressants approximately 88 subjects.   
The first group (called OL TID) of approximately 8 subjects 
will receive oral ganaxolone (capsules) titrated to a daily 
dose of 900 mg/day over 10 days, followed by a taper over 4 
days.   
The second group (called OL QHS) of approximately 20 
subjects will receive oral ganaxolone (capsules) at bedtime 
(QHS), titrated to a dose of 675 mg QHS over 4 days, which 
is then maintained until day 10, followed by a taper over 4 
days.  
The third group (called OL QHS 4 -week) of approximately 
20 subjects, oral ganaxolone (capsules) will be administered 
at a dose of 675 mg QHS for 28 days, followed by a taper 
over 4 days.  
The fourth group (called OL 1,125 mg group) of 
approximately 20 subjects will receive, on the first 2 days, 
oral ganaxolone capsules at a dose of 675 mg at 
approximately 7 pm (with dinner) and 675 mg at 10 pm; 
followed, by 26 days of ganaxolone 1,125 mg at dinner time; 
followed by a taper over 4 days. Approximately 6 subjects 
will participate in PK collect ion that requires an overnight 
stay on Day 1.  
The fifth group (called OL Bolus -Oral) of approximately 20 
subjects will receive ganaxolone starting with a single IV 
bolus 12 mg over 2 minutes at approximately 4 pm of Day 1; 
followed by ganaxolone oral suspe nsion 750 mg at 6pm (with 
a fatty meal) and 750 mg at 10pm. On Day 2 subjects will 
receive ganaxolone oral suspension 750 mg at dinner time 
and 750 mg at bedtime, followed by 26 days of ganaxolone 
oral suspension 1,000 mg at dinner time, Treatment will be 
tapered over 4 days. Approximately 6 subjects will 
participate in PK collection that requires an overnight stay 
on Day 1.  
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 96 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
will be similar in each treatment group .   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 1A: Design of Open -Label Part  
 
For the double -blind placebo -controlled (DBPC) part , 
approximately 100 women with PPD 18 to 48  years of age will 
be screened to randomize 50 women in a 1:1 ratio to receive 
ganaxolone or matching placebo for 14 days.  The dosing , 
treatment duration and timing of evaluations  for the double -
blind portion of the study will be decided based on the resu lts of 
the Open Label Part  and recommendations of the Data Review 
Committee (DRC).  The total daily dose will not exceed 1,600  
mg.  Randomization will be stratified by the use of concomitant 
OlTID 
·········+--················GNXn'8 
\lcreeningOldo1ing lODay 
lwk lwk ~ l~-0p 
OlQHI 
········· ·l- ················ GNXn'lO 
L,--1-,~ 
lwk lwk folmw-0p 
\lcreemng Oldo1mg lOD~ 
OlQHlheel _______________ • GNXn'lO 
(lcree ning O loo1ing 
\i" " l 
\ 
lmon ~ 
~IIOW·UP 
Ol0rall,111mg ------• GNXn'10 
lwk 4wk 
OlW8olus-Oral 6weet 
~llow-0p 
\lcreening Oloosing 
---- ------, GNXn'10 
laming Oldo1ing 6w~t 
1wk 4wk ~lmww D Ming; 
Ondi'fllandl: 
'°6Jlmgatd innertimeand 
mmgatie~ime 
1 ,111mgwnldinnerdi'fll·18 ; 
la"r:da~1!· l1 
D o ing: 
Wlolus11mg/1minondailat 'lpm 
'°JSOmgatdinnert imeand 
J50mgat~ imeondi'flland1 
1000mgw lidinnerondi'fll ·18 ; 
la"r:dais1!·l1 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 97 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 antidepressants so that the number of subject s who are treated 
with antidepressants and who are not treated with 
antidepressants will be similar in each treatment group.   
 
FIGURE 1 B: Design of the Double -Blind Placebo -Controlled 
Part  
 
 
 
 
 
 
 
 
 
The investigator has the flexibility to adjust the dose  and/or 
timing  of the dose if the subject  experiences sedation, dizziness 
or other untoward effects in each dosing group , by reducing the 
dose first to a lower level and possibly increasing it back again 
later if tolerance develops to the untoward effects (see section 
6.2.7).  
Reason for change :  Clarification of number of subjects and dose regimen for each treatment arm  
15 Study Synopsis  Objectives:  
Open -label safety group:  
 
 
 
 
 
 
 
 
 
 
 
 
 Objectives:  
Open -label Part: Safety, dosing, efficacy and 
pharmacokinetics:  
3. To assess the efficacy of ganaxolone using the Hamilton 
Depression Rating Scale 17 -item version (HAMD17), 
Edinburgh Postnatal Depression Scale (EPDS), 
Spielberger State -Trait Anxiety Inventory 6-item 
version (STAI6) and Clinical Global Impression -
Severity and Improvement (CGI -S and CGI -I) scales.  
4. To collect samples of blood for pharmacokinetic (PK) 
analysis after administration of oral and IV ganaxolone 
to use in population -pharmacokinetics analyses, the 
results of which will be reported separately by the 
Sponsor.   
 
Screening  
2 wks  
DB 
dosing  
2wk 
GNX 
n=25 
PLA 
n=25  
30 Day  
Follow -up 
Taper  
4 days 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 98 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
Double -blind phase:  
 
 
The primary efficacy  variable  in this study is  change from 
baseline in the HAMD17 total score on Day 10 between 
ganaxolone and matching placebo.  Double -Blind  placebo controlled (DBPC) Part:  Safety, 
efficacy, and pharmacokinetics : 
The primary efficacy  variable  in this study is  change from 
baseline in the HAMD17 total score  on Day 10 of the DBPC 
part between ganaxolone and matching placebo.  
Reason for change:   Clarification of study objectives  
15 Study synopsis  Investigational product, dose, and mode of administration:   
Ganaxolone  oral capsule (225 mg /capsule ) formulations and 
matching placebo will be used.   Investigational product, dose, and mode of administration:  
Ganaxolone IV, oral suspension, and oral capsule 
(225 mg/capsule) formulations and matching placebo will be 
used.   
Reason for Change:  Addition  of intravenous administration of Ganaxolone to study and clarification of oral formulations  
15 Study synopsis  
 
4.1 – Inclusion criteria  6. HAMD17 score of ≥ 20 but < 26 at screening  
7. HAMD17 ≥ 18 at the time of randomization (Day 1)  6. HAMD17 score of ≥ 20 at screening rated by a certified 
site rater  
7. HAMD17 ≥ 18 on Day 1 prior to study drug 
administration   
Reason for change :  Clarification of exclusion criteria  
16 Study synopsis  Maximum duration of subject involvement in the study :  
Approximately 7 weeks  for the OL TID and OL QHS groups 
and the double -blind phase. The duration for the OL QHS 4 
week group is approximately 18 weeks.  Maximum duration of subject involvement in the study :  
Approximately 7 weeks for the OL TID and OL QHS groups 
and the DBPC part .  The duration for the OL QHS 4 -week 
group is approximately 18 weeks and the duration for the OL 
1,125 mg and OL Bolus -oral groups  is approximately 
12 weeks . 
Reason for change:  Addition  of 2 treatment groups  
16 Study synopsis  Key variables:  
Safety:  Adverse events, vital signs, CSSRS, ECG, SSS, and 
physical examination.  
Efficacy:  Hamilton Depression Rating Scale (HAMD17), 
Edinburgh Postnatal Depression Scale (EPDS), Spielberger 
State -Trait Anxiety Inventory 6 item version (STA I6) and Key variables:  
Safety:   Adverse events, laboratory measures,  vital signs, 
CSSRS, ECG, SSS, and physical examination.  
Efficacy:   HAMD17 , EPDS , STAI6, CGI-I and CGI -S scales . 
 
IND No. 135256 
Protocol 1042-PPD -2003 
Page 
Confidential Sectio n, Title , 
Para ra h, Line O1iginal Text 
Clinical Global Impre ssion-Impro vement (CGI- 1) scale. 
Statistical Method s: Approxim ately continuou s endpoin ts 
will be analyzed using a mixed model repeated measure s 
(MMRM ) analysis of covariance (ANCOV A) with fixed 
factor s of treatment , visit, the treatment -by-visit interaction , 
and baseline value of the endpoint. Ordered categoric al 
endpoin ts will be analyzed at each visit by the Cochran -
Man tel-Haenszel (CMH ) row mean scores test using rank 
scores. Dichotomou s categorical endpoint s will be analyzed 
at each visit by Fisher's exact test. Marinus Phrumaceutical s, Inc. 
Version 5.0 / 22 Oct 2018 
Revised Text 
Pharmacokinetic s: For the OL TID and OL QHS group s, a t otal 
of 5 srunple s of blood will be collec ted to dete1mine gana xolone 
plasma concentration s during the study. Srunples will be 
collec ted on 3 occasions during treatmen t with ganaxolone to 
dete1mine trough concen trations in plasma. An additional 2 
sample s of blood will be collected at follow up visits, after 
ganaxolone treatmen t has been comple ted, to moni tor the 
disappearance of ganaxolone follo wing cessation of treatment. 
For the OL QHS 4-week, OL 1,125 mg, and OL Bolu s-oral 
groups, 6 sample s of blood will be collected to determine 
ganaxolone plasma concentration s during the study. Sample s 
will be collected on 4 occasions during treatment in the OL 
QHS 4 weeks group and on 5 occa sions during treatment in the 
OL 1,125 mg and OL Bolu s-oral group s to determine 
ganaxolone trough concentration s in plasma. Two additional 
sample s of blood will be collected in the first 2 follo w up visits 
in the OL QHS 4 weeks group and 1 additional sample will 
be collected in the OL 1,125 mg, and OL Bolus-oral groups 
at the first follow up visit after ganaxolone treatment has be.en 
comple ted, to moni tor the disapperu·ance of ganaxolone 
follo wing cessation of treatment. 
Statistical Method s: Data will be presented by study part 
(OL, DBPC), dosing 01· treatment group within study parts 
and if applicable , study visit. Continuou s variable s ,vill be 
summarized as number s of obse1·vations , mean s, measures 
of variance (e.g., standard deviation ), and percentiles (e.g., 
median , minimum, maximum ). Categorical va1iables will be 
summarized as number s of obse1·vations and percentages. 
Analysis Populations : The Screened Set will consist of all 
subject s who have signed an informed consent. The 
Randomized Set will consist of subject s randomized in the 
DBP C part of the ti·ial. The Safety Set will consist of all 
subject s who recei ved investigational product. (IP). The 
modified Intent to Treat (mITT) Set ,vill consist of all 
sub·ects in the DBPC a11 of the trial who received IP, and 
Page 99 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 100 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
who have at least 1 post -baseline HAMD17 assessment.  The 
Per-Protocol Set will consist of all subjects i n the mITT set 
who do not have major protocol deviations that may affect 
key efficacy  endpoints.  
Efficacy Analysis :  Efficacy parameters will be summarized 
for both the OL and DBPC parts, but will be analyzed only 
for the DBPC part.  The primary time point  of interest for 
all efficacy parameters will be Day  10 for the DBPC part 
and the visit at end of treatment (before initiation of taper) 
for the OL part.  The primary efficacy endpoint will be 
change from baseline in HAMD17 total score at Day 10 for 
the DB PC part and at the visit at end of treatment for the 
OL part.  The primary efficacy analysis will be done using 
the mITT set (DBPC group only), and the analytical method 
will be  mixed model repeated measures (MMRM) with baseline 
HAMD17 total score as a cov ariate.  Significance will be 
tested at a two -sided 0.05  level.  
Secondary efficacy  endpoints will be change from baseline in 
HAMD17 total score other than at the primary endpoint 
time point, HAMD17 response defined as at least a 50% 
reduction from baseline  in total score, HAMD17 remission 
defined as total score < = 7, change from baseline in EPDS 
total score, change from baseline in STAI6, and 
CGI -Improvement.  
Reason for change :  Clarification and addition  of key study variables  
22 2.2.1. Objectives of the 
Open -label Safety Part   
 
 
 
 
 
 
 
 2.2.1.3   Efficacy Objective  
To assess the efficacy of ganaxolone using the Hamilton 
Depression Rating Scale 17 -item version (HAMD17), 
Edinburgh Postnatal Depression Scale (EPDS), Spielberger 
State -Trait Anxiety Inventory 6 -item version (STAI6) and 
Clinical Global Impression -Severity and Improvement 
(CGI -S and CGI -I) scales.  
 
2.2.1.4   Pharmacokinetic Objective  

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 101 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
 
 To collect samples of blood for pharmacokinetic (PK) 
analysis after administration of oral and IV ganaxolone to 
use in population -pharmacokinetics analyses, the results of 
whic h will be reported separately by the Sponsor.  
Reason for Change: Addition of efficacy  and pharmacokinetic objectives in the Op en-label Safety Part  
24 3.1.  Study Design and 
Study Population   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the open -label safety group approximately 48 women 18 
to 48 years of age with PPD will be screened to enroll 
approximately 24 patients.  During this open -label safety 
phase, for the first approximately 8 patients, ganaxolone will 
be titrated to a daily  dose of 900 mg/day over 10 days, 
followed by a taper over 4 days.  This dosing group is called 
OL TID group.  
For the next approximately 8 patients of the open -label 
safety group, ganaxolone will be administered at bedtime 
(QHS). For these patients ganaxo lone will be titrated to a 
QHS dose of 675 mg over 4 days which is then maintained 
until day 10, followed by a taper over 4 days. This dosing 
group is called OL QHS group  The investigator has the flexibility to adjust the dose amount 
and/or timing of dosing if the subject experiences untoward 
effects during the OL part, by reducing the dose first to a 
lower level and possibly incre asing it back again later if 
tolerance to the untoward effects develops.  
 
The open -label safety part will be enrolled, and dosing 
completed before proceeding to the double -blind part.  The 
goal of the open -label part is to explore safety of IV and oral 
ganaxolone in this population and identify a dosing regimen 
for the double -blind part.  
 
Open -label Part  
For the open -label safety part, approximately 172 women 18 to 
48 years of age with PPD will be screened to enroll 
approximately 88 subject s.  
In the first group with  approximately 8  subjects , ganaxolone 
will be titrated to a daily dose of 900 mg/day over 10 days, 
followed by a taper over 4 days.  This dosing group is called OL 
TID group.  
The second group with  approximately 20 subjects will receive  
ganaxolon e administered at bedtime (QHS). For these subjects , 
ganaxolone will be titrated to a QHS dose of 675 mg over 4 
days which is then maintained until day 10, followed by a taper 
over 4 days. This dosing group is called OL QHS group  
The third group with  appro ximately 20 subjects will receive  
ganaxolone administered at a dose 675 mg QHS for 28 days, 
followed by a taper over 4 days. This dosing group is called OL 
QHS 4 -week dosing group.  
The fourth group with approximately 20 subjects will 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 102 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
For the next approximately 8 patients of the open -label 
safety group, ganaxolone will  be administered at a dose 675 
mg QHS for 28 days, followed by a taper over 4 days. This 
dosing group is called OL QHS 4 -week dosing group.  
The investigator has the flexibility to adjust the dose if the 
patient experiences sedation, dizziness or other unto ward 
effects during the OL phase.  
The open -label safety group will be enrolled, and dosing 
completed before proceeding to the double -blind group.  The 
goal of the open -label group is to explore safety of oral 
ganaxolone in this population and identify a d osing regimen 
for the double -blind phase .  receive on the first 2  days ganaxolone capsules 675 mg at 
dinner time and 675 mg at bedtime (for a total of 1,350 mg 
per day on the first 2 days) followed by 26 days of 
ganaxolone capsules 1,125 mg at dinner time, followed by a 
taper over 4 days. This dosing group is called OL 1,125 mg 
group.  
The fifth group with  approximately 20  subjects  will receive 
ganaxolone as IV bolus 12 mg over 2 minutes at 
approximately 4 pm of the first day followed by ganaxolone 
oral suspension 750 mg at dinner time and 750 mg at 
bedtime for a total of 1,512 mg on Day 1. On Day 2, subjects 
will receive ganaxolone oral suspension 750 mg at dinner 
time and 750 mg at bedtime, for a total of 1,500 mg, followed 
by 26 days of ganaxolone oral suspension 1,000 mg at dinner 
time, followed by a taper over 4  days. This dosing group is 
called OL Bolus -oral group  
Reason for C hange:  Clarification  of study design and addition of 2 treatment groups  
25 3.2.  Rationale for Study 
Design  This study is intended to test whether ganaxolone is 
efficacious and safe in treatment of PPD.  Various dose amounts, formulations, dosing schemes and 
treatment durations will be evaluated in the Open Label 
Part to inform the choice of the treatment scheme for the 
DBPC  Part.  
Approximately 8 or 20 subjects, depending of the group, will 
receive open l abel ganaxolone to evaluate safety, tolerability, 
kinetics and efficacy of the drug in women diagnosed with 
PPD. Assessments of adverse events, laboratory and ECG, 
and clinical ratings for safety and efficacy will be gathered 
to evaluate the possible diffe rential effect of the various 
dosing schemes.  
A double -blind evaluation of safety and efficacy will follow 
the completion of the  open label groups.  This  study part will 
utilize a randomized, parallel -group, placebo -controlled 
design in women diagnosed with PPD. Evaluations of safety 
and tolerability, as well as efficacy will utilize the same 
evaluation methods as in the open label part. The primary 
effica cy endpoint will be change from baseline in HAMD -17 
of active vs placebo treatments. The concomitant use of 
antidepressants or no use of antidepressants will be 
stratified 1:1 to enroll similar numbers of subjects in each 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 103 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
stratum for both ganaxolone and pl acebo treatment groups.  
Reason for Change:  Clarification of the rationale for the study design  
26 3.3.  Dose Selection  Open -label QHS dosing group  
Approximately 8 patients will be allocated to the OL QHS 
group.  The enrollment for the OL QHS group will start after 
all patients allocated to the OL TID group have started their 
dosing.  
 
Open -label QHS 4 -week dosing group  
Approximately 8 patients will b e allocated to the OL QHS 4 -
week dosing group.  The enrollment for the OL QHS 4 -week 
group will start after all patients allocated to the OL QHS 
group have started their dosing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Open -label QHS dosing group  
Approximately 20 subjects  will be allocated to the OL QHS 
group.  The enrollment for the OL QHS group will start after all 
subjects  allocated to the OL TID group have started their 
dosing.  
 
Open -label QHS  4-week dosing group  
Approximately 20 subjects  will be allocated to the OL QHS 4 -
week dosing group.  The enrollment for the OL QHS 4 -week 
group will start after all subjects  allocated to the OL QHS group 
have started their dosing.  
 
Open -label 1,125 mg  dosing group  
The OL 1,125 mg dosing group  is included in the open -label 
part to explore whether administering ganaxolone orally at 
doses up to 1,125 mg per day over 4 weeks (including 1,350 
in the first 2 days) are safe and well -tolerated and show 
sustained effects, and whether the therapeutic effects are 
maintained over a 6 -week follow -up period.  
The two evening  675 mg oral doses, within 3  hours of each 
other on Day 1 are expected to provide mean C max plasma 
concentrations of ap proximately 250 -300 ng/mL, which may 
be mildly sedating. Day 2 twin evening dosing is expected to 
lead to similar exposure. In previous studies ganaxolone has 
been given up to a daily dose of 2000 mg, and at single doses 
of 1000 mg. Based on the previous e xperience this dose is 
expected to be safe.  
Approximately 20 subjects will be allocated to the OL 1,125 
mg dosing group.  The enrollment for the OL 1,125 mg 
group will start after all subjects allocated to the OL QHS 4 -
week group have started their dosing .  
Open -label Bolus -Oral dosing group  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 104 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The OL Bolus -Oral dosing group will explore whether 
administering ganaxolone IV bolus 12 mg followed by oral 
suspension dosing of up to 1,000 mg per day (including up to 
1,500 mg in the first 2 days) is safe and  well-tolerated and 
shows sustained therapeutic effect over 4 -weeks of dosing, 
and whether the therapeutic effects are maintained over a 6-
week  follow -up period.  
This initial bolus infusion is targeted to provide a fast onset 
of antidepressant activity by deliv ery of rapid plasma 
exposures to ganaxolone. Together with the two evening 750 
mg oral doses, within 3 hours of each other, Day 1 dosing is 
expected to provide mean C max plasma concentrations of 
approximately 250 -300 ng/mL, which may be mildly 
sedating. Da y 2 twin evening dosing is expected to lead to 
similar exposure. In previous studies ganaxolone has been 
given up to a daily dose of 2,000 mg, and at single doses of 
1,000 mg. Based on the previous experience this dose is 
expected to be safe.  
 
Approximate ly 20 subjects  will be allocated to the OL Bolus -
Oral  dosing group.  The enrollment for the OL Bolus -Oral  
group will start after all subjects  allocated to the OL 1,125 
mg group have started their dosing.   
Dose justification in context of previous experienc e with IV 
ganaxolone  
In Study 1042 -0405, which was a Phase 1 study in healthy 
volunteers investigating the safety of IV ganaxolone, the 
highest bolus dose tested was 30 mg, which was infused over 
5-minutes (the same rate, 6 mg/min., as in the OL Bolus -
Oral  group). This dose led to peak concentration levels 
(Cmax) of > 1,000 ng/mL with no safety concerns (except 
sedation).  This safety profile is consistent with findings from 
previous studies with the oral formulation of ganaxolone, in 
which C max levels of up to 200 to 300 ng/mL were commonly 
observed and were not associated with major safety findings 
or toxicity (apart from sedation -related effects) .  
 
Double -blind Placebo -controlled (DBPC) Part  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 105 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Double -blind phase  
 
  
Blinding Scheme  
Subjects will be randomized to ganaxolone or placebo in a 
1:1 ratio. The randomization scheme will be prepared by an 
independent third -party vendor. Treatment assignments will 
be obtained by the investigator (or designee) via an 
Interactive Voice and/or Web Response System (IxRS). The 
placebo infusion and placebo capsules are identical to the 
ganaxolone infusion and capsules, respectively, in their 
appearance.  An unblinded study pharmacist at the 
investigative site will prepare the ganaxolone and placebo IV 
solutions and allocate capsul e supply for the double -blind 
part. Members of the DRC will be unblinded. All other 
study personnel, including persons involved in the 
evaluation of the study subjects (e.g. investigators, 
sub-investigators, and physicians/nurses), with the exception 
of th e study pharmacist, will remain blinded at all times, 
except in case of an emergency.  Subjects will be blinded.   
 
Reason for Change:  Clarification of dose selection, update  to number  of subjects per treatment group  and addition of 2  treatment groups and blinding scheme  
28 3.4.  Study Duration  For both the open -label safety OL TID and OL QHS groups, 
and the double -blind phase of the study the screening period 
will be up to 2 weeks, followed by a 14 -day outpatient 
treatment period and a 14 -day follow -up period. For the OL 
QHS 4 -week dosing group the screening period will be up to 
2 weeks, followed by a 28 -day outpatient treatment period, a 
4-day taper and a 3 month follow -up period.  For both the open -label safety OL TID and OL QHS groups, and 
the doubl e-blind part of the study, the screening period will be 
up to 2 weeks, followed by a 14 -day outpatient treatment period 
and a 14 -day follow -up period. For the OL QHS 4 -week dosing 
group, the screening period will be up to 2 weeks, followed by a 
28-day outp atient treatment period, a 4 -day taper and a 3 -month 
follow -up period.  For the OL 1,125 mg and OL Bolus -Oral 
dosing groups, a screening  period of up to 2  weeks will be 
followed by a 28 -day outpatient treatment period, a 4 -day 
taper, and a 6 -week follow -up period (from Day  29). 
Reason for Change:  Addition  of study duration for additional treatment groups  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 106 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
29 3.6.  Definition of 
Completion   A dosing group is considered complete when the final 
subject in the group has completed the final protocol -defined 
assessment, including follow -up visits, for the group.  
Reason for Change:  Addition of the definition of completion  
32 4.4.  Discontinuation of 
Subjects  A subject may withdraw from the study at any time for any 
reason without prejudice to their future medical care by the 
physician or at the institution.  The investigator or sponsor 
may withdraw the subject at any time (e.g, in the interest of 
subject safety).  The investigator is encouraged to discuss 
withdrawal of a subject from the investigational pro duct with 
the medical monitor when possible.  
 
 
 
If the investigational product is discontinued, regardless of 
the reason, the evaluations listed for Day 10 for OL TID and 
OL QHS groups or Day 28 for the OL QHS 4 -week group 
are to be performed as completely  as possible.  Whenever 
possible, all discontinued subjects should also undergo the 
protocol -specified follow -ups.  Comments (spontaneous or 
elicited), complaints, or AEs reported by the subject must be 
recorded in the source documents.  The reason for 
discontinuation and the date and time of discontinuation of 
the investigational product must be recorded in the electronic 
case report form (eCRF) and source documents.  A subject may withdraw from the study at any time for any 
reason without prejudice to thei r future medical care by the 
physician or at the institution.  The investigator or sponsor may 
withdraw the subject at any time (e.g., in the interest of subject 
safety).  The investigator is encouraged to discuss withdrawal of 
a subject from the investiga tional product with the medical 
monitor when possible. Withdrawn subjects who have not 
received IP will be replaced.  
 
If the investigational product is discontinued, regardless of the 
reason, the evaluations listed for Day 10 for OL TID and OL 
QHS groups o r Day 29  for the OL QHS 4 -week, OL 1,125 mg, 
and OL Bolus -Oral groups  are to be performed as completely 
as possible.  Whenever possible, all discontinued subjects 
should also undergo the protocol -specified follow -ups.  
Comments (spontaneous or elicited), c omplaints, or AEs 
reported by the subject must be recorded in the source 
documents.  The reason for discontinuation and the date and 
time of discontinuation of the investigational product must be 
recorded in the electronic case report form (eCRF) and sourc e 
documents.  
Reason for Change:  Clarification of study discontinuation procedure and addition of 2 treatment groups  
34 5.3 - Concomitant 
Psychological Treatment  Concomitant psychological treatment refers to all 
psychological care the subject is receiving at the time of the 
screening visit.  Concomitant psychological treatment 
information must be recorded on the concomitant 
psychological treatments eCRF page.  Concomitant psychological treatment refers to all psychological 
care the subject received  from  the time of the screening visit 
through the end of the follow -up period.   Concomitant 
psychological treatment information must be recorded on the 
concomitant psychological treatments eCRF page.  
Reason for Change:  Clarification of period of concomitant psychological treatment  
IND No. 135256 
Protocol 1042-PPD -2003 
Page 
34 Section , Title, 
Para ra h, Line 
5.3.1.1-Peimitted O1iginal Text 
The subject may conti nue their cul1'ent fo1m of 
Psychological Treatmen ts psychological treatment (e.g, cogn itive behavioral therapy , 
psychodynamic psycho therapy, support ive psycho therapy) 
throughout the treatment period. Initiation of a new therap y 
(a new treatmen t modality or switching a therapist) is 
prohibite d during the treatmen t perio d. After the treatmen t 
period , psychotherapy should be continued using the same 
modal ity and at the same frequenc y as during the treatment 
period , provided that this is medically justified , in order to 
be able to dete1mine whether there ru·e sustained effect s from 
the treatment the over the 30-day follow-up period. Any 
change s must be recor ded on the concomi tant psycho logica l 
treatment s eCRF a.0e. 
3 7 6.1.2 -Gana.xolone IV 
Infusion Solution 
Reason for Change : Addi tion of identity of intra.venou s Ganaxolone infusion solution 
37 6.1.3 -Gana.xolone Oral 
Suspension 
Reason for Change : Addi tion of identity of Ganaxolone oral suspension 
Confi dential Marinus Phrumaceuticals , Inc. 
Version 5.0 / 22 Oct 2018 
Revise d Text 
The subject may continue their cwTen t form of psycho logical 
treatmen t (e.g., cogni tive beha vioral therapy , psychodynrunic 
psycho therapy , supporti ve psychotherapy) throughout the 
treatmen t period . Initiation of a new therapy (a new treatment 
moda lity or switching a therap ist) is prohibited during the 
treatmen t period . After the treatmen t period, psychotherapy 
should be continued using the same modality and at the srune 
frequency as during the treatment period, provided that this is 
medically justified , in order to be able to d etennine whether 
there are sustained effec ts from the treatment the over the 30-, 
42-, or 90-day follo w-up periods. Any changes must be 
recorded on the conco1nitan t psychological treatments eCRF 
a _ e. 
IV solution 
Fo1mu lation: IV 
Strength: 3 mg/ml so lution in a glass vial, which is to be dilute d 
with 0.9% saline for the infusion. For detail s regarding 
prepara tion of the infusion solution, please see phannacy 
manua l. 
Route of adminis tration: IV 
Ve 1cle: The oral suspension contains ganaxo lone (50 mg/mL), 
hydroxypropy l methylcellu lose, polyv inyl 
alcoho l, sodium la.wyl sulfate, simethicone , methylparaben , 
propylparaben , sodium benzoa te, citric acid, and sodium citrate 
at pH 3.8 to 4.2, and is swe.etened with sucra.lose and flavored 
with artific ial cheny . 
Fo1mu lation: Oral suspension 
Strength: 50 mg/mL oral suspension; 110 mL in 125 mL high -
densi ol eth lene bottles 
Page 107 of 131 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 108 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
38 6.2 – Administration of 
Investigational Product(s)  All study medication will be stored at the research pharmacy 
prior to dispensing, or in a locked cabinet accessible only to 
members of the investigational research team.  Study 
medication oral capsules) should be stored at room 
temperature 15°C to 25°C (59 °F to 77°F).   
Ganaxolone will be administered orally with food (breakfast, 
lunch, dinner, or snack).  Ganaxolone should be taken just 
before or together with a meal or snack and with 240 mL (8 
oz) of water.   
 All study medication will be stored at the research pharmacy 
prior to dispensing, or in a locked cabinet accessible only to 
members of the investigational research team.  Ganaxolone 
capsules and ganaxolone oral suspension  should be stored at 
room temperatu re 15°C to 25°C (59°F to 77°F).  Ganaxolone 
stock solution investigational product for IV administration 
will be stored at refrigerated temperature 2ºC to 8ºC (36ºF 
to 46ºF).   Oral IP should be taken within ±15 minutes of a 
fatty meal or snack (e.g., yogur t, nuts, avocado), and with 
240 mL (8 oz) of water .   
For the IV bolus, ganaxolone  12 mg in 24  mL will be 
administered over 2  minutes via an indwelling catheter, or a 
butterfly, inserted in a vein on the arm or hand.  The IP 
should be given as continuous i nfusion as instructed.  The 
catheter should be flushed with saline at the end of the bolus 
infusion.   For details please see pharmacy manual.  
Reason for Change:  Clarification of storage of oral formulations and addition of storage and administration of intravenous ganaxolone  
38 6.2.1 – Allocation of 
Subjects to Treatment  In the open -label phase the first approximately 8 patients 
will be assigned to OL TID dosing group. After 
approximately 8 patients have started dosing in the OL TID 
group the dosing for  the OL QHS group will commence. 
Approximately eight patients will be dosed for the OL QHS 
group. After approximately 8 patients have started dosing in 
the OL QHS group, the enrollment into the OL QHS 4 -week 
group will commence.  In the open -label part, the first approximately 8  subjects  will be 
assigned to OL TID dosing group. After approximately 8 
subjects  have started dosing in the OL TID group the dosing for 
the OL QHS group will commence. Approximately 20 subjects 
will be dosed for the OL QHS group. Af ter approximately 20 
subjects have started dosing in the OL QHS group, the 
enrollment into the OL QHS 4 -week group will commence.  
After approximately 20  subjects have started dosing in the 
OL QHS 4 -week group, enrollment into the OL 1,125 mg 
group will co mmence.  Approximately 20 subjects will be 
dosed for the OL 1,125 mg group.  After approximately 20 
subjects have started dosing in the OL 1,125 mg group, 
enrollment into the OL Bolus -Oral group will commence.  
Approximately 20 subjects will be dosed for the OL Bolus -
Oral group . 
Reason for Change:  Update of subject numbers in treatment groups and addition of 2 treatment groups to study  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 109 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
45 6.2.5 – Dosing for the 
Open -label Treatment 
Part – OL 1,125  mg 
Group   Subjects will start taking ganaxolone capsules, 675 mg 
(3 capsules) at dinner time (7 pm) followed by 675 
mg (3 capsules)  at bedtime ( HS) on Day 1 and Day 2 
followed by 1,125  mg (5 capsules ) at dinner time (7 
pm) on the next 26 days (Day 3  through Day 28 ). A 4 -
day taper  will follow: 900 mg (4 capsules)  on Day 29, 675 mg 
(3 capsules) on  Day 30, 450 mg (2 capsules) on  Day 31, and 
225 mg (1 capsule) on Day 32 (Table 4) all  at dinner time.  
In addition to screening, there  will be study visits  on days 1, 
2, 8, 15, 22, 29, 36, 57, 71.  
Day 29 is the f inal visit before taper is started. The visit 
should occur in the morning of Day 29 before noon.  
All doses taken must be recorded in the eCRF.   
The study visits are intended to allow evaluation of the 
subject  by the principal investigator and making dose and/or 
timing adjustments when necessary  (see Section 6.2.7).   If 
there have been no adverse events the investigator should 
follow the dosing schedule.   
Oral ganaxolone should be taken within ±15 minutes of a 
fatty meal or snack (e.g., yogurt, nuts, avocado) and with 
240 mL (8 oz) of water.  
 
Table 4.  Study Drug Dosing Schedule – Open -label 
1,125  mg Group  
Visit  V
2 V
3  V
4 V
5 V6 V7  
Day 1 2 3 8 15 22 29 30 31 32 
Q7P
M 67
5 
m
g 6
7
5 
m
g 1,
12
5 
m
g 1,
12
5 
m
g 1,
12
5 
m
g 1,1
25 
mg 900 
mg 67
5 
m
g 45
0 
m
g 225 
mg 
QHS  67
5 
m6
7
5  
       
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 110 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
g m
g 
Total  1,
35
0 
m
g 1
,
3
5
0 
m
g 1,
12
5 
m
g 1,
12
5 
m
g 1,
12
5 
m
g 1,1
25 
mg 900 
mg 67
5 
m
g 45
0 
m
g 225 
mg 
 
There will be total of 10 study visits for the OL 1,125 mg  
dosing group: Screening, Day 1, Day 2, Day 8, Day 15, Day 
22, Day 29 and 3 safety follow -up visits on Day 36, Day 57, 
and Day 71. 
Reason for Change:  Addition of dosing information  for OL 1,125  mg Group  
46 6.2.6 – Dosing  for the 
Open -label Treatment 
Part – OL Bolus -Oral mg 
Group   Dosing in the Bolus -Oral group will start with g anaxolone IV 
bolus 12 mg over 2  minutes at approximately 4 pm on Day 1. 
Subjects will start taking ganaxolone 750 mg oral suspension 
(15 mL at 50 mg per mL) at dinner time (7 pm) followed by 750 
mg oral suspension at bedtime (HS) on Day 1.  On Day 2 , 
subjects will again take 750 mg oral suspension at dinner time 
(7 pm) followed by 750 mg at bedtime (HS).  For the following 
26 days (Day 3 through Day  28), subjects will take ganaxolone 
1,000 mg oral suspension (20 mL at 50 mg per mL) at dinner 
time (7 pm). A 4 -day taper will follow: 750 mg (15 mL) on Day 
29, 500 mg (10 mL) on Day 30, 500 mg (10 mL) on Day 31, and 
250 mg (5 mL) on Day 32 (Table 5) all a t dinner time.  
In addition to screening, there will be study visits on days 1, 2, 
8, 15, 22, 29, 36, 57, 71.  
Day 29 is the final visit before taper is started. The visit should 
occur in the morning of Day 29 before noon.  
All doses taken must be recorded in the eCRF.  
The study visits are intended to allow evaluation of the subject 
by the principal investigator and making dose and/or timing 
adjustments when necessary (see Section  6.2.7).  If there have 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 111 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
been no adverse events the investigator should follow t he dosing 
schedule.   
Oral ganaxolone should be taken within ±15 minutes of a fatty 
meal or snack (e.g., yogurt, nu ts, avocado) and with 240 mL 
(8 oz) of water.   
Table  5. Study Drug Dosing Schedule – Open -label Bolus -oral 
Group  
Vi
sit V2 V
3  V
4 V
5 V
6 V
7    
Da
y 1 2 3 8 15 22 29 30 31 32 
4P
M 12 
mg 
IV 
Bo
lus         
           
Q7
P
M 75
0 
mg 75
0 
m
g 1,
00
0 
m
g 1,
00
0 
m
g 1,
00
0 
m
g 1,
00
0 
m
g 75
0 
m
g 500 
mg 50
0 
m
g 25
0 
m
g 
Q
H
S 75
0 
mg 75
0 
m
g  
       
To
tal  1,5
12 
mg 1,
50
0 
m
g 1,
00
0 
m
g 1,
00
0 
m
g 1,
00
0 
m
g 1,
00
0 
m
g 75
0 
m
g 500 
mg 50
0 
m
g 25
0 
m
g 
 
There will be a total  of 10 study visits for the OL Bolus -Oral 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 112 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
dosing group: Screening, Day 1, Day 2, Day 8, Day 15, Day 
22, Day 29 and 3 safety follow -up visits on Day 36, Day 57, 
and Day 71.  
Reason for Change:  Addition of dosing information for OL Bolus -oral Group  
47 6.2.7 – Dose Adjustments 
During Open -label   Adjusting dose and/or timings for the OL 1,125 mg dosing 
group  
The investigator has the flexibility to adjust dose by 
reducing the dose to 450 mg (2 capsules) at the second of 
Day 1 doses (at HS) and/or at either of Day 2 doses, and/or 
reduce to 900 mg, 675 mg, or 450 mg on Day 3 through Day 
28 (at dinner time) if sub ject experiences sedation, dizziness 
or other untoward effects during the OL part. The 
investigator can also change the timing of the evening dose 
bringing it closer to bedtime and taking it with a fatty snack 
instead of dinner. Any further adjustments as well as 
adjusted taper period doses should be discussed with the 
medical monitor. The investigator may increase the dose 
back to default levels if tolerance develops to the untoward 
effects.  
Adjusting dose and/or timings for the OL Bolus -Oral dosing 
group   
The investigator has the flexibility to adjust dose by 
reducing the dose to 500 mg (10 mL) for the second of Day 1 
doses (at HS) and/or either of Day 2 doses, and/or reduce to 
750 mg (15 mL), or 500 mg (10 mL) at dinner time on Day 3 
through Day 28 if subj ect experiences sedation, dizziness or 
other untoward effects during the OL part. The investigator 
can also change the timing of the evening dose bringing it 
closer to bedtime and taking it with a fatty snack instead of 
dinner. Any further adjustments as w ell as adjusted taper 
period doses should be discussed with the medical monitor. 
The investigator may increase the dose back to default levels 
if tolerance develops to the untoward effects.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 113 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
Reason for Change:  Addition  of dose adjustment information for the 2 new treatment groups  
48 6.3.2 – Packaging and 
Dispensing the Study 
Drug  Detailed instructions when to take the medication and a 
reminder to take the study medication with food (just before 
or with a meal or snack) and with 240 mL (8 oz) of water 
will be provided to the patient.  Detailed instructions on when to take the medication and a 
reminder to take  oral study medication within ±15 minutes of a 
fatty meal or snack (e.g., fatty yogurt, nuts, avocado) and 
with 240 mL (8 oz) of water, will be prov ided to the subject . 
Reason for Change:  Clarification of instructions for taking the study drug  
49 6.3.3 – Storage  The 0.3 micron ganaxolone capsules (225  mg) and matching 
placebos are stored in HDPE bottles with a foil induction 
seal and child resistant closure at room temperature (15oC to 
25oC).  The ganaxolone stock solution investigational product for 
the IV administration will be stored at refrigerated 
temperature 2ºC to 8ºC (36ºF to 46ºF).   
The 0.3 -micron ganaxolone capsules (225  mg), oral 
suspension,  and matching placebos are stored in HDPE bottles 
with a foil induction seal and child resistant closure at room 
temperature (15oC to 25oC; 60ºF to  75ºF ).  
Reason for Change:  Addition of storage instructions for IV Ganaxolone  
50 6.5 – Drug Administration  Oral doses of ganaxolone should be taken with food just 
before or with a meal or snack and with 240 mL (8 oz) of 
water at home.   
 
 
 
 
 
 
 
 
 
 
The patient must have a reliable family member, significant 
other or a trusted friend who can take th e role for being the 
primary childcare provider and a support person at home 
(including at nighttime) while the patient is participating in 
the trial.  Oral doses of the IP should be taken within ±15 minutes of a 
fatty meal or snack (e.g., fatty yogurt, nuts, avocado), and with 
240 mL (8 oz) of water.   
For the IV bolus, ganaxolone 12 mg in 24  mL will be 
administered over 2  minutes via an indwelling catheter, or a 
butterfly, inserted in a vein on the arm or hand.  The IP 
should be given as continuous infusion as instructed.  The 
catheter should be flushed  with saline at the end of the bolus 
infusion. For details please see pharmacy manual.  
 
The subject must have a reliable family member, significant 
other or a trusted friend who can take the role for being the 
primary childcare provider and a support pers on at home 
(including at nighttime) while the subject  is participating in the 
trial, including for subjects who may stay overnight on the 
unit as part of the screening process and/or the PK 
subgroup.  
Reason for Change:  Addition of information for IV gana xolone administration and clarification of subjects who require support during the trial 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 114 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 51 7 – Study Procedures  For the open -label safety group approximately 48 women 18 
to 48 years of age with PPD will be screened to enroll 
approximately 24 patients.  During this open -label safety 
phase, for the first approximately 8 subjects, ganaxolone will 
be titrated to a daily  dose of 900 mg/day over 10 days, 
followed by a taper over 4 days.  This dosing group is called 
OL TID group.  
For the next approximately 8 subjects, ganaxolone will be 
administered at bedtime (QHS). For these subjects 
ganaxolone will be titrated to a QHS dose of 675 mg over 4 
days which is then maintained until day 10, followed by a 
taper over 4 days. This dosing group is called OL QHS 
group.  
For the next approximately 8 subjects, ganaxolone will be 
administered at bedtime (QHS). For these subjects 
ganaxol one treatment will be a QHS dose of 675 mg over 28 
days, followed by a taper over 4 days. This dosing group is 
called OL QHS 4 -week group.  
The investigator has the flexibility to adjust the dose if the 
patient experiences sedation, dizziness or other untow ard 
effects during the OL phase.  
 
 
 
 
 
 
 
 
 
 For the  open -label safety part approximately 172 women 18 to 
48 years of age with PPD will be screened to enroll 
approximately 88 subjects .  During this open -label safety part, 
for the first approximately 8 subjects, ganaxolone will be titrated 
to a daily dose of  900 mg/day over 10 days, followed by a taper 
over 4 days.  This dosing group is called OL TID group.  
For the next approximately 20 subjects, ganaxolone will be 
administered at bedtime (QHS). For these subjects ganaxolone 
will be titrated to a QHS dose of  675 mg over 4 days which is 
then maintained until day 10, followed by a taper over 4 days. 
This dosing group is called OL QHS group.  
For the next approximately 20 subjects, ganaxolone will be 
administered at bedtime (QHS). For these subjects ganaxolone 
treatment will be a QHS dose of 675 mg over 28 days, followed 
by a taper over 4 days. This dosing group is called OL QHS 4 -
week group.  
The next approximately 20 subjects of the open -label safety 
part will receive on the first 2 days ganaxolone capsules 675 
mg at dinner time and 675 mg at bedtime (for a total of 
1,350 mg per day on the first 2 days) followed by 26 days of 
ganaxolone capsules 1,125 mg at dinner  time, followed by a 
taper over 4 days. This dosing group is called OL 1,125 mg 
group.  
For the next a pproximately 20 subjects of the open -label 
safety part, ganaxolone will be administered as IV bolus 12 
mg over 2 minutes at approximately 4 pm on Day 1 followed 
by ganaxolone oral suspension 750 mg at dinner time and 
750 mg at bedtime, for a total of 1,512  mg on the first day. 
On Day 2 subjects will receive ganaxolone oral suspension 
750 mg at dinner time and at 750 mg at bedtime, for a total 
of 1,500 mg, followed by 26 days of ganaxolone oral 
suspension 1000 mg at dinner time, followed by a taper over 
4 days. This dosing group is called OL Bolus -Oral group. 
The investigator has the flexibility to adjust the dose and/or 
timing of the dose if the subject experiences sedation, 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 115 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
 
The open -label safety group will be enrolled, and dosing 
completed before proceeding to the double -blind group.  The 
goal of the open -label group is to explore safety of oral 
ganaxolone in this population and identify a dosing regimen 
for the double -blind phase .  
For the double -blind group, approximately 100 women with 
PPD 18 to 48 years of age will be screened to randomize 50 
women in a 1:1 ratio to receive ganaxolone or matching 
placebo for 14  days.  The dosing for the double -blind portion 
of the study will be decided based on the results of the open -
label portion and recommendations of the DRC.  The DRC 
is comprised of Marinus’ Chief Medical Officer and 2 
external physician experts.  The daily dose will n ot exceed 
1200 mg.  Randomization will be stratified by the use of 
concomitant antidepressants so that the number of patients 
who are treated with antidepressants and who are not treated 
with antidepressants will be similar in each treatment group.  dizziness or other untoward effects during the OL part (see 
Section 6.2.7).  
The ope n-label safety  part will be enrolled, and dosing 
completed before proceeding to the double -blind part.  The goal 
of the open -label part is to explore safety of IV and  oral 
ganaxolone in this population and identify a dosing regimen for 
the double -blind part. 
For the double -blind part, approximately 100 women with PPD 
18 to 48 years of age will be screened to randomize 50 women 
in a 1:1 ratio to receive ganaxolone or matching placebo for 
14 days.  The dosing for the double -blind portion of the study 
will be decided based on the results of the open -label portion 
and recommendations of the DRC.  The DRC is comprised of 
Marinus’ Chief Medical Officer and 2 external physician 
experts.  The daily dose will not exceed 1,600  mg.  
Randomization will be stratified by the use of concomitant 
antidepressants so that the number of subjects  who are treated 
with antidepressants and who are not treated with 
antidepressants will be similar in each treatment group.  
Reason for Change:  Update  to the number  of subjects in each treatment group  and maximum daily dose, and addition of 2  new treatment groups  
51 7 – Study Procedures   Collect urine drug screen and urine pregnancy test   Collect urine for urinalysis, urine  drug screen and urine 
pregnancy test  
Reason for Change:  Clarification of urinalysis procedure  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 116 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
60 7.7 – Screening Period 
(Day -14 to -1) for OL 
1,125  mg and OL 
Bolus -oral Groups   7.7  Screening Period (Day -14 to -1) for OL 1,125  mg and 
OL Bolus -oral Groups  
7.7.1  Screening Visit (Visit  1) 
 Obtain written informed consent  
 Collect demographics, medical history, review prior 
medications, review of concomitant medications and 
therapies,  
 Assess CGI -S 
 Conduct Mini International Neuropsychiatric Interview 
7.0 (MINI 7.0)   
 Conduct HAMD17 interview  (if a HAMD17 interview 
was conducted for Marinus PPD study 1042 -PPD -2002 
at the same investigative site within 2 weeks of the 
screening visit the screening HAMD17 interview does 
not have to be repeated).  
 Perform EPDS  
 Perform STAI6  
 Perform a physical exam ination  
 Collect vital signs (blood pressure [BP], pulse, 
temperature, respiratory rate [RR])  
 Collect ECG  
 Collect urine for urinalysis, urine drug screen and urine 
pregnancy test  
 Collect safety laboratory tests  
 Measure height and weight  
 Conduct CSSRS in terview  
 Review inclusion and exclusion criteria.  Screen failure 
is defined as a subject who has given informed consent, 
and failed to meet the inclusion criteria and/or met the 
exclusion criteria  
 Schedule a SAFER interview if the subject meets the 
eligib ility criteria.  The SAFER interview will be 
conducted during the screening period.  The 
investigational site must wait for the results of the 
SAFER interview before enrolling the subject into the 
treatment phase of the study (if a SAFER interview was 
cond ucted within 2 weeks for Marinus PPD study 1042 -
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 117 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
PPD -2002 at the same investigative site the SAFER 
interview does not have to be repeated. In this instance 
the HAMD17 score from the SAFER interview can be 
used to qualify the subject for the study).  
 Screeni ng period may be extended to 21 days with 
approval from the medical monitor (e.g., a laboratory 
sample was hemolyzed and had to be repeated causing a 
delay).  
Reason for Change:  Addition of screening period information for new treatment groups  
60 7.8 – Treatment Period 
(Day 1 to Day  29; Visits 2 
to 7) for OL 1,125  mg and 
OL Bolus -oral Groups   7.8  Treatment Period (Day  ! to Day  29; Visits 2 to 7) for OL 
1,125  mg and OL Bolus -oral Groups)  
7.8.1  Start of the Open -label Safety Period (Enrollment 
Visit for the OL 1,125  mg and OL Bolus -oral Groups) 
(Day  1) 
 The subject arrives in the clinic to compl ete baseline 
assessments on Day  1.  
 CTNI to conduct HAMD17 interview  
 Perform EPDS  
 Perform STAI6  
 Assess CGI -S 
 Review concomitant medications and therapies  
 Collect vital signs (BP, pulse, temperature, RR)  
 Measure weight  
 Collect ECG  
 Collect urine for urinalysis, urine drug screen and urine 
pregnancy test  
 Collect safety laboratory tests  
 Collect neurosteroid level  
 Collect SSS  
 Collect AEs  
 Conduct CSSRS intervie w  
 Review inclusion and exclusion criteria (including 
hematology, chemistry, urinalysis, urine drug screen 
and pregnancy tests from the screening visit); HAMD17 
(as determined by CTNI) must be ≥ 18 for enrollment.  
 If the subject continues to meet the inclu sion criteria 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 118 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
and has not developed any exclusion criteria the subject 
will be enrolled in the study  
 Dispense medication bottle after enrollment. Provide the 
subject with dosing  instructions and subject diary 
completion.  
 For the OL 1,125 mg group: the sub ject will be 
instructed to take the first oral doses of the study 
medication that evening (675 mg [3 capsules] at dinner 
time [at 7 pm] and at bedtime [at 10 pm])  
 For the OL Bolus -Oral group: the subject will receive 
IV bolus 12 mg over 2 minutes at appro ximately 4 pm 
(preferably ±1 hour) while on the unit, be observed for 
development of sedation and/or other untoward effects 
for at least 1 hour post -bolus and then be discharged 
and instructed to take the first oral doses of the study 
medication that eveni ng (750 mg [15 mL oral suspension 
at 50 mg per mL] at dinner time [at 7 pm] and at 
bedtime [at 10 pm])  
 Oral IP should be taken within ±15 minutes of a fatty 
meal or snack (e.g., yogurt, nuts, avocado), and with 240 
mL (8 oz) of water.   
 A sub -group of 6 s ubjects (to be called ‘PK sub -group’, 
Section 7.10.7) in each of the OL 1,125 mg and OL 
Bolus -Oral groups will stay overnight on the unit 
between Day 1 and Day 2 to undergo comprehensive PK 
assessment as follows: for the OL 1,125 mg group 
plasma samples fo r PK analysis will be drawn at the 
following times after the first oral dose on Day 1 (i.e., the 
675 mg oral capsules dose at 7 pm at dinner time; 0hr): 
+1hr, +2hr, +3hr (i.e., just prior to the 10 pm 675 mg 
dose), at +4hr, +5hr, +6hr, and at 8 am on Day 2 . For 
the OL Bolus -Oral group plasma samples for PK 
analyses will be drawn at the following times after the 
IV bolus on Day 1 (e.g., the 12 mg IV bolus at 4 pm; 
0hr): +1hr, +2hr, +3hr (i.e., just prior to the first oral 
dose of 750 mg oral suspension at di nner time), at +4hr, 
+5hr, +6hr (i.e., just prior to the second 750 mg oral 
suspension evening dose), at + 7hr, +8hr, and at 8 am on 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 119 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
Day 2.  
 If the subject is breastfeeding, she is encouraged to 
“pump and dump” during the study period and for 45 
days after the last dose.  She should be provided with a 
breast pump if she does not have one.  Breast feeding is 
prohibited during the treatment phase and until 45 days 
following the last dose of the study drug.   
7.8.2  Treatment Visits (Days  2, 8, 15, 22, 29 ±  3 days [except 
Day 2]) for OL 1,125  mg and OL Bolus -oral Groups  
 CTNI to conduct interview for HAMD17  
 Conduct interview for CGI -I  
 EPDS  
 STAI6  
 Collect AEs  
 Collect ECG (Day 2, Day 8, Day 15, Day 29)  
 Collect vital signs (BP, pulse, RR, temperature)  
 Measure weight (Day 15, Day 29)  
 Collect SSS  
 Collect a PK  sample  
 Record concomitant medications  
 Collect safety laboratory tests (Day 15, Day 29)  
 Collect neurosteroid level (Day 2, Day 8, Day 15, Day 
29) 
 Collect urine for urinalysis, urine drug screen and urine 
pregnancy test (Day 8, Day 15, Day 22, Day 29)  
 Conduct CSSRS interview  
 Perform a physical examination (Day 29)  
 Dispense study medication with a supply to last until the 
next visit (+ 3 days overage to cover for unexpected need 
to re -schedule  a study visit or weekends).  Provide the 
subject with dosing instructions.  
 For the OL 1,125 mg group: the subject will be 
instructed to take Day 2 oral doses of the study 
medication that evening (675 mg [3 capsules] at dinner 
time [at 7 pm] and 675 mg [3 capsules] at b edtime [at 10 
pm]) followed by 26 days of 1,125 mg (5 capsules) at 
dinner time  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 120 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 For the OL Bolus -Oral group: the subject will be 
instructed to take Day 2 oral doses of the study 
medication that evening (750 mg [15 mL oral suspension 
at 50 mg per mL] at dinn er time [at 7 pm] and 750 mg 
[15 mL oral suspension at 50 mg per mL] at bedtime [at 
10 pm]) followed by 26 days of 1,000 mg (20 mL oral 
suspension at 50 mg per mL) at dinner time  
 Oral IP should be taken within ±15 minutes of a fatty 
meal or snack (e.g., yo gurt, nuts, avocado), and with 240 
mL (8 oz) of water.   
 During Visit 7 (Day 29) start study drug taper (Day 29 -
32) (See Sections 6.2.5 and 6.2.6)  
Reason for Change:  Addition  of treatment period information for new treatment groups  
63 7.9 - Follow -up Visit 1 
(Day 36 ± 3), Follow -up 
Visit 2 (Day 57 ± 3), and 
Follow -up Visit 3 (Day 
71 ± 3) for the OL 1,125 
mg and OL Bolus -Oral 
groups   7.9 – Follow -up Visit 1 (Day 36 ± 3), Follow -up Visit 2 (Day 
57 ± 3), and Follow -up Visit  3 (Day 71 ± 3) for the OL 
1,125  mg and OL Bolus -Oral Groups  
 The Follow -up Visit 1 should occur about 1 week after D29 
visit, and about 4 days after the subject has taken her last 
dose of the study medication.  The Follow -up Visit 2 should 
occur approximately 21 days after Follow -up Visit 1. The 
Follow -up Visit 3 should occur approximately 14 days after 
Follow -up Visit 2 (All Follow -up visits should be scheduled 
within visit window unless there is a medical need to see 
the subject sooner; an additional safety visit can be 
scheduled as  per the investigator’s discretion).  
 CTNI to conduct interview for HAMD17  
 Conduct interview for CGI -I  
 Perform EPDS  
 Perform STAI6  
 Review concomitant medications and therapies  
 Collect vital signs (BP, pulse, temperature, RR)  
 ECG (Follow -up Visit 1 only)  
 Collect safety laboratory tests (Follow -up Visit 1 and 3 
only)  
 Collect neurosteroid level (Follow -up Visit 1 and 3 only)  
 Collect PK sample (Follow -up Visit 1 only)  
 Collect urine for urinalysis, urine drug screen and urine 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 121 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
pregnancy test  
 Measure weight (Fo llow-up Visit 3 only)  
 Conduct CSSRS interview  
 Collect SSS  
 Collect AEs  
 Collect study medication bottle dispensed at Day 29 
(Follow -up Visit 1 only).  Review subject dosing diary and 
complete drug accountability while subject is present.  
Table  8.  Schedule  of Assessments for the Open -label OL 
1,125  mg and OL Bolus oral Groups  
VISIT Scr
een
ing 
(V1
) D
ay
1  
(V
2) D
ay
2  
(V
3) Day
8 
±3d 
(V4)  D15 
±3d 
(V5
) Day
22 
±3d 
(V6
)  Day
29 
±3d 
(V7
) Day3
6 ±3d  
(V8; 
1st 
FU) Day
57 
±3d 
(V9; 
2nd 
FU) Day7
1 
±3d 
(V10
; 3rd 
FU) 
Informed 
 X          
Demographics, 
  X          
MINI 
  X          
Inclusion/Exclu
  X X         
Dispense 
medication / 
 
 
  X X X X X X X   
Concomitant 
Medications 
  
 
 X X X X X X X X X X 
Physical 
  X      X    
SAFER 
 
 
 X          
Vital signs 
  
 
 X X X X X X X X X X 
Height 
 
  
  X X   X  X   X 
ECGs X X X X X  X X   
Safety 
 
 X X   X  X X  X 
b Bolus (OL 
 
   X         
PK sample 
   X X X X X X   
PK subgroup 
sample 
collection   c X         
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 122 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
Neurosteroid 
 
  X X X X  X  X  X 
Urinalysis,  
  
  
 X X  X X X X X X X 
Record AEs   X X X X X X X X X 
a HAMD17  X X X X X X X X X X 
CGI-I   X X X X X X X X 
CGI-S X X         
EPDS  X X X X X X X X X X 
STAI6 X X X X X X X X X X 
CSSRS  X X X X X X X X X X 
SSS  X X X X X X X X X 
Start Taper        X    
a CTNI will conduct all HAMD ratings except the one at screening  
b IV bolus is to be done at approximately 4 pm (preferably within ±1 hour) and 
allowing for at least 1 -hour post -bolus follow -up at the site before discharge  
c A sub -group of 6 subjects (to be  called ‘PK sub -group’) in each of the OL 
1,125 mg and OL Bolus -Oral groups will stay overnight on the unit between 
Day 1 and Day 2 to undergo comprehensive PK assessment as follows: for the 
OL 1,125 mg group plasma samples for PK analysis will be drawn at  the 
following times after the first oral dose on Day 1 (e.g., the 675 mg oral 
capsules dose at 7 pm at dinner time; 0hr): +1hr, +2hr, +3hr (i.e., just prior to 
the 10 pm 675 mg dose), at +4hr, +5hr, +6hr, and at 8 am on Day 2. For the 
OL Bolus -Oral group plasma samples for PK analyses will be drawn at the 
following times after the IV bolus on Day 1 (e.g., the 12 mg IV bolus at 4 pm; 
0hr): +1hr, +2hr, +3hr (i.e., just prior to the first oral dose of 750 mg oral 
suspension at dinner time), at +4hr, +5hr, +6h r (i.e., just prior to the second 
750 mg oral suspension evening dose), at + 7hr, +8hr, and at 8 am on Day 2.  
The following priority order will be in effect when more than 1 assessment is 
required at a particular time point:  1) HAMD17 2) CGI -I/CGI -S 3) EPDS 
4) STAI6 5) SSS 6) CSSRS 7) vital signs 8) ECG 9) safety labs 10) 
neurosteroid sample 11) PK sample 12) urinalysis, urine drug screen and 
pregnancy test 13) physical examination.  SAFER interview is scheduled if 
subject meets the eligibility criteria at the Screening visit.  The SAFER 
interview will be conducted during the screening period.  The investigational 
site must wait for the results of the SAFER interview before enrolling the 
subject into the treatment phase of the study. Screening period may be 
extended to 21 days with approval from the medical monitor .   
 
 
 
 
 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 123 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
Reason for Change:  Addition  of follow -up period information for new treatment groups  
66 7.10.4 – Prior Medication, 
Concomitant Medication 
and Concomitant Therapy 
Review  At screening, prospective subjects will be asked about 
medications they have taken in the previous 60 days, 
including prescription medications, non -prescription 
medications, vitamins, and supplements.  At subsequent 
visits, the subjects will be asked about  mediations taken 
since the last visit.   
The type of psychological counseling the subject is receiving 
at the time of screening will be recorded on the Concomitant 
Psychological Treatment eCRF page.  At screening, prospective subjects will be asked about 
medications they have taken in the previous 60 days, including 
prescription medications, non -prescription medications, herbal 
medications,  vitamins, and supplements.  At subsequent visits, 
the subjects will be asked about medications taken since the last 
visit.   
The type of psychological counseling the subject received from  
the time of screening through the last follow -up visit  will be 
recorded on the Concomitant Psychological Treatment eCRF 
page.  
Reason for Change:  Clarification  of concomitant medicati ons and time period for follow -up 
66 7.10.5 - Physical 
Examination  A complete physical examination will be performed at 
screening and at Day 10 visit (Day 29 for OL QHS 4 week 
group).  A complete physical examination will be performed at screening 
and at Day 10 visit (Day 29 for OL QHS 4 week, OL 1,125 mg 
and OL Bolus -Oral groups ).  
Reason for Change:  Addition  of 2 new treatment groups  
70 7.10.6.7 – SAFER 
Interview   CTNI will also perform all HAMD ratings except the one 
done at screening.  
Reason for Change:  Clarification of SAFER interview for study  
70 7.10.7 – Pharmacokinetic 
Sampling   A sub -group of 6 subjects (to be called ‘PK sub -group’) in 
each of the OL 1,125 mg and OL Bolus -Oral groups will stay 
overnight on the unit between Day 1 and Day 2 to undergo 
comprehensive PK assessment as follows: for the OL 1,125 
mg group plasma samples for PK analysis will be drawn at 
the following times after the first oral dose on Day 1 (i .e., the 
675 mg oral capsules dose at 7 pm at dinner time; 0hr): 
+1hr, +2hr, +3hr (i.e., just prior to the 10 pm 675 mg dose), 
at +4hr, +5hr, +6hr, and at 8 am on Day 2. For the OL 
Bolus -Oral group plasma samples for PK analyses will be 
drawn at the follow ing times after the IV bolus on Day 1 
(e.g., the 12 mg IV bolus at 4 pm; 0hr): +1hr, +2hr, +3hr 
(i.e., just prior to the first oral dose of 750 mg oral 
suspension at dinner time), at +4hr, +5hr, +6hr (i.e., just 
prior to the second 750 mg oral suspension e vening dose), at 
+ 7hr, +8hr, and at 8 am on Day 2.  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 124 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
The first 6 consecutively enrolled subjects who are in units 
with overnight inpatient capabilities and who consent for 
inclusion in the PK subgroup will be included in the PK 
subgroup.  
Reason for Change:   Addition of PK sub -group from the additional treatment groups  
71 7.10.9 – Volume of Blood 
to be Drawn from Each 
Subject  Table  7. Volume of Blood to Be Drawn from Each Subject 
for the OL QHS  4 Week  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 10. Volume of Blood to Be Drawn from Each 
Subject for the OL QHS  4 Week, OL 1,125 mg, and OL 
Bolus -Oral groups  
 
Table  11.  Volume of Blood to be Drawn from Each 
Subject for the PK Subgroup of OL 1,125  mg Group  
Assessment  Approxima
te Sample 
Volume  
(mL)a Number of 
Samples  Approxima
te Total 
Volume 
(mL)  
Pharmacoki
netic 
samples  4 12 48 
Safety 
hematology  3 6 18 
Safety 
chemistry  7 6 42 
Neurosteroi
d level  4 7 28 
Total mL    136 
 
Table  12.  Volume of Blood to be Drawn from Each 
Subject for the PK Subgroup of OL Bolus -oral Group  
Assessment  Approxima
te Sample 
Volume 
(mL)a Number of 
Samples  Approxima
te Total 
Volume 
(mL)  
Pharmacoki
netic 
samples  4 14 56 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 125 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During this study, approximately 58 mL of blood will be 
drawn from all subjects during the study for the OL TID,OL 
QHS and Double -blind groups. Approximately 112 mL of 
blood will be drawn from all subjects during the study for 
the OL QHS 4 week group.  
 
 
 
 
 
 
 Safety 
hematology  3 6 18 
Safety 
chemistry  7 6 42 
Neurosteroi
d level  4 7 28 
Total mL    144 
 
During this study, approximately 58 mL of blood will be drawn 
from all subjects during the study for the OL TID, OL QHS and 
Double -blind groups. Approximately 112 mL of blood will be 
drawn from all subjects during the study for the OL QHS 4 
week, OL 1,125 mg, and OL Bolus -Oral groups.  
Subjects in the ‘PK subgroup’ of the OL 1,125 mg and OL 
Bolus -Oral groups (6 subjects in each subgroup) will have 
additional 6 and 8 samples, respectively, at 4 mL each, for a 
total of approximately 136 mL and 144 mL of blood drawn, 
respectively .  
Reason for Change:  Addition  of 2 treatment groups  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 126 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
78 9.3 -  Statistical Analysis 
Plan The SAP will be finalized prior to completion of the double -
blind phase to preserve the integrity of the statistical analysis 
and study conclusions.  The SAP will be finalized prior to database lock and/or 
unblinding of any portion of the trial  to preserve  the integrity 
of the statistical analysis and study conclusions.  
Reason for Change:  Clarification of SAP finalization  
78 9.3.1 – Data Review 
Committee (DRC) and 
Recommendations for 
Dosing  Marinus may decide to stop the study, or make the data 
public, after completion of the open -label group or the 
double -blind phase of the study.  Marinus may decide to stop the study, or make the data public 
at any time during the open -label portion of the trial or  after 
completion of the double -blind part of the study.  
Reason for Change:  Clarification of study stopping procedures  
79 9.3.2 – Justification for 
Sample Size  A sample size of 20 patients per group would be needed to 
detect a 3.5 point difference on the HAMD17 scale assuming 
standard deviation of 3.5 with power=86%, alpha=0.05, and 
2-sided t -test.  A sample size of 20 patients per group would 
be needed to detect a 5 point difference on the HAMD17 
scale assuming standard deviation of 3.5 with power=99%, 
alpha=0.05, and 2 -sided t -test.  In a recent study by Hantsoo 
et al., (2014)  sertraline was shown to be effective in 
treatment of PPD over 6 weeks of treatment (n=27; subset of 
women with strictly defined PPD).  The separation between 
sertraline and placebo was 7.8 points at the stud y end -point.  
Standard deviations were 2.8 and 3.9 for the placebo and 
sertraline groups, respectively.  With a sample size of 50 subjects/group, the DBPC part of 
the trial will be able to detect a medium effect size (per 
Cohen’s d) with 93% power using a two -sided significance 
level of 0.05.   
Reason for Change:  Clarification of justification for sample si ze 
79 9.3.3 – Study Population   
 
 
The modified  Intent to Treat Set  (mITT) will consist of all 
subjects in the Safety Set who have at least 1 post -
enrollment HAMD17 assessment.  The mITT set will be 
used for all efficacy assessments.  The Randomized Set  will consist of subjects randomized in the 
DBPC part of the trial.  
The modified  Intent to Treat Set  (mITT) will consist of all 
subjects in the DBPC part of the trial who received IP and 
who have at least 1 post-baseline  HAMD17 assessment.  The 
mITT set wi ll be the primary efficacy population for the 
DBPC part of the trial.   
Reason for Change:  Addition of definition of randomized set and clarification of mITT set  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 127 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
79 9.4 – Analysis Methods   Data will be presented by study part (OL, DBPC), dosing or 
treatment group within study part and, if applicable, study visit. 
Continuous variables will be summarized as numbers of 
observations, means, measures of variance (e.g., standard 
deviation), and percentiles (e.g., median, minimum, maximum).  
Categorical va riables will be summarized as numbers of 
observations and percentages.  
Reason for Change:  Addition of analysis  methods  
79 9.4.1 – Demographic and 
Baseline Characteristics  Descriptive summaries of demographic and baseline 
characteristics as well as subject disposition will be 
presented by study phase (open -label safety group, double -
blind phase) and by treatment within the double -blind phase.  
Baseline characteristics will include a summary of the 
following:  
 Subject demographics  
 Pre-existing medical c onditions  
 Prior therapies.  
Continuous variables such as age, weight, and height will be 
summarized using number of observations, mean, standard 
deviation, median, minimum, and maximum values.  
Categorical variables, like sex and race, will be summarized 
using number of observations and percentages.  
Medical history will be summarized by treatment group 
using the number of observations and percentages of 
subjects reporting each category . Baseline characteristics will include a summary of the 
following:  
 Subjec t demographics  
 Pre-existing medical conditions  
 Prior therapies  
 Medical history  
Reason for Change:  Clarification  of analysis method  
80 9.4.2 – Subject 
Disposition   Frequencies and percentages of subjects who discontinued 
the study and reasons for discontinuation will be 
summarized.  
Reason for Change:  Clarification of analysis method  
80 9.4.3 – Investigational 
Medicinal Product  Summary statistics for the duration of exposure to 
investigational medicinal product, will be presented by study 
phase and by treatment group.  Overall exposure to IP, such as  duration of exposure, as well 
as dose adjustments (i.e, deviations from the scheduled 
titration scheme)  will be summarized.  
Reason for Change:  Clarification of analysis method  
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 128 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
80 9.4.4 – Concomitant 
Medication  Concomitant medications will be listed and summarized by 
preferred drug name by study phase and treatment group.  Concomitant medications will be coded using the World 
Health Organization Drug Dictionary (WHO -DD) and will 
be summarize d by drug class and  preferred drug name.  
Reason for Change:  Clarification of analysis method  
80 9.4.5 – Safety Analyses  Reported AEs terms will be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA).  The 
incidence of Treatment Emergent AEs (TEAEs) will be 
summarized by treatment group, system organ class 
preferred terms, severity and relatedness for the o pen-label 
safety group and double -blind phase.  SAEs and AEs leading 
to discontinuation of the study drug will be summarized by 
study phase (open -label safety group and double -blind 
phase) and treatment group.  
The absolute values and change from baseline in laboratory 
tests, vital signs, SSS, ECGs, and CSSRS will be 
summarized by study phase (open -label safety group and 
double -blind phase) and treatment group.  
Dose adjustments (i.e, deviations from the scheduled 
titration scheme) will be summarized.  
Potentially clinically important findings will be summarized 
or listed.  
Results of the physical examination will be listed.  Reported AEs terms will be coded using the Medical Dictionary 
for Regulatory Activities (MedDRA).  The incidence of 
treatment emergent AEs (TEAEs), defined as AEs that started 
or worsened after first administration of IP,  will be 
summarized by system organ  class  and preferred term.  
Separate summaries of TEAEs  by severity and relatedness 
will be done .  SAEs and TEAEs  leading to discontinuation of 
the study drug will also be summarized separately.   
The absolute values and change from baseline in laboratory 
tests, vital signs, SSS, ECG parameters , and CSSRS will be 
summarized.  
Results of physical examinations will be listed.  
Reason for Change:  Clarification  of safety analyses  
80 9.4.6 – Efficacy Analyses  Approximately continuous endpoints (e.g, HAMD17, 
HAMD6, STAI6, and EPDS) will be analyzed by mixed 
model repeated measures (MMRM) analysis of covariance 
(ANCOVA) including all post -baseline treatment visits (but 
not the follow -up visits).  The model will include fixed 
effects of treatment, visit, treatme nt-by-visit interaction, and 
baseline value of the endpoint.  If at least 8 subjects are 
taking concomitant antidepressants during the study, it will 
also be included as a fixed effect.  An unstructured residual 
covariance matrix will be used; however alte rnate structures, Efficacy parameters will be summarized for both the OL 
and DBPC parts but will be analyzed only for the DBPC 
part.  For the OL part, referring to efficacy endpoints as 
“primary,” “secondary,” and “exploratory” is related to the 
degree of influence each type of endpoint is expected to have 
on decision -making rather than to considerations associated 
with inferential analy sis (such as control of type 1 error).  
The primary time point of interest for all efficacy 
parameters will be Day 10 for the DBPC part and the visit at 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 129 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
to be specified in the SAP, will be used in the event of 
convergence issues.  Differences between the treatments 
overall and at each visit will be tested for statistical 
significance.  
Ordered categorical endpoints (CGI -I, EPDS obsessive 
thoughts - time occupied, EPDS obsessive thoughts – 
distress) will be analyzed at each visit by the Cochran -
Mantel -Haenszel (CMH) row mean scores test using rank 
scores.  Dichotomous categorical endpoints will be analyzed 
at each visit by Fisher's exact tes t [HAMD17 response (≥ 
50% decrease from Baseline), HAMD6 response (≥ 50% 
decrease from Baseline), HAMD17 remission (HAMD17 
total score ≤  7].  However, if concomitant antidepressants 
are included in the model of approximately continuous 
endpoints, then the CMH row means scores test will control 
for their use, and the Fisher's exact test will be replaced with 
the CMH general association test, controlling for their use.  
Items related to sleep and anxiety within the HAMD17 and 
EPDS scales may be tabulated separ ately.   
After the completion of the double -blind phase and analysis 
of the data by the DRC Marinus may decide to enroll 
another group of subjects who are randomized to receive 
ganaxolone or placebo.  Since this is a Phase 2 study, no 
adjustments to the Ty pe I error protections are considered 
necessary.  
Efficacy data for the open -label safety group will be 
summarized descriptively.  end of treatment (before initiation of taper) for the OL part.  
Reason for Change:  Clarification of ef ficacy analyses  
80 9.4.6.1 – Primary 
Endpoint   The primary efficacy endpoint will be HAMD17 total score 
change from baseline; this will be assessed at Day 10 for the 
DBPC part and at the visit at end of treatment for the OL 
part. The primary efficacy analysis will be done using the 
mITT set (DBPC part only). The analytical method will be 
mixed model repeated measures (MMRM) with baseline 
HAMD17 total score as a covariate. Significance will be 
IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 130 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
tested at a two -sided 0.05 level. Unstructured covariance wi ll 
be specified although alternative covariance structures may 
be used, if appropriate, to achieve convergence or greater 
efficiency. Sensitivity analysis will be used to evaluate the 
assumption of data missing at random (MAR), if applicable.  
Reason for C hange:  Addition of analysis method  
81 9.4.6.2 – Secondary 
Endpoints   The trial will also evaluate the following secondary 
endpoints at each post -baseline data collection time point to 
provide additional evidence of the efficacy of ganaxolone in 
treating PPD:  
• Change from baseline in HAMD17 total score other 
than at the primary endpoint time point  
• HAMD17 response defined as at least a 50% 
reduction from baseline in total score  
• HAMD17 remission defined as total score <= 7  
• Change from baseline in EPDS  total score  
• Change from baseline in STAI6  
• CGI -I 
Reason for Change:  Addition of analysis method  
81 9.4.6.3 – Exploratory 
Endpoints   

IND No. 135256 Marinus Pharmaceuticals, Inc. 
Protocol 1042- PPD-2003  Version 5.0 / 22 Oct 2018 
 
Confidential Page 131 of 131 Page  Section, Title, 
Paragraph, Line  Original Text  Revised Text  
Reason for Change:  Addition of analysis method  
81 9.4.6.4 – Statistical 
Methods   Efficacy parameters will be summarized for OL and DBPC 
parts. Observed values and changes from baseline for 
HAMD17, EPDS, and STAI6 total scores, subscales, and 
individual items will be summarized by visit.  The 
categorical outcomes of HAMD17 response, HAMD17 
remission, and CGI -I will be summarized by visit.  
For the DBPC part, the preferred approach for analyses of 
treatment group differences in secondary and exploratory 
continuous effica cy variables will be MMRM but other 
approaches such as t -tests, analysis of covariance, or non -
parametric methods may be used if necessary or more 
practical. Similarly, the preferred approach for analysis of 
secondary and exploratory categorical efficacy v ariables will 
be repeated measures (e.g., generalized estimating 
equations) but other approaches such as chi square or 
Fisher’s exact tests may be used.  
Reason for Change:  Addition of statistical methods for each part of the study  
 
